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1.INTRODUCTION 
  Siddha system is the most ancient and divine medical system meant for 
its uniqueness. According to the tradition it was Shiva who unfolded the knowledge of 
Siddha system of medicine to his concert Parvati who handed it down to Nandhi devar 
and he in turn to the 18 siddhars. Therefore, it is called ‘Shiva Sampradayam, (tradition 
of Siva), or ‘Siddha Sampradayam. The medicines were prepared by the Siddhars on 
herbs, metals and minerals. The father of Siddha Medicine is the primordial 
Guru, Agasthiar.  
                        According to the ancient Siddha texts, a human body is made up of 
several elements. The elements that form a human body are the earth (MANN), fire 
(THEE), water (NEER), air (VAYU) and space (AKASAM). Siddhars believes that, 
the changes in the nature environment may directly or indirectly affect the body. So, 
these factors must also be considered when diagnosis and treatment are given. The 
principles of treatment are therefore expected to accord to different season and 
environments. 
                     Additionally, there are three humors or the DOSHAS called the Vata, 
Pitta and Kapha. Siddha medicine believes that diseases occur when there is a 
disequilibrium or imbalance in these humors or if their individual harmony is 
disturbed. The balance can be restored by correcting the underlying dosha by the 
application of the Siddha medicines. 
                      Siddha system does not consider treatment and prevention separately. The 
main aim of this system is prevention of disease, as it is well said that “Prevention is 
better than cure”. According to the Siddha system, the individual is a microcosm of the 
universe. Food is the basic building material of the human body and gets processed into 
humours, tissues and wastes. The equilibrium of humours is considered as health and 
its disturbance or imbalance leads to a diseased state; Saint Thiruvalluvar has indicated 
the same view in his Thirukural, 
 
"மிகினும் குறையினும் ந ோய்செய்யும் நூந ோர்  
வளிமுத ோ எண்ணிய மூன்று." - குைள் 941 [28] 
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             Plants have been used for medicinal purposes long before prehistoric period. 
Recently, WHO estimated that 80 percent of people worldwide rely on herbal medicines 
for some aspect of their primary health care needs. According to WHO, around 21,000 
plant species have the potential for being used as medicinal plants. Treatment with 
medicinal plants is considered very safe as there is no or minimal side effects, they are 
comparatively safe, eco-friendly and locally available. These remedies are in sync with 
nature, which is the biggest advantage. Although synthetic drugs exhibit quicker 
efficacy, there are at present, unsubstantiated opinion of higher incidents of adverse 
reactions following the use modern drugs when compared with herbal remedies. 
Traditional medicine has always been considered as an efficient and acceptable option 
even when modern health facilities are available. As a result of recent advances in 
biochemistry, immunology, medical botany and pharmacognosy, research findings 
have established the descriptive capacity, effectiveness and rationality of herbal 
medicines. 
              Maha manjisthathi kashayam has water soluble active principle herbs. Hence 
kashayam is the best way to enjoy the maximum benefits out of the herbs. Water soluble 
components are readily absorbed by the intestines. The freshly prepared kashayam have 
medicinal herbs in active mode and bring about fast action. A major benefit of herbal 
medicine is that they are generally safer than synthetic pharmaceuticals. Herbs taken as 
a whole, will have compounds in them that buffer their action. This is because plants, 
being chemically complex living organisms, often have several medicinal actions. 
             Psoriasis is a chronic, non-infectious skin disease characterized by well-defined 
slightly raised dry erythematous macules with silvery scales and typical extensor 
distribution. It is an auto immune disease. The modern treatments include steroid 
creams, vitamin D3 cream, ultraviolet light and immune system suppressing 
medications, such as methotrexate. 
             Majority of patients with moderate-to-severe being subjected to discrimination, 
humiliation and being stared at in public. Stress is the common trigger for psoriasis flare 
at the same time psoriasis flare can also cause stress. There are many ways to reduce 
stress and the impact it has on psoriasis. Yoga is one among them which possess a 
tremendous effect on stress free life.  
              
 
Deep relaxation techniques are a great way to help with stress management, it quietness 
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your mind and releases physical tension in your body. In a state of deep relaxation, your 
heart beat and breathing slow down, and your body and mind become deeply calm. The 
technique could be described as a lying down form of meditation that uses the whole 
body as a focus of awareness. Nearly all spiritual traditions acknowledge the existence 
of a body of energy that permeates the physical body and is responsible for our health 
and wellbeing. Yoga nithra also aims to enhance and balance this energy. The aim is to 
surf the interface between sleeping and waking consciousness. Practicing yoga also 
improves the vitality and life expectancy.  
              External treatment for psoriasis often involves topical application of ointments 
and creams. Emollients reduce the risk of cracking and scaling of dry skin. Chemparuthi 
poo ennai has ingredients such as coconut oil, chemparuthi petals which moisturizes, 
and controls inflammation thereby reduce the symptoms of psoriasis. 
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2.AIM AND OBJECTIVES 
 
AIM: 
To evaluate the safety and efficacy of Siddha Herbal Drugs “Maha manjishtathi 
kashayam” (Internal), “Chemparuthi poo ennai” (External) & “Deep 
relaxation technique” in management of Thadippu Perunoi (Psoriasis). 
OBJECTIVES: 
PRIMARY OBJECTIVE: 
To evaluate the efficacy of the Siddha Herbal Drugs “Maha manjishtathi 
kashayam”(Internal), “Chemparuthi poo ennai” (External) & “Deep 
relaxation technique” in management of Thadippu Perunoi (Psoriasis). 
SECONDARY OBJECTIVES: 
o To study the safety profile of trial drug Maha Manjishtathi 
Kashayam(Internal). 
o To discuss the various literature evidences of Thadippu Perunoi 
in Siddha Medicine and Psoriasis in modern science. 
o To Study the Siddha purification method of raw drugs. 
o To get the authentication of the raw drugs. 
o To standardize the standard operating procedure. 
o To Study the physico- chemical analysis of the selected trial drug. 
o To study the acute & sub - acute toxicity of the trial drug Maha 
Manjishtathi Kashayam according to OECD guidelines. 
o To analyze the pharmacological activities of the selected trial drug. 
o To estimate the quantity of heavy metals analysis in the trial drug. 
o To evaluate the safety of the trial drug Maha Manjishtathi Kashayamin 
Psoriasis patients before and after treatment. 
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                        3. LITERATURE REVIEW 
SIDDHA ASPECT OF DISEASE( THADIPPU PERU NOI)[12] 
         The skin diseases are classified as 18 in siddha system of medicine. These 
diseases are commonly classified under Kuttam. They are otherwise known as   
Perunoi, sarma noi, Thol noi.  So the term is used for various skin disease like 
Psoriasis, vitiligo, eczema, Hansen’s  disease , etc. 
 
DEFINITION OF SKIN DISEASES: 
         According to the definition in siddha maruthuvam sirappu, Thadippu peru noi is 
a chronic, non- infectious, recurrent, inflammatory disorder of the skin characterized 
by reddish, slightly elevated patches covered with slivery scales. 
 
AETIOLOGY: 
In the Siddha literature “Thirumular Vaithiyam” Said in 
                 “வியாதியுண் மூவாறு விளங்கிய குட்டங்கேள் 
          சுயாதிக் கிரந்தி சுழன் மேகத்தாலாறும் 
          பயாதி ேண்ணுளப் பலவண்டினா லலட்டும் 
          நியாதிப் புழுநாலாய் நின்றதிக் குட்டகே.”[29] 
    
 3 ததொகுதிேளொே பிரிக்ேப்பட்டுள்ளது அவையொைன,  
➢ கிரந்தி, மேகம் மபான்ற பிணிகளினால் வருபவவ  - 6  
➢ வண்டு மபான்ற உயிரினங்களால் எற்படுபவவ     - 8 
➢ புழு மபான்ற நுண்கிருேிகளால் வருபவவ         - 4 
 
In the Siddha literatures “Guru Naadi Nool” Said in 
ேிருேியொல் ைரும் க ொய்ேள்:[28] 
               “கிருேியால் வந்தமதாடம் லபருக வுண்டு 
                     மகட்கவதின் பிரிவதவனக் கிரே ோக 
               . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
                     மதகேதில் ம ாவகக்குட்டங் கிருேியாமல 
               துருேிவருஞ் சுமராணிதங் கிருேியாமல 
                     சூட் முடன் கிரிவ ப்பால் லதாழில்ல ய் வமீர”. 
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அவையொைன: 
➢ லபாருேல் 
➢ வாய்வு 
➢ புழுக்கடி 
➢ பவுத்திரம் 
➢ ம ாவக 
➢ குட்டம் 
➢ சுக்கிலப்பிரமேகம். 
 
  ேிருேியொல் உண்டொகும் குட்டம் ைரலொறு 
            
      “குட்டேது விடகரப்பான் விடநீர் சூவல 
                   சுமராணிதத்தால் தாதுலகட்டுத் தடிப்புண்டாகும் 
             ேட்டறமே கிருேில ன்று ேருவும் மபாது  
                   வவகயாய்க் கிருேியுட விடநீர் ல ன்று 
             குட்டமுடன் மதகலேல்லாம் பறக்கும் மபாது 
                   குழிகுழியாய்க் கிருேியினகீ் லகாள்ளும் புள்ளி 
             தட்டறமவ கிருேியுட நீரால்வந்த 
                   சேலகுட்டம் விடகரப்பான்  ாற்ற லாமே.” 
 
➢ குன்ேம், கயமநாய், சுரம், பாண்டு, ேலடு, லபருவயிறு, விடகரப்பான், 
விடநீர் சூவல, சுக்கிலநட்டம் இவற்றால் தாதுக்கள் லகட்டுத் 
தடிப்புண்டாகும். 
➢ அதில் கிருேியுண்டாய், கிருேியுட விஷநீர் மதகலேல்லாம் பரவி, 
குழி குழியாய்ப் புள்ளிப்புள்ளியாய்க் கிருேியுட விடநீரால் குட்டம், 
விடகரப்பான் உற்பத்தியாகும். 
 
In the Siddha literatures “THANVANTHIRI VAITHIYAM” Said in   
 
                  குட்டகரொே  ிதொனம்30 
 
        “அறிவின்றி விபரிதஞ் ம ராகாரம் பு ிக்கலாலும் 
         துவறயன்றி லதாடாத லதான்வற லதாட்டவவப் பு ிக்கலாலும் 
          . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 
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         வந்திந்துப் பூருவா ல ன் ோந்திர பாவத்தாலுஞ் 
          ந்திக்கக் கற்புோதர் தங்கவளக் கருதலாலும் 
         லதாந்தித்த குட்டமராகந் லதாடுக்குலேன்றுவரத்தார் முன்மனார்.” 
 
➢ அறிவின்வேயால் ஒன்றுக்லகான்று விமராதோன ஆகாரங்கவள 
லயான்று ம ர்த்துச்  ாப்பிடுதல். 
➢  காரணேின்றி  ாப்பிடக் கூடாதவவகவள  ாப்பிடுதல். 
➢ லபரியார்கவள நிந்தவன ல ய்தல். 
➢  ிமநகிதர்கவளப் பிரித்தல். 
➢ கற்புள்ள ோதர்கவள இச் ிப்பது. 
➢ பூர்வ விவனகளால் குஷ்டம் பிறக்கும். 
 
In the Siddha literatures “AGATHIYAR KANMA KANDAM” Said in   
                   குட்டம் ைரலொறு31 
      “ம ர்ந்தகுட்ட மோடுகுவற மநாய்கள் வந்த 
             ம திகள் ேலராதவரும்பு லகாய்தல் 
        தாரிந்த  ீவல ந்து வவதகள் ல ய்தல் 
             தாய் தந்வத ேனதுலநாந்தது மராகந்தாமன“. 
➢  ீவ ந்துகவள வவத ல ய்தல் 
➢ தாய் தந்வத ேனம் வருந்தச் ல ய்தல் 
இவவகளினால் குட்டமநாய் உண்டாகும் என கூறப்பட்டுள்ளது.  
 
CLASSIFICATION OF KUTTAM: 
 
According to YUGIMUNI Kuttam are 18 types. These are, 
 
                   “முத்தாகும் குட்டந்தான் பதிதனட் டுக்கும் 
                   முனியான யூகியான் ல ால்லக் மகளாய் 
            புத்தாகும் புண்டரீகக் குட்டத் மதாடு 
                     . . . . . . . . . . . . . . . . . . . . . . . . . .  
            துட்டோஞ் சுமவதகுட்டந் தன்மனா லடாக்கச் 
                    சுயம்பான பதிலனட்டுக் குட்ட ோச்ம ”. 
 
அவவயாவன: 
1. புண்டரிகம்  
2. விற்மபாடகம்  
3. பாேம்  
4. கஜ ர்ேம்  
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5. கரணம்  
6.  ிகுரம் 
7. கிருஷ்ணம்  
8. அவுதும்பரம்  
9. ேண்டலம்  
10. அபரி ம்  
11. வி ர்ச் ிகம்  
12. விபாதிகம்  
13. கிடீபம்  
14.  ர்ேதலம்  
15. தத்துரு  
16.  ித்துோ  
17.  தாரு  
18. சுமவதம்  
 
In the Siddha literature “Siddhar Aruvai Maruthuvam” Said in 
 
குற்றத்தின் அளவாக மநாய்எண் [25] 
                      ஏழு 
 
அவவயாவன 
1. வளிக் குட்டம் 
2. அழற் குட்டம் 
3. ஐயக் குட்டம் 
4. வளிஐயக் குட்டம் 
5. வளியழற் குட்டம்  
6. அழல் ஐயக் குட்டம் 
7. முக்குற்றக் குட்டம். 
   1.   வளியின் கீழ்          : கபால குட்டம் 
2. அழலின் கீழ்           : அத்திக்காய்க் குட்டம் 
 
3. ஐயத்தின் கீழ்          : ேண்டலக் குட்டம் 
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           ல ாறிக் குட்டம் 
4. வளியழற் கீழ்         : ேவர நாக்குக் குட்டம் 
5. வளிவயயத்தின் கீழ்   : லவடிப்புக் குட்டம் 
6. அழவலயத்தின் கீழ்   : திேிர்க் குட்டம் 
                      யாவனத்மதால் குட்டம் 
    பன்றித்மதால் குட்டம் 
     புவடக் குட்டம் 
     கூழாங்கற் குட்டம் 
7. முக்குற்றத்தின் கீழ்      : தடிப்புக் குட்டம் 
     மபாவரக் குட்டம் 
     படர்தாேவரக் குட்டம் 
     எரிக்லகாப்புளக் குட்டம் 
      ிரங்குக் குட்டம் 
     பிளப்புக் குட்டம் 
     காகக் குட்டம். 
 
T. V. SAMBASIVAM PILLAI Authors classify this disease only under 8 verities[22], 
They are:   
1. Blisters in feet 
2. Deformity of generative organs 
3. Cutaneous fissures 
4. Elephantiasis 
5. Ulcers 
6. Coppery blotches -  lepra maculosa 
7. Black leprosy – lepra graecorum 
8. White leprosy – lepra mosaic 
சொத்தியம் என கூறப்பட்டுள்ள குட்டங்ேள்15:  
யூேிமுனி கூற்றுப்படி - பத்து 
 
அவையொைன 
1. விற்மபாடகம். 
2. பாேம் 
3. க  ருேம் 
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4. கிருட்டிணம் 
5. அவுதும்பரம் 
6. தத்துரு 
7.  ித்துோ 
8. கிடிபம் 
9.  தாரு 
10.  ருேம். 
According to Yugimuni Thethutru Kuttam (Psoriasis) is curable. 
 
அசொத்தியம் என கூறப்பட்டுள்ள குட்டங்ேள்15: எட்டு 
    அவை 
1. புண்டரிகம் 
2. கரணம் 
3.  ிகுரம் 
4. ேண்டலம் 
5. அபரி ம் 
6. வி ர்ச் ிகம் 
7. விபாதிகம் 
8. சுமவதம். 
                  
 கதத்துரு குட்டம் 
 
            “ ர்ேந்தான் சிைப்பொே ைட்டதணிதுச்  
                   சலவைகபொல் தைளுக்குகே தினவுண்டொகும் 
            கூர்ேந்தான் மராகேது ேிகவுண்டாகும் 
                   ேயிலரல்லாஞ் சுருண்டுமே உண்வடயாகும் 
           கர்ேந்தான் பித்தம  டுேேி குக்கும் 
                   காயந்தான் கதித்துமே திேிருண்டாகும்  
           தர்ேந்தான்  டலேல்லா மூதலாகும் 
                   தாக்கான மதத்திருக் குஷ்டந்தாமன.” 
     
➢ மதாலில் வட்ட வட்டோகப் பவடகவளயுண்டாக்கும்- Coin shaped lesion 
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➢  ிறிது லவளுத்தாற்மபாலக் காணும் - White silvery scales. 
➢  ிவந்து காணும் - Erythematous 
➢ தினவவ உண்டாக்கும் – Itching 
➢ ேயிர்கள் சுருண்டு திரட் ியாகும் – Curling of hair 
➢ அழவலயம் லபருகி உடவலக் கதிக்கச் ல ய்து திேிவர உண்டாக்கும். 
➢ உடவல ஊதச் ல ய்யும். 
In THETHURU KUTTAM nowadays said in siddha system of medicine was 
THADIPPU PERU NOI (Psoriasis)                       
கைறுதபயர்ேள்32: 
➢ லவண்பரு ல தில்மநாய்  
➢ ல தில் உதிர் மநாய் 
➢ காளாயகஞ்  வாதம் 
➢ காளாஞ் க வாதம் 
➢ கிடீப குட்டம் (பன்றிமதால் லபருமநாய்) 
➢ கஜ ருே குட்டம் (யாவனமதால் லபருமநாய்) 
ேொளொஞ்சே ைொதம்: 
     “வாதோேங் கால் வகயிற் குரங்கிரண்டும் வகுத்து ந்து 
               முறுக்கிமய உவடந்து லநாந்து 
       நாதோ நவடதானுந் தான் லகாடாே 
               னலிந்துமே முடோகிக் கரடுகட்டிச் 
       ம தோஞ்  டந்தானு ேிக லவளுத்துத் 
               தினலவாடு  ிரங்கு ோய்ச்  ிமலட்டுே ோகிக் 
       காதோ யரு ிலயாடு ேயக்கோகங் 
                கருதியகா ளாஞ் கோம் வாத ோமே10” 
 
➢ வளி மநாய் எண்பது வவககளில் ஒன்றாகும் 
➢ இந்மநாயில் வக, கால், லதாவட, மூட்டு இவவகளில் பிளப்பது 
மபான்றும், முறுக்குவது மபான்றும், குவடவது மபான்றும், லநாந்து 
நடக்க லவாட்டாேற் ல ய்யும் – Pain present in all joints 
➢ உடல் லேலிந்து,  ந்துகள் மதாறும் முடங்கி, கரடு கட்டிக் லகாள்ளும் - 
Restricted movements. 
➢ நடக்கலவாட்டோற்ச் ல ய்யும் - Difficulty in walking 
➢ உடல் ேிக லவளுக்கும் - Aaenemia  
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➢ தினலவடுக்கும் - Itching  
➢ ல ாறி  ிரங்குண்டாகும் – Pustule 
➢ உடலில் ஐயங்ககூடி சுவவயின்வே, ேயக்கம் முதலியனவும் 
உண்டாக்கும். 
 
க ொய் இயல்12: 
 
        காளாகஞ் கப்பவட புறத்மதாவலயும்,  ளிச் வ்வவயும் பாதிக்கும் 
இயல்புவடயது.    
        புறக்காரணங்களாலும், அகக்காரணங்களாலும் ேிகுந்தும் தனிந்தும் 
ோறி ோறி சுழற் ி முவறயில் ஏற்படும் இயல்புவடய மநாய். 
        ேிகுவதும் குவறவதுோன இயல்புவடய இந்மநாய் எறக்குவறய 12 
வாரங்கள் தீவிர நிவலக்குட்பட்டுப் பின்னர் படிப்படியாகத் தன்னிவலக்கு 
வரும் இயல்புவடய மநாய். 
 
க ொய் பொதிப்பு32: 
 
➢ ேக்கள் லதாவகயில்  ற்மறறக்குவறய 2 முதல் 3  தவிதத்தினர். 
இந்மநாயால் பாதிக்கப் பட்டிருக்கின்றனர். 
➢ இந்திய ேக்கள் லதாவகயில் எறக்குவறய 1 முதல் 5 மகாடி 
ேக்கள் பாதிப்புக்குள்ளாவதாக ேருத்துவச் ல ய்திகள் 
கூறுகின்றன. 
➢ இன,  முதாய, கலாச் ார மவறுபாடின்றி அவனத்து 
ேக்கவளயும் பாதிக்கும் தன்வே உவடயது. 
➢ முன்மனறிய நாடுகளிலும் கூட இமத அளவுக்கு மநாயின் 
தாக்கம் உள்ளலதனப் புள்ளி விவரங்கள் கூறுகின்றன 
➢ 20 லிறுந்து 40 வயதினர் லபரும்பாலும்முதலில் பாதிப்புக்கு 
உள்ளாகின்றனர். 
➢ படீிப்புக்குப் பிறகு குணம் ஆவது குவறவு. 
➢ குணம் கிவடத்தாலும் நீடிப்பதில்வல. 
➢ திரும்பத் திரும்ப வரும். 
➢ 10  தவிதத்தினருக்கு திரும்ப 5 ஆண்டுகள் வராேல் இருக்கிறது. 
➢ ஆண்கவள விட லபண்கள் அதிகோக பாதிக்கப்டுகின்றார்கள். 
➢ பரம்பவர மநாயாக மூவரில் ஒருவருக்கு வருக்கின்றது. 
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➢ கருப்பமுற்றிருக்கிற காலத்தில் குணோவதும் குழந்வத 
பிறந்தபிறகு திரும்பவும் மநாய்வருவதும் உண்டு. 
➢ கால் வா ிப் மபருக்கு நகங்கவளப் பாதிக்கின்றது. 
➢ இப்பிணிக் கண்டவர்களில் 7  தவிதத்தினருக்கு கீல்கவளப் 
பற்றிய  ந்துவாதசூவலயும் உண்டாகின்றது. 
➢ முதல்முவற தாக்கத்திற்க்கு உரிய வயமதா, மவறுக் 
காராணங்கமளா இதுவவர அறியப்படவில்வல.   
க ொய்க்ேொரணம்: 
 
➢ வரும் காரணம்  ரியாக லதரியவில்வல. 
➢ ஒமர குடும்பத்தில் உள்ளவர்களுக்கு மநாய் ஏற்ப்படுவதற்க்குக் 
காரணம் 
➢ வம்  வழி மதாற்றமே என அறியலாம்.  
 
அேத்தியர் பரிபூரணம் 400 ல் ேன்ேக ொவயத் ததொடர்ந்து ைரும்33 
என கூறியுள்ளொர். 
 
         “பழவிவனயால் விஷப்பூச் ி கடித்த மதாஷம் 
               பாதகர்க்கு ஒருநாளும் திர்வ தில்வல. . . . . . . 
          . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
               அவடயாளம் விரல்குறுகு ேின்னங் மகமள”.                         
 
க ொய் ைரும் ைழி32: 
 
➢ ேரபு  ார் மநாயாக இந்மநாய்க் கூறப்படுகிறது. 
➢ தன்விவன 
➢ பழவிவன 
➢ சுற்றுசுழல் பாதிப்பு 
➢ வளி முதலிய தாது ோறுபாடு 
➢ அடிபடுதல் 
➢ மவதியல்  ார்ந்த லதாழில் 
➢ அறுவவ  ிகிச்வ யின் பின்விவளவு 
➢ பூச் ி ேற்றும் இதரப்  பிராணிகளால் ஏற்படும் காயங்கள் 
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➢ தீப்புண்கள் 
➢ அக்கி 
➢ லவண்பவட 
➢ தந்வத தாய் வழியாலும் இந்மநாய் வருவதாக கூறப்படுகிறது. 
 
 க ொவய அதிேப்படுத்தும் ேொரணிேள்2: 
 
➢ சுனதாபிதம் 
➢ புப்பு ப்பிணிகள் 
➢ ஒவ்வாவே 
➢ ேனஉவளச் ல் 
➢ கவவல 
➢ அதிர்ச் ி 
➢ காலோறுபாடுகள் 
➢ மபவதப்லபண்பருவம் 
➢ மபரிளம்லபண்பருவம் 
➢ குழந்வதப்பிறந்தப் பிறகு வரும் என கூறப்பட்டுள்ளது. 
 
க ொவய அதிேப்படுத்தும் ேருந்துேள்12: 
 
➢ வலிக்குன்ேத்திற்குத் தாேிரச்ல ந்தூரம் லகாடுத்தப் மபாது 
வலிக்குன்ேம்   நீங்கி, குணோகி இருந்த காளாகஞ் கப்பவட 
தீவிரேவடக்கிறது. 
➢ இளம்பிள்வளத் தடுப்பு ேருந்தான குமளாமராகுயின் 
குருக்கவளயும், பவடவயயும் உண்டுபண்ணுகிற்து. 
 
க ொயின் முற்குறி32: 
                 எவ்விதோன முற்குறிகளும் மதான்றுவதில்வல,ஆயினும் 
திரும்பத் திரும்ப தாக்கக்கூடிய இயல்புள்ள முற்குறியாக  ிறு  ிறு புள்ளிகள் 
மதான்றி, அவவ பின்னர் விரிவவடந்து லபருகும். 
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க ொயின் குறிகுணங்ேள்12: 
 
➢ மதால்  ிவந்து ல ந்நிறப் பருக்கள் மதகமேங்கும் பவடமபால் 
பரவுதல். 
➢ தடித்தல். 
➢ லேன்வேயும், லவண்வேயும், பளபளப்பும் உவடய ல தில்களால் 
மூடப்பட்டிருக்கும். 
➢ மதால் உரிதல் 
➢ கனத்தல் 
➢ தினலவடுத்தல் 
➢ திடீர் என உடல் லவப்பம் குவறவது மபால நடுக்கம் 
➢ ல தில்கள்கவளச் ல ாறிய இரத்தக்க ிவு ஏற்ப்படும் 
➢ பவட உண்டாம் இடங்களும் பவடயின் உருவங்களும், அளவும், 
வடிவமும் மவறுபடுவதுண்டு 
➢  ிறுவர்களில் நீர்துளிகள் மபால் உடலிலும் அவயங்களிலும் 
ஏற்படுவதுண்டு. 
➢ தவலயிலும்  ில ேயம் முகத்திலும் குருக்கள் உண்டாகும். 
நாட்பட்டுவிட்டால் ல தில்கள் முழங்கால்களிலும், 
முழங்வககளிலும் காணும். 
➢  ிலருக்கு உள்ளங்வககளிலும், பாதங்களிலும் மதால் கனத்து 
லவடித்துச் ல தில்கள் மதான்றும். 
➢ உடல் முழுவதும் பாதிக்கப்பட்டு ல தில்கள் அதிக அளவில் 
உதிர்ந்து  ிவந்து காண்பதும் உண்டு. 
➢ நாணயங்கள் மபான்ற வடிவத்வதவுவடய பவடகள் காணப்படும். 
➢ கிருேிகளற்ற  ீழ்க் லகாப்புளங்களும் மதான்றும் பவடகள் 
வட்டங்களாகவும், நீளோகவும் காட் ியளிப்பதுண்டு. 
➢ லபண்களுக்கு அக்குள், லதாவடேடிப்பு, லதாப்புள் இவ்விடங்களில் 
ஏற்ப்பட்டால் நீர்க ிவு எற்படுவதுண்டு. 
➢  ிலமநரம் காய்ச் ல் காணும். 
➢ மநாயுற்றப் பகுதி குறிப்பாகப் பாதங்களின் மூட்டுப் பகுதிகள், 
ேற்றும் மதாள்கள், வகயின் புறப்பக்கம் ஆகிய இடங்களில் வகீ்கம் 
உண்டாதல். 
➢ உறக்கம் லகடல். 
➢ ேனஉவளச் ல். 
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➢ அயர்வு 
➢ உணவில் விருப்பேின்வே. 
➢ மநாய் முற்றிய நிவலயில் லவறுப்பு. 
➢ தனிவேவய விரும்புதல். 
➢ தற்லகாவல முயற் ியில்  ிலர் இடுபடுவர் உளத்லதாடர்பான 
நிகழ்வுகளும் எற்படும்.  
 
 ொடி  வட34: 
 
     பிணிேளின் முதற் ேொரணத்தில் கதவரயர்: 
 
                 “ைொதேலொது கேனிதேடொது” 
 
            மதஜஸ் (மதகத்தின் ஒளி) என்னும் அழகும், வன்வேயும் 
லகடுவதற்கு முக்கியோன முதற்காரணம் வளிக்குற்றமேயாகும். 
            வளித் தாதுவும் அவதத் லதாடர்ந்து ஐயத் தாதுவும் தன்னிவலக் 
லகட்டு குறிப்பாகத் மதாலுக்குறிய உதானன், மதவதத்தன் எனும் வாயுக்கள் 
மதாலில் லபரும் ோற்றங்கவளத் மதாற்றுவிக்கின்றன. 
            ஏழு உடற்கட்டுகளில், முதற்கட்டோக லேய்லகட்டுப் பின்னர் 
ேற்ற உடற்கட்டுகளும் மகடவடயும். 
            லேய் நீங்கலாக ஏவனய உடற்கட்டுகள் குவறந்த அளமவ 
மகடவடவதால் இந்மநாய் தீவிர நிவலக்கு ஆட்படுவதில்வல. 
           மநாய் ேிகு நிவலயில் அபானன் ேற்றும் வியானன் மகடவடயும். 
 
DIET RESTRICTION (PATTHIYAM)12: 
1. Fish, crab, prawn are some sea foods should be avoided. 
2. Curd, Jaggery, oil, White gram should be avoided. 
3. Non vegetarian diet should be avoided.  
4. Alcohol beverages should be avoided. 
5. Brinjal should be avoided. 
6. In severe cases tamarind should be avoided. 
7. Dietary taken salt in minimum quantities. 
 
 17 
 
2018 LITERATURE REVIEW 
 
MODERN LITERATURE REVIEW 
 
                                ANATOMY OF SKIN[1]  
 
The skin is the protective covering of the body, Skin which covers the entire surfaceof 
the human body. The human skin shows 2 wide variations in structure. 
1. Thick skin found in Scalp 
Ear lobes 
Palms 
Soles 
2. Thin skin over the rest of the body. 
The average thickness of the skin is about 1 to 2 mm. In the sole of the foot, palm of 
the hand and in the inter scapular region, it is considerably thick measuring about 5 
mm. Skin is very thinnest in eyelids and penis measuring about 0.5mm only. 
 
The skin is composed of a 
Superficial epithelial layer – The epidermis 
Connective tissue layer – The dermis or Corium 
Another Connective tissue layer loose in texture – The hypodermis or subcutaneous 
layer. 
 
Fig :3.1 Human skin  
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STRUCTURE OF EPIDERMIS: 
The epidermis is formed of nonvascular stratified epithelium. The average thickness 
of the skin is between 0.07 mm to0.12 mm. Certain parts like the soles of the feet and 
the palms of the hands it isvery thick ranging from 0.8mm to1.4mm. 
Squamous epithelium is 10 to 11 cells thick in the palms and soles. Squamous 
epithelium is 3 to 4 cells over the eyelids. The nutrition is provided to epidermis by 
the capillaries of dermis. 
 
The epidermis is mainly divided into two main systems, 
1. Malpighian system which forms the bulk (Keratinocytes) 
2. Pigmentary system which produce pigment ( Melanocytes) in addition of four types 
of cells.  
These are 
1. Keratinocytes 
2. Melanocytes 
3. Langerhans cell 
4. Intermittent cells 
In the epidermis, another unique cell known as Markel cell or Haascheiben or Touch 
cells here found at the base of epidermal ridges, which are in contact with nerve 
fibers, they are mostly present in palms, soles, nail beds, oral and genital epithelium, 
and act as slow touch receptors. 
 
LAYERS OF EPIDERMIS: 
Epidermis layer can be made out microscopically in a section of perpendicular to the 
skin surfaces, the following 5 main layers of the epidermis. 
These are 
1. Stratum germinatum 
2. Stratum malpighii 
3. Stratum granulosum 
4. Stratum lucidum 
5. Stratum corneum. 
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SRATUM GERMINATUM: 
This is the deepest potion of the epidermis and it is composed of columnar cells 
placed perpendicular to the skin surface, it is also known as basal cell layer. The 
whole of the epidermis germinates from this stratum hence the name “Stratum 
Germinatum” Any trauma to this layer would result in scarring, trauma above the 
level of this layer heals without scarring. Melanoblasts or melanocytes are found in 
this layer. Stratum Germinatum contain granules of pigment called melanin. 
 
STRATUM SPINOSUM: 
It is also known as stratum malpighii or the prickle cell layer. It issuperficial to the 
basal cell layer. It is composed of several layers of polyhedral cells connected to each 
other by intercellular bridges. Desmosomes present in this layer only. Half size 
desmosomes occur on the under surface on the under surfaceof the basal cells, which 
play an important part in the anchoring the epidermisand dermis. All keratinocytes 
adhere together by desmosomes. 
 
STRATUM GRANULOSUM: 
It is superficial to the stratum malpighii. It is composed of flat, fusiform cells which 
are one to three layers thick, the. Cells contain irregular granules of keratohyalin and 
lysosomal enzymes and cystine richproteins. Lamellar granules also known as odland 
bodies. These odland bodies take part in the waterproof barrier function of the 
epidermal permeability. 
 
STRATUM LUCIDUM: 
Superficial to the stratum granulosum. It is pale, wavy looking layer known as stratum 
iucidum. It is made up of many layers of flattened epithelial cells. This layer contains 
refractile droplets of eleidin. 
 
STRATUM CORNEUM: 
This is the most superficial layer, the outer surface of which is exposed to the 
atmosphere. It is also known as horny layer. It is outer most layers and consists of 
dead cells, which are called as corneocytes. It consists of many layers of 
nonnucleated, flattened, cornfield cells. It is this layer which becomes thicker with the 
application of intermittent mechanical pressure. This layer is thickest in the palms of 
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the hands and the soles of the feet, but thinnest on the outer surface of the lips, on the 
glans penis and the eyes. 
 
DENDRITIC CELLS OF EPIDERMIS: 
These are melanocytes, Langerhans cells, and indeterminate cells. The melanocytes 
are the pigment producing cells and are derived in foetal life from neural crest. The 
cells of langherhans are found about the middle of epidermis. The junction of 
epidermis and dermis is formed by basement membrane(Basallamina). 
 
DERMIS: (CUTIS VERA OR CORIUM) 
Dermis is profusely supplied with blood vessels, Thickness of dermis is 1 to 3mm, it 
is made up of dense collagen fibers and fibroblasts. The collagen fibers contain the 
enzyme collagenase which is responsible for wound healing. 
 
Dermis is made up of 2 layer, these are 
1. Superficial papillary layer 
2. Deeper reticular layer 
 
1. SUPERFICIAL PAPILLARY LAYER: 
The layer projects in to the epidermis, it contains blood vessels, lymphatics and nerve 
fibers. Dermal papillae are finger like projections arising from the superficial 
papillary dermis. 
 
2. DEEPER RETICULAR LAYER: 
It is made up of reticular and elastic fibers. It is found around the hair, sweat glands 
and sebaceous glands.It also contain mast cells, Nerve ending, lymphatics and 
fibroblasts. 
APPENDAGES OF THE SKIN: 
The appendages of the skin are five these are, 
1. Sweat gland 
2. Sebaceous gland 
3. Hair 
4. Arrector pili muscle 
5. Nails. 
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1. SWEAT GLAND: 
  These are 2 types 
i. Eccrine gland 
ii. Apocrine gland 
 
i. ECCRINE GLAND: 
      They are the ordinary, small sized 0.3 mm to 0.4 mm. Sweat glands are distributed 
all over the skin except on the beds of nail, margins of lips and the glans penis. Over 3 
million sweat gland presents at birth. 
 
ii. APOCRINE GLAND: 
Glandular portion is very large and may measure 3 mm to 5 mm in diameter. They 
occur in the axilla, areola and nipples of breasts, umbilicus, around the anus and the 
genitalia. They are specialized sweat glands, and their secretion is odoriferous with 
secondary sexual significance. 
 
2. SEBACEOUS GLAND: 
They are scattered all over the integument in association with the hair follicles. They 
are absent from the hairless portions of the body like the palms of the hands, the soles 
of the feet. The ducts of the sebaceous glands are lined by stratified squamous 
epithelium which is continuous with the external sheath of the hair, and with the 
malpighian layer of epidermis. 
3. HAIR: 
Hair is fund on almost every part of the body surface except on the palms, soles, the 
dorsal surface of the terminal phalanges, the inner surface of the labia, the inner 
surface of the prepuce and the glans penis. Hairs differ in length, thickness and colour 
in different parts of the body and in different races. There are three types of hair, long, 
short, thick bristles. Hair grows about 1-2 cm per month. Hair follicle and its hair can 
be anatomically divided in to 3 segments 
• Infundibulam 
• Isthumus 
• Inferior 
 22 
 
2018 LITERATURE REVIEW 
 
4. ARRECTOR PILI: 
Arrector pili muscles are the small bundles of plain muscles fibers, which is extend 
from the connective tissue sheath of the hair follicles to the epidermodermal junction. 
When these contracts under the effect of cold or emotions. They move the hair into a 
more vertical portion is called appearance of “ghoose flesh”. 
 
5. NAILS: 
These are semi transparent, plate like horny structure, covering the dorsal surfaces of 
the distal phalanges of the fingers and toes. Nail parts are : 
• Root 
• Nail plate 
• Nail bed 
• Lunula 
• Lateral and posterior nail fold 
The blood supply of the skin originates from the large number of arteries forming 
anastomosis in the deepest part of the dermis. From the single vessels run upwards 
and form a second network in the upper dermis. Finally, terminal arterioles ascend in 
to the papillae ending in capillary loops, which drain into connective venules. The 
blood is returned to the large veins in the subcutaneous tissues. 
 
LYMPHATICS OF THE SKIN : 
The skin contains a rich network of lymphatics which drains in to a larger vessel in 
the hypodermis. 
 
NERVE SUPPLY OF SKIN : 
The nerve supply of the skin consists of a motor sympathetic portion derived from the 
sympathetic ganglia. Sensory spinal portion arising from the dorsal root ganglia. 
 
PHYSIOLOGY OF SKIN: 
The skin performs a multiple of functions, though the primary function of skin is the 
protection of organs, it has many other important functions. 
These are 
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1. Protective function 
2. Sensory function 
3. Storage function 
4. Synthetic function 
5. Regulation of body temperature 
6. Regulation of water and electrolyte balance 
7. Excretory function 
8. Absorptive function 
9. Secretary function 
10. Gaseous exchange 
 
1. PROTECTIVE FUNCTION: 
Skin forms the covering of all organs of the body and protects these organs 
from the 
following factors: 
• Bacteria and toxic substances 
• Mechanical flow 
• Ultraviolet rays 
 
2. SENSORY FUNCTION: 
Skin is considered as the largest sense organs in the body. It has many nerve endings, 
which form the specialized cutaneous receptors. These receptors are stimulated by the 
sensations of touch, pain, pressure or temperature sensation and convey these 
sensations to the brain via afferent nerves. 
 
3. STORAGE FUNCTION: 
Skin stores fat, waters, chlorides and sugar. It can also store blood by the dilatation of 
the cutaneous blood vessels. 
 
4. SYNTHETIC FUNCTION: 
Vitamin D3 is synthesized in skin by the action of ultraviolet rays on cholesterol. 
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5. REGULATION OF BODY TEMPERATURE: 
Skin plays an important role in the regulation of body temperature. Excess heat is lost 
from body through skin by radiation, conduction and evaporation. 
 
6. REGULATION OF WATER AND ELECTROLYTE BALANCE: 
Skin regulates water balance and electrolyte balance by excreting water and salts 
through sweat. 
 
7. EXCRETORY FUNCTION: 
Skin can excrete small quantities of waste materials like urea, salts and fatty 
substances. 
 
8. ABSORPTIVE FUNCTION: 
Skin can absorb the fat soluble substances and some ointments. 
 
9. SECRETORY FUNCTION: 
Skin regulates sweat through sweat glands and sebum through sebaceous glands. 
Sebum keeps the skin smooth and moist. 
 
10. GASEOUS EXCHANGE: 
A small amount of gaseous exchange through the skin. 
 
 
PSORIASIS 
DEFINITION: 
 
The word psoriasis is derived from the Greek word “PSORA” meaning 
“ITCH” or“RASH”. The name psoriasis was given by the Viennese dermatologist 
Von Hebra. 
Psoriasis is a common, non-contagious and chronic skin disease characterized 
by well defined slightly raised, dry erythematous macules with silvery Scales, and 
typical extensor distribution.It commonly causes red scaly patches to appear on the 
skin. The scaly patches caused by psoriasis, called plaques, are areas of inflammation 
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and excessive skin production. Skin rapidly accumulates at these sites and takes a 
silvery-white appearance. Plaques frequently occur on the skin of the elbows and 
knees, but can affect any area including the scalp and genitals. 
Psoriasis is an inflammatory skin disease in which skin cells replicate at an 
extremely rapid rate. New skin cells are produced about eight times faster than 
normal--over several days instead of a month--but the rate at which old cells slough 
off is unchanged. This causes cells to build up on the skin's surface, forming thick 
patches, or plaques, of red sores (lesions) covered with flaky, silvery-white dead skin 
cells (scales). 
 
Fig :3.2, Psoriasis Image 
 
 
 
PREVALANCE:[2] 
 
1. It affects 0.6%-4.8% of people worldwide.  
2. Men and women are equally affected. 
3. It is pandemic in temperate climate. First peak of onset between 20-30 yrs. 
4. Second peak of onset between 50-60 yrs. 
5. 1,50,000-2,60,000 new cases of psoriasis are diagnosed each year. 
6. About 400 people die from complications caused by psoriasis every year. 
7. About 11% patients have psoriatic arthritis. 
8. Plaque type is most common in 80% of psoriasis patients. 
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AETIOLOGY: 
 
1. The exact cause is unknown- Autoimmune Disease 
2. Stress 
3. Hormonal imbalance 
4. Septic focus 
5. Allergy 
6. Anxiety states 
7. Lowered response of the cyclic AMP system to prostaglandin E1 in epidermis 
8. Mental trauma 
9. Fever 
10. Digestive upsets 
11. Physical injury: 
Scratches 
Surgical incisions and injuries 
12. Infection: 
ß - Hemolytic streptococcal infection- precipitates guttatelesions. 
HIV infection-Explosive psoriasis. 
13. Herido familial and Genetic factors: 
Increased in familial cases 
Increased association of HLA- CW6 20 times increased risk with early onset of 
psoriasis 
 
PATHOGENESIS OF PSORIASIS: 
Fig no:3.3  
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Psoriasis appears to be largely a disorder of keratinization 
 The basic defect is rapid replacement of epidermis in psoriatic lesion.3 to 4days 
instead of 28 days in normal skin. 
 
There are marked vascular changes in upper dermis in the form of Recently 
the presence of abnormal neural cells has been demonstrated in Psoriatic plaques. 
Psoriasis was long considered either a disorder of keratinocytes growth or a chronic 
inflammation.  
Advancement in immunologic techniques and in genetic analyses has resulted 
in a reappraisal of the pathophysiology involved. 
  Psoriasis consider as an organ specific autoimmune disease that is triggered by 
an activated cellular immune system and it similar to other immune mediated 
disease.The definition of autoimmune disease as “a clinical syndrome caused by the 
activation of T cells and B cells, or both, in the absence of an ongoing infection or 
other discernable cause”. 
Pathogenesis of psoriasis still poses a challenge to the scientific community to 
once and for all, establish how and why it occurs and consequently to develop the 
magic drug to treat it. Psoriasis is an immunological disease, characterized by 
interplay of 
• Immunological factors. 
• Cellular components. 
• Signaling molecules. 
• Biochemical changes. 
• Histological changes. 
These are plays major role in pathogenesis. 
I.IMMUNOLOGICAL F ACTORS IN PSORIASIS:10 
Both innate or acquired immune changes are thought be responsible for the 
development of psoriatic plaques different types of helper T subsets, dendritic cells, 
plasmacytoid dendritic cells as well as Langerhans cells have been found to play a 
role in psoriasis. T cells plays important role in psoriasis autoimmunity as a major 
factor in pathogenesis. The presence of T cells in the inflammatory infiltrate in 
psoriatic plaque obviously Indicated in immune mediated or an autoimmune basis for 
the Pathogenesis of psoriasis. 
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II.CELLULAR COMPONENTS IN PATHOGENESIS OF PSORIASIS: 
Cellular components are: 
a) T cells 
b) Keratinocytes 
c) Langerhans 
 
A. T CELLS: 
T cells play a key role, with the epidermal T cells being CD8+ & Dermal cells 
being CD4+.These cells include memory T cells, natural killer cells T cells& Th17& 
Th22. Th17& Th22 cells which are subsets of CD4+ cells are now considered 
important in pathogenesis of the psoriatic plaque. They are stimulated by IL-23 & 
respectively produce IL-17& IL-22 which mediate dermal inflammation and 
epidermal hyperplasia. 
 
B. KERATINOCYTES: 
Keratinocytes cells express transcription factor STAT- 3, which may be pathogenic. 
 
C. LANGERHANS CELLS: 
Langherhans cellssecrete cytokines, which are mitogenic and chemotatic. 
 
III.SIGNALLING MOLECULES IN PATHOGENESIS OF PSORIASIS: 
Include cytokines growth factors like interleukins, Chemokines, Interferon’s 
and their respective receptors. Characterized by up regulation of Th1 cytokines and 
reduction of anti inflammatory cytokines IL-10.Other important molecules include 
TNF-a, IL-15, IL-17, IL-22 and IL-23. 
 
IV.BIOCHEMICAL PSORIASIS: 
Cyclic nucleotide increased levels in cGMP or decreased levels of 
Arachidonic acid level is increased and it metabolites. 
Polyamines also increased in levels. 
PROTEINASE: increased in levels of plasminogen activator and their inhibitors. 
Calmodulin also increased in levels. 
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V.HISTOLOGICALPSORIASISCHANGES IN PATHOGENESIS 
Epidermal changes is increased epidermal proliferation in two ways, One is 
increased growth fraction from normal of 30 to 100% in psoriasis.2nd is shortened 
epidermal turn over time from normal of 60 to10 days in psoriasis.Important changes 
seen in dermal layer.Include dilated and tortuous capillary loops and proliferation of 
fibroblasts.Secondary lichenification present Scalp is involved almost all casesNo 
matting of hair 
 
MOST COMMON SITES AREAS COMMONLY AFFECTED: 
• Scalp 
• Back of elbows 
• Front of knees and legs 
• Lower part of the back of the trunk 
MAY ALSO BE AFFECTED: 
• Nail 
• Sole 
• Palm 
 
RARELY AFFECTED: 
Mucus membrane. 
 
CLINICAL FEATURS OF PSORIASIS: 
 
➢ Typical distribution is extensor 
➢ Lesions are bilaterally symmetrical 
➢ Typical coin shaped lesion 
➢ Big plaques of the size of palm of the hand 
➢ The lesions are slightly raised above the surface of skin 
➢ Absence of itching 
➢ But itching present in tropical countries 
➢ Slight or moderate purities present 
➢ Secondary psychogenic stress present 
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IMPORTANT SIGNS OF PSORIASIS: 
 
1. Candle greeze sign. 
2. Auspitz sign. 
3. Koebner’s phenomenon. 
 
1. CANDLE GREEZE SIGN ( Tache de bouge) : 
Psoriatic lesion is scratched with the point of a dissecting forceps a candle 
greeze like scale can be repeatedly produced even from the non-scaling lesions this is 
called candle greeze sign (Tache de bouge) 
 
2. AUSPITZ SIGN: 
The complete removal of scale produces pin point bleeding. There are 3 steps 
to this test: 
STEP 1: Gently scrape lesion with a glass slide. This accentuates the silvery scales 
(GRATTAGE TEST POSITIVE) scrape off all the scales. 
STEP 2: As you continue to scrape the lesion, a glistening, white adherent membrane 
(BERKLEY’S MEMBRANE) appears. 
STEP 3: On removing the membrane, punctuate bleeding points become visible, this 
is positive AUSPITZ SIGN. 
 
 3. KOBNER’S PHENOMENON: 
Psoriatic lesions may develop along the scratch lines in the active phase this is 
called Koebner’s phenomenon. 
 
TYPES OF PSORIASIS : 
 
❖ Plaque Psoriasis 
❖ Nail Psoriasis 
❖ Guttate Psoriasis 
❖ Inverse Psoriasis 
❖ Pustular Psoriasis 
❖ Erythrodermic Psoriasis 
❖ Psoriatic Arthritis 
 31 
 
2018 LITERATURE REVIEW 
 
 
PLAQUE PSORIASIS: 
The most common form, palque psoriasis causes dry, raised, red skin 
lesions(plaque) covered with silvery scales. The plaques might be few or itchy or 
painful and there may be few or many. They can occur anywhere on your body, 
including your genitals and the soft tissue your mouth. 
 
Fig :3.4 , Plaque psoriasis 
 
 
 
NAIL PSORIASIS: 
Psoriasis can affect fingernails and toenails, causing pitting, abnormal nail 
growth and discoloration. Psoriatic nails might loosen and separate from the nail bed. 
Severe cases may causes the nail to crumble. 
Fig no:3.5, Nail Psoriasis 
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GUTTATE PSORIASIS: 
This type primarily affects young adults and children. Its usually triggered by 
a bacterial infection such as strep throat. Its marked by small, water-drop-shaped, 
scaling lesions on your trunk, arms, leg and scalp. You may have a single outbreak 
that goes away on its own, or you may have repeated episodes. 
Fig no:3.7, Guttae Psoriasis 
 
 
 
INVERSE PSORIASIS: 
This mainly affects the skin in the armpits, in the groin, under the breasts and 
around the genitals. Inverse psoriasis causes smooth patches of red, inflamed skin that 
worsen with friction and sweating. Fungal infection may trigger this type of psoriasis. 
Fig no:3.8, Inverse Psoriasis 
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PUSTULAR PSORIASIS: 
This uncommon form of psoriasis can occur in wide spread 
patches(generalized pustular psoriasis) or in smaller areas on your hands, feet or 
fingertips. It generally develops quickly,with pus-filled blisters appearing just hours 
after your skin becomes red and tender. The blisters may come and go 
frequently.Generalized pustular psoriasis can also cause fever, chills, severe itching 
and diarrhea. 
Fig no:3.9,Pustular Poriasis 
 
 
 
ERYTHRODERMIC PSORIASIS: 
The least common type of psoriasis, erythrodermic psoriasis can cover your entire 
body with a red, peeling rash that can itch or burn intensely. 
Fig no:3.10, Erythrodermic Psoriasis 
 
 
PSORIATIC ARTHRITIS: 
In addition to inflamed, scaly skin, psoriatic arthritis causes swollen, painful 
joints that are typical of arthritis. Sometimes the joint symptoms are the first or only 
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manifestation of psoriasis or at times only nail changes are seen. Symptoms range 
from mild to severe and psoriatic arthritis can affects any joint. Although the disease 
usually is not as crippling as other forms of arthritis, it can cause stiffness and 
progressive joint damage that in the most serious cases may lead to permanent 
deformity. 
FIG NO:3.11, Psoriatic Arthritis 
 
 
COMPLICATIONS: 
Psoriatic arthritis: 
This complication of psoriasis can cause joint damage and a loss of function in 
some joints, which can be debilitating. 
Eye conditions:  
Certain eye disorders-such as conjunctivitis, blepharitis and uveitis-are more 
common in people with psoriasis. 
Obesity: 
People with psoriasis especially those with more severe disease, are more 
likely to be obese. It’s not clear that these diseases are linked, however. The 
inflammation linked to obesity may play a role in the development of psoriasis. Or it 
may be that people with psoriasis are more likely to gain weight, possibly because 
they are less active because of psoriasis. 
Type 2 diabetes: 
The risk of type 2 diabetes raises in people with psoriasis. The more severe the 
psoriasis, the greater the likelihood of type two diabetes. 
High blood pressure: 
The odds of having high blood pressure are higher for people with psoriasis. 
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Cardiovascular disease: 
For people with psoriasis, the risk of cardiovascular disease is twice as high as 
it is for those without the disease. Psoriasis and some treatments also increase the risk 
of irregular heartbeat, stroke, high cholesterol and atherosclerosis. 
Metabolic syndrome: 
This cluster of conditions-including high blood pressure, elevated insulin 
levels and abnormal cholesterol levels-increases your risk of heart disease. 
Other autoimmune diseases: 
Celiac disease, sclerosis and the inflammatory bowel disease called crohn’s 
disease are more likely to strike people with psoriasis. 
Parkinson’s disease: 
This chronic neurological condion in more likely to occur in people with 
psoriasis. 
Kidney disease: 
Moderate to severe psoriasis has been linked to a higher risk of kidney disease. 
Emotional problems: 
Psoriasis can also affect your quality of life. Psoriasis is associated with low 
self-esteem and depressions. You may also withdraw socially. 
 
DIFFERENTIAL DIAGNOSIS OF PSORIASIS: 
1.ECZEMA  
Distribution: Face/ Flexures 
Morphology: poorly defined erythema and scaling lichenification. 
 
2. SEBORRHOEIC DERMATITIS 
Scalp, axilla, sterna Scalp patches are diffuse, region ill-defined and moist, 
hair is matted with crust. 
 
3.PITYRIASIS ROSEA 
“Fire tree pattern” on Well-defined erythematous torso papules and plaques 
with scales. 
 
4.DRUG ERUPTION 
Wide spread, Maculopapular, erythematous scaly areas which merge and are 
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followed by exfoliation. 
 
5.PITYRIASIS VERSICOLOR 
Upper torso and Hypo and hyper pigmented scaly patches upper shoulders 
 
6.LICHEN PLANUS 
Distal limbs, Shiny, flatopped violaceous especially wrists and papules with 
Wickham’s lower back striae. 
 
7.TINEA CORPORIS 
Asymmetrical, often Scalyplaques which expand isolated, lesions red scaly 
with central healing. 
 
LAB INVESTIGATION OF PSORIASIS : 
Skin biopsy shows the following as 
 
EPIDERMAL CHANGES: 
• Parakeratosis 
• Loss of granular layer and regular acanthosis 
• Supra papillary thickening 
• Collection of polymorphs in the epidermis to form spongiform pustuleof kogoj 
and Munro’s micro abscess seen in epidermis. 
DERMAL CHANGES: 
• Dilatation and tortuosity of capillary loops in the dermal papillae 
• Lymphocytic infiltrate in the upper dermis is seen. 
HISTOLOGICAL CHANGES: 
• Thinning of supra papillary portion of stratum malpinghii 
• Elongation of ridges 
• Oedema and clubbing of papillae seen in histological study. 
HISTOCHEMICAL CHANGES: 
Histochemical studies have revealed an increase in both oxidative and 
anaerobic metabolism with increased pentose, glycon, purines, sulphydral groups, 
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soluble proteins increased in level. Decreased in activity of dipeptidases. It has been 
discovered that apparently normal skin of both the psoriatics and their relations show 
these changes in miniature is called latent psoriasis. 
 
RADIOLOGICAL CHANGES: 
Simultaneous presence of ankylosis, periosteal new bone formation, erosions 
and osteolytis are strongly suggestive of psoriatic arthritis. 
 
TREATMENT OF PSORIASIS PATIENTS : 
Depending on the type of psoriasis, various therapeutic options are available 
• Topical agents like liquid paraffin, petroleum gel, vegetable oils etc. 
• Systemic agents like Methotrexate, Acitretin, and Cyclosporine. 
• Corticosteroids mostly in cream base. 
• Photochemotherphy and phototherapy in PUVA methods. 
• Biological response modifiers used in treatment of psoriasis. 
DIET FOR PSORIASIS PATIENTS: 
TO TAKE: 
1. All green leafy vegetables. 
2. Low consumption of animal fats and the quantity of food. 
3. High protein diet 
4. Fish and sea foods 
5. Carrot 
6. Tomatoes 
7. Grains. 
 
TO AVOID: 
1. Oil foods. 
2. High fat diet 
3. Alcohol 
4. Junk foods 
5. Red meat 
6. Dairy products 
7. Night shade vegetables 
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8. Citrus fruits 
9. Gluten protein in diet 
10. Condiments. 
 
PROGNOSIS: 
A permanent cure is not yet known individual attacks can, almost always 
controlled satisfactorily disease non-infectious the disease does not leave scar 
Flexural, erythrodermic and pustular psoriasis take longer to heal than the typical 
variety the palmar and nail lesions are rather resistant to treatment. Patient suffer from 
the disease on and off throughout their lives. Complications in psoriasis are 
infrequent. 
 
MANAGEMENT: 
The general health of the patient should be maintained. The patient’s life 
should be regulated so that no undue stress affects either body (or) mind. A moderate, 
warm climate, frequent sunbaths before the onset of the winter, and visits to Sulphur 
springs, all of which are useful in bringing down the relapse rate. Natural Sulphur 
baths should be taken during the holidays, especially in the winter season. 
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                               TRIAL DRUG REVIEW 
 
MANJITTI:4 
 
GENERAL PROPERTIES OF MANJITTI: 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Dicotyledons 
SUBCLASS Eudicots 
ORDER Gentianales 
FAMILY Rubiaceae 
GENUS Rubia 
SPECIES R.cordifolia 
BOTANICAL 
NAME 
Rubia cordifolia 
ENGLISH NAME Indian madder 
CHEMICAL 
CONSTITUENT 
purpurin (trihydroxy anthraquinone), munjistin 
(xanthopurpurin-2-carboxylic acid), peudopurpurin 
(purpurin-3-carboxylic acid) and free alizarin and glucoside. 
PART USED Root bark 
ACTION Anti-oxidant17, Immunomodulator, Anti-psoriatic agent. 
SUVAI-THANMAI-
PIRIVU 
Karppu and kaipu – Veppam – Karppu 
USES Psoriasis, Kustam (Skin disease), Herpes virus (Akki), 
Hemorrhoids. 
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2. KADUKAI THOL              
கடுக்கோய்நதோ ் ச ோதுகுணம்: 
“தாவட கழுத்தக்கி தாலு குறியிவிடப் 
பவீட  ிலிபதமுற் மபதிமுடம் ஆவடலயட்டாத் 
தூலேிடி புண்வாதம ாணி காோவல யிரண் 
டால ேிடிமபாம் வரிக்காயால்” 
 
GENERAL PROPERTIES OFKADUKAI THOL: 
KINGDOM Plantae 
DIVISION     Angiosperm 
CLASS Eudicots 
SUBCLASS Rosids 
ORDER Myrtales 
FAMILY Combretaceae 
GENUS Terminalia 
SPECIES T.chebula 
BOTANICAL NAME Terminalia chebula 
ENGLISH NAME Ink nut 
CHEMICAL 
CONSTITUENT 
 Gallic acid, Chebulagic acid, Chebulinic acid, Tri terpenoid 
glycoside. 
PART USED Fruit 
ACTION Astringent, Anti-oxidant, Blood purifier, Anti-fungal, 
Immunomodulator18. 
SUVAI-THANMAI-
PIRIVU 
Thuvarppu, inippu, pulippu, karppu, Kaippu – 
Thatpam – Inippu 
USES Chronic ulceration, Ulcerated wounds. 
 
3.THANDRIKAI 
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 “சிலந்தி விடம்காமியப்புண் சீழான மமகங் 
கலந்துவரும் வாதபித்தங் காமலாட லரந்்துடலில் 
ஊன்றிக்காய் வவப்ப முதிரபித்துங் கரக்கும் 
தான்றி ககயிவலடுத்தால்” 
 
GENERAL PROPERTIES OF THANDRIKAI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicot 
SUBCLASS 
 
Rosids 
ORDER 
 
Myrtales 
FAMILY 
 
Combretaceae 
GENUS 
 
Terminalia 
SPECIES 
 
T.bellarica 
BOTANICAL NAME 
 
Terminalia bellarica 
ENGLISH NAME 
 
Indian Myrobalan 
PARTS USED 
 
Leaf, fruit and seed. 
CHEMICAL CONSTITUENT 
 
Beta sistosterol, Gallic acid, Ellagic acid. 
ACTION 
 
Astrigent, Immunomodulator16. 
SUVAI- THANMAI- PIRIVU 
 
Thuvarppu – Veppam – Inippu 
USES               
 
This herb is beneficial for skin disease 
and premature growing of hair . 
                                
 
 
 
4.NELLIMULLI: 
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                ஆகவனலஞ்சசி அசிரக்்வகன் புருக்கி கண்மணாய் 
                தாகமுதிர வித்தந் தாதுநீஷ்டம்  மமகனத்தின் 
   இல்லிமுள்ளி மபாலருகல் எண்காமியங்கல் 
   வநல்லிமுள்ளி யாற்மபா நிகன “ 
 
GENERAL PROPERTIES OF NELLIMULLI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperm 
CLASS 
 
Eudicots 
SUBCLASS 
 
Rosids 
ORDER 
 
Malpighiales 
FAMILY 
 
Phyllanthaceae 
GENUS 
 
Phyllanthus 
SPECIES 
 
P.emblica 
BOTANICAL NAME 
 
Phyllanthus emblica 
ENGLISH NAME 
 
Indian Gooseberry 
PARTS USED 
 
Leaf, flower, Stem bark, Root, Fruit, Seed.  
CHEMICAL 
CONSTITUENT 
 
Emblicanin A & B, Aspartic acid.  
ACTION 
 
Anti-oxidant19, Anti-viral. 
SUVAI- THANMAI- 
PIRIVU 
 
Pulippu, Thuvarppu, Inippu – Thatppam – Inippu 
USES               
 
Best among rejuvenating herbs. It relieves cough and skin disease. 
Its fruit juice mixed with honey provides strength and immunity.  
 
 
 
5. KADUGUROHINI: 
 43 
 
2018 LITERATURE REVIEW 
 
கடுகநரோகணி ச ோதுகுணம்: 
“மாந்தசுர கமயம் வாயுகரப் பானாமஞ் 
மசரந்்த மலக்கடட்ு திரிமதாடம் மபாந்தப்வபாடட்ுப் 
புண்வயிறுமநாயி கவப்மபாம் வபாற்க்வகாடிமய மபதியுண்டாம் 
தண் கடுகுமராகிணிக்குத் மதர”் 
 
GENERAL PROPERTIES OF KADUGUROHINI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicots 
SUBCLASS 
 
Asterids 
ORDER 
 
Lamiales 
FAMILY 
 
Plantaginaceae 
GENUS 
 
Picrorhiza 
SPECIES 
 
P.scrophuleriflora 
BOTANICAL NAME 
 
Picrorhiza scrophuleriflora 
ENGLISH NAME 
 
Kutki 
PARTS USED 
 
Root 
CHEMICAL 
CONSTITUENT 
 
D-mannitol, Kutkiol, Kutkisterol, Picroside. 
ACTION 
 
Anthelmintic,Immunomodulator15, Stomachic. 
SUVAI- THANMAI- 
PIRIVU 
 
Kaippu, Karppu – Veppam – Karppu 
USES               
 
It acts as a laxative. It is used for fever, liver disorder 
and skin disease. 
 
 
 
6.VASAMBU: 
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வெம்பு ச ோதுகுணம்: 
 
“பாம்பா திநஞ்சற் புதப்புண் வலிவிடபாகங் குன்மம் 
சூம்பா ரிரத்தபித்தம் முகநாற்றம் வன்சூகல சன்னி 
வீம்பா ம்கபகாசம்பீலிகஞ்சிலிபதம்வீறிருமல் 
தாம்பா ங்கிருமியிகவமயகுமாசிவசம்பிகனமய” 
 
GENERAL PROPERTIES OF VASAMBU: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Monocots 
ORDER 
 
Acorales 
FAMILY 
 
Acoraceae 
GENUS 
 
Acorus 
SPECIES 
 
A.calamus 
BOTANICAL NAME 
 
Acorus calamus 
ENGLISH NAME 
 
Sweet flag 
PARTS USED 
 
Root 
CHEMICAL 
CONSTITUENT 
 
Calamenol, Acoric acid, Camphene, Eugenol. 
ACTION 
 
Germicide, Disinfectant, Insecticidal, Stimulant. 
SUVAI- THANMAI- 
PIRIVU 
 
Karppu – Veppam – Karppu 
USES               
 
Anti-microbial, relieve constipation, Fever, 
Syphilis. 
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7.MARAMANJAL: 
 
மரமஞ்ெள் ச ோதுகுணம்: 
“அழன்ற கண மூலம் அருசியுடமன 
உழன்ற கணசச்ுரமும் ஓடுஞ்சுழன் றுள்மள 
வீறிசுர முந்தணியும் வீசு மரமஞ்சளுக்குத் 
மதறு மமாழியனமம வசப்பு” 
 
GENERAL PROPERTIES OFMARAMANJAL: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicots 
ORDER 
 
Ranunculales 
FAMILY 
 
Menispermaceae 
GENUS 
 
Coscinium 
SPECIES 
 
C.fenestratum 
BOTANICAL NAME 
 
Coscinium fenestratum 
ENGLISH NAME 
 
Tree turmeric 
PARTS USED 
 
Stem and Root. 
CHEMICAL 
CONSTITUENT 
 
Berberine, Palmatine and Jatrorrhizine. 
ACTION 
 
Bitter, Febrifuge, Stomachic, Tonic. 
SUVAI- THANMAI- 
PIRIVU 
 
Kaippu – Veppam – Karppu 
USES               
 
It is used for ophthalmic, skin disease, abdomen 
disorder and jaundice. 
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8.VEPPAM MARAPATTAI: 
 
“ஓதரிய மவம்கப யுகரக்கிற் சுரமுடமன 
வாதமறு மூலகண மாந்தம் மபாந்தீதா 
யுதிரு வமரிபூசச்ி குன்மமமாதா வதாழியுஞ் 
சிதறுமலம் மபாகுவமனத் மதர”் 
 
GENERAL PROPERTIES OFVEPPAM MARAPATTAI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicots 
SUBCLASS 
 
Rosids 
ORDER 
 
Sapindales 
FAMILY 
 
Meliaceae 
GENUS 
 
Azadirecta  
SPECIES 
 
A.indica 
BOTANICAL NAME 
 
Azadirecta indica 
ENGLISH NAME 
 
Neem tree 
PARTS USED 
 
All parts are used 
CHEMICAL 
CONSTITUENT 
 
Nimbin, Nimbinin, Nimbidin, Azadirone, Nimbin, 
Azhadirachtin, Isophrenoid, tannin. 
ACTION 
 
Immuno modulator15, Tonic, Astrigent, Disinfectant.  
SUVAI- THANMAI- 
PIRIVU 
 
Kaippu – Veppam – Karppu 
USES               
 
It cures acne, chronic wounds, chicken pox, fever. 
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9.SEENTHIL KODI: 
 
GENERAL PROPERTIES OFSEENTHIL KODI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicots 
ORDER 
 
Rununculales 
FAMILY 
 
Menispermaceae 
GENUS 
 
Tinospora 
SPECIES 
 
T.cordifolia 
 
BOTANICAL NAME 
 
Tinospora cordifolia 
 
ENGLISH NAME 
 
Tinospora 
PARTS USED 
 
Leaf, Climber, Tuber. 
CHEMICAL 
CONSTITUENT 
 
Tinocordifolin, Cordioside, Syringin, 
Cordiol,Cordifolioside A & B, Amritoside A,B,C and D. 
ACTION 
 
Immunomodulator, Demulcent, Stomachic, Tonic. 
SUVAI- THANMAI- 
PIRIVU 
 
Kaippu – Veppam – Karppu 
USES               
 
Ulcer, Febrifuge for malaria and small pox, Itches, 
wounds. 
 
 
 
 
 
 
 
 48 
 
2018 LITERATURE REVIEW 
 
3.2. EXTERNAL MEDICINE - CHEMPARUTHI POO ENNAI 
 
1.CHEMPARUTHI POO : 
 
செம்மரத்றதச ோதுகுணம்: 
வசம்மரத்கத வமகவவடக்ட தீராப்பிரமி வயாடு 
வம்பிரத்த வவள்கள வழுவழுப்பும் வவப்பும் 
வபரும்பாடு ரத்தபித்த மபதம் அகற்றும் 
கரும்பா வமாழிமயிமல காண் 
 
GENERAL PROPERTIES OF CHEMBARUTHI POO: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Eudicots 
SUBCLASS 
 
Rosids 
ORDER 
 
Malvales 
FAMILY 
 
Malvaceae 
GENUS 
 
Hibiscus  
SPECIES 
 
H.rosa-sinensis 
BOTANICAL NAME 
 
Hibiscus rosa-sinensis 
ENGLISH NAME 
 
Shoe flower plant 
PARTS USED 
 
Leaf, Flower and Root. 
CHEMICAL 
CONSTITUENT 
 
Alpha-arabinopyranoside,. 
ACTION 
 
Emollient, Refrigerant, Laxative, Demelcent.  
SUVAI- THANMAI- 
PIRIVU 
 
Inippu – Thatpam – Inippu 
USES               
 
Used for diarrhea, reduce swelling, mumps, aid in 
healing of ulcer and promote hair growth. 
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2.SOORAI PATTAI: 
 
சூறரச ோதுகுணம்: 
“மந்தம் அதிகரிக்கும் வன்சீதளஞ் மசரும் 
உந்துகுடல் வலியும் உண்டாங்காண் முந்துநவில் 
காகரப் பழத்தில் கதித்தவதாரு மபதமுமாஞ் 
சூகரப் பழத்திற்குச ்வசால்” 
 
GENERAL PROPERTIES OF SOORAI PATTAI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Tracheophyta 
SUBCLASS 
 
Magnoliopsida 
ORDER 
 
Rosales 
FAMILY 
 
Rhamnaceae 
GENUS 
 
Ziziphus 
SPECIES 
 
Z.oenoplia 
BOTANICAL NAME 
 
Ziziphus oenoplia 
ENGLISH NAME 
 
Jackal jujube 
PARTS USED 
 
Tuber and fruit 
CHEMICAL 
CONSTITUENT 
 
Ziziphines 
ACTION 
 
Nutritive, Anthelmintic, Astringent, Antimicrobial. 
SUVAI- THANMAI- 
PIRIVU 
 
Inippu – Thatpam – Inippu 
USES               
 
It heals the wounds and good remedy for hyperacidity, 
Ascaris infection and dysentery.  
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3.VEMBADAM PATTAI: 
 
GENERAL PROPERTIES OF SOORAI PATTAI: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Tracheophyta 
SUBCLASS 
 
Mangnoliopsida 
ORDER 
 
Rosales 
FAMILY 
 
Rhamnaceae 
GENUS 
 
Ventilago 
SPECIES 
 
Maderasapatana 
BOTANICAL NAME 
 
Ventilago maderasapatana 
ENGLISH NAME 
 
Red creeper 
PARTS USED 
 
Bark, root and flower 
CHEMICAL 
CONSTITUENT 
 
Anthraquinones, Beta sitosterol, Glucosides, Lupeol. 
ACTION 
 
Carminative, Depurative, Thermogenic, Tonic and 
Stomachic. 
SUVAI- THANMAI- 
PIRIVU 
 
Thuvarppu, kasappu– Thatpam – Karppu 
USES               
 
It is used against scabis, treats atonic dyspepsia and 
skin diseases. 
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COCONUT OIL: 
 
நதங்கோசயண்றண ச ோதுகுணம்: 
“இலாங்கலி வயண்கணயு வமண்கணகயப் மபான்மற 
வபாலாங்கு வசய்திடம் மபாற்ற வலாண்ணாமத” 
 
GENERAL PROPERTIES OF COCUNUT OIL: 
KINGDOM 
 
Plantae 
DIVISION 
 
Angiosperms 
CLASS 
 
Monocots 
SUBCLASS 
 
Commelinids 
ORDER 
 
Arecales 
FAMILY 
 
Arecaceae 
GENUS 
 
Cocos 
SPECIES 
 
C.nucifera 
BOTANICAL NAME 
 
Cocos nucifera 
ENGLISH NAME 
 
Coconut tree 
PARTS USED 
 
Whole plant 
CHEMICAL 
CONSTITUENT 
 
Fatty acid, tartic acid, Albumin, Alkaloid, Palmitic, 
Steric, Caprillic acid, Lauric, Mystric. 
ACTION 
 
Demulcent, Emollient 
SUVAI- THANMAI- 
PIRIVU 
 
Inippu – Thatpam – Inippu 
USES               
 
Burns, Wounds, Colling effect, Posses Healing 
property, Prevent scar formation.  
  
 
2018 MATERIALS AND METHODS 
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                   4.MATERIALS AND METHODS 
SELECTION OF DRUGS: 
I have selected the trail drug “MAHA MANJISHTATHI KASHAYAM” 
(Internal) for the study from classical Siddha literature “AGASTHIYAR 
VAIDHIYA PILLAI TAMIL”and “CHEMPARUTHI POO ENNAI” (External)  
from “ THE PHARMACOPOEIA OF SIDDHA RESEARCH  MEDICINES” . 
The raw drugs were procured from the raw drug shop R.N.RAJAN & CO, 
Chennai. After proper authentication by the Pharmacognosist, Siddha central research 
institute, Arumbakkam, Chennai-106. 
My CTRI number is CTRI/2018/05/013686. 
 
4.1. MAHA MANJISTATHI KASHAYAM (INTERNAL MEDICINE): 
 
INGREDIENTS:7 
➢ Manjitti-    Rubia cordifolia -  35gms 
➢ Kadukai thol - Terminalia chebula -  35gms 
➢ Thandrikai  -Terminalia bellarica  -35gms 
➢ Nellimulli- Phyllanthus emblica-  35gms 
➢ Kadugurohini- Picrorhiza scrophuleriflora– 35gms 
➢ Vasambu- Acorus calamus- 35gms 
➢ Maramanjal -   Coscinium fenestratum- 35gms 
➢ Veppam marapattai -   Azadirecta indica- 35gms 
➢ Seenthil kodi -   Tinospora cordifolia- 35gms 
Fig no :4.1, Maha manjishtathi kashayam 
 
PURIFICATION OF THE INTERNAL DRUG MAHA 
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MANJISHTATHIKASHAYAM23 
 
Kadukaai:Seed of Kadukaai is removed and the outer skin is used. 
Neelimulli:The seeds are removed, and the outer part is used. 
Thandrikaai: The seeds are removed, and the outer part is used. 
Manjitti: The dust particles are removed and then used. 
Kadugurohini: Fried in a low flame and then used  
Vasambu: The rhizome is burnt in flame; it is buried under the sand and allow it to 
cool. It is powdered and then used. 
Maramanjal: The dust particles are removed and then used. 
Veppam mara pattai: External skin is removed and then used. 
Seendhil kodi:The dust particles are removed and then used. 
 
MATERIALS REQUIRED 
 
    Fig no :4.2 ,Manjitti                                           Fig no :4.3, Kadukaai thol 
            
 
       Fig no :4.4, Thandrikai                                   Fig no :4.5,Nellimulli 
            
     Fig no :4.6,Kadugurohini                            Fig no :4.7.Vasambu 
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     Fig no :4.8,Maramanjal                                Fig no :4.10,Veppamarapattai 
         
 
                                      Fig no :4.11,  Seenthil kodi 
 
 
 
 
 
METHOD OF PREPARATION 
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Standard operating procedure for Maha manjishtathi kashayam : 
1. All ingredients are dried and coarsely powdered. 
2. Powder is added in 3.5litres of boiling water and heated. 
3. Reduced to 1.5 liters and made as kashayam. 
4. After cooling, pour it into a sterilized container or bottle. 
 DOSAGE: 
30 ml,Twice a day for 48 days. 
 
INDICATION: 
All kinds of “KUTTAM”. 
    Fig no :4.12  
                                           
    Fig no :4.13                                                      Fig no :4.14 
                   
 
     
 
Fig no :4.15                                                        Fig no :4.16 
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4.2. CHEMPARUTHI POO ENNAI (EXT MEDICINE)  
INGREDIENTS:8  
Chemparuthi poo                         -  ¼ kg 
Soorai pattai chooranum  -35 gms 
Vembadampattai chooranam              - 35 gms 
Coconut oil                            - 2 liters 
 
PURIFICATION OF THE EXTERNAL DRUG CHEMPARUTHI POO ENNAI 
The drugs used for the preparation of chemparuthi poo ennai are purified and 
dried under classical text procedure. 
MATERIALS REQUIRE 
    Fig no :4.17, Chemparuthi                           Fig no :4.18, Soorai pattai 
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    Fig no :4.19, Vembadam pattai                    Fig no :4.20, Thenkaai ennai 
           
 
 METHOD OF PREPERATION: 
➢ The flowers are kept soaked in oil for 10-20 days and then filtered. 
➢ Suraipattai chooranam and Vembadam pattai chooranam are added. 
➢ Keep in sunlight for 3 days. 
  
 INDICATIONS: 
             Psoriasis, Allergic dermatiti 
 
DRUG STORAGE: 
           The trial drug is stored in clean air tight glass container (borosil container) and 
it is dispensed to the patients. 
 
DISPENSING: 
 The kashayam is given in the container. External oil is given in pet bottles. 
 
                                         Fig no :4.21,Chemparuthi poo ennai 
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4.3. DEEP RELAXATION TECHNIQUE: (THERAPY)6 
PROCEDURE: 
➢ Lie down in SAVASANAM 
➢ Gently move your Whole body, make yourself relax. 
PHASE 1: 
             Bring awareness to the tip of the toes, loosen the ankle joint, relax the calf 
muscles, gently pull up the knee caps, relax the calf muscles,loosen the hip joint, relax 
the pelvic and waist region. Chant “A-Kara” and feel the vibration. 
PHASE 2: 
➢ Gently observe the abdominal movements, relax the abdomen muscles and chest 
muscles. 
 
➢ Relax your lower vertebral joints, upper back muscles, mid back, shoulder 
blades. 
➢ Relax your fingers one by one, fore arm, loosen the wrist, and relax the elbow 
joint, back of the arms and shoulder. 
➢ Slowly turn your head to right and left. 
➢ Relax the middle part of the body and chant “U-kara”. 
PHASE 3: 
➢ Bring the awareness to head region, relax your chin, lower and upper jaws and 
gums, throat, vocal chords. 
➢ Observe on nostrils, slowly inhale and exhale. 
➢ Relax your eye balls, eye brows, forehead, back of head and crown head, chant 
“M-kara”. 
PHASE 4: 
➢ Now your whole body from head to toe is totally relaxed. For further 
relaxation chant “AUM” 3 times. 
Feel the vibration in whole body and enjoy the complete relaxation of the whole body. 
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    Fig no :4.22 , Deep relaxation technique 
 
4.4. STANDARDIZATION OF MAHA MANJISHTATHI KASHAYAM 
                     Standardization of herbal drugs is essential to access quality of the drugs 
for therapeutic value. Standardization of Maha manjistathi kashayam based on 
Organoleptic, physical characteristics , physiochemical properties. 
 
 
4.4.1. ORGANO LEPTIC CHARACTER 
Sample Description of MAHA MANJISHTATHI KASHAYAM 
 
    Fig no :4.23 
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Table.4.1 – Oraganoleptic characters 
 
 
MAHA MANJISHTATHI KASHAYAM (MMK ) : 
S.No CHARACTERS RESULTS RESULTS 
1 
 
State Solid- Mixed Crude 
raw Material- Mostly 
Woody/ Hard solid 
Decoction- Water 
Extraction-  
2 Appearance Dark Brownish   Reddish Brown 
3 Nature Woody bark 
Consistency 
Clear Liquid 
4 Odor Mild Mild Aromatic 
5 Taste Astringent Astringent 
 
 
 4.4.2. PHYSIOCHEMICAL ANALYSIS 
 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish .The sample was 
dried at 105oC for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the 
furnace a temperature 400 ºC until it turns white in color which indicates absence of 
carbon. Percentage of total ash will be calculated with reference to the weight of air-
dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute 
hydrochloric acid for 6mins. Then the insoluble matter is collected in crucible and will 
be washed with hot water and ignited to constant weight. Percentage of acid insoluble 
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ash will be calculated with reference to the weight of air-dried ash. 
Acid insoluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. 
The insoluble matter is collected in crucible and will be washed with hot water, and 
ignite for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter 
will be subtracted from the weight of the ash; the difference in weight represents the 
water soluble ash. Calculate the percentage of water-soluble ash with reference to the 
air-dried drug. 
Water Soluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Alcohol Soluble Extractive 
About 5 g of test sample will be macerated with 100 ml of Alcohol in a closed 
flask for twenty-four hours, shaking frequently during six hours and allowing to stand 
for eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 
25 ml of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, 
to constant weight and weigh. Calculate the percentage of alcohol-soluble extractive 
with reference to the air-dried drug. 
Alcohol sol extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of Water Soluble Extractive 
About 5 g of the test sample will be macerated with 100 ml of chloroform water 
in a closed flask for twenty-four hours, shaking frequently during six hours and 
allowing to stand and for eighteen hours. Filter rapidly, taking precautions against loss 
of solvent, evaporate 25 ml of the filtrate to dryness in a tared flat bottomed shallow 
dish, and dry at 105ºC, to constant weight and weigh. Calculate the percentage of water-
soluble extractive with reference to the air-dried drug. 
Water soluble extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of pH 
About 5 g of test sample will be dissolved in 25ml of distilled water and filtered 
the resultant solution is allowed to stand for 30 mins and the subjected to pH evaluation  
Table no :4.2, Final Test report MMK 
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S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 9.76  ±  0.85 
2.  Total Ash (%)  8.51  ±  1.35 
3.  Acid insoluble Ash (%) 15.27  ±  0.83 
4.  Water Soluble Ash (%) 13.07  ±  0.70 
5.  Alcohol Soluble Extractive (%) 34  ±  2.88 
6.  Water soluble Extractive (%) 23.37  ±  0.94 
       7. PH  4.4 
 
4.4.3. HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
Methodology: 
Atomic Absorption Spectrometry (AAS) is a very common and reliable 
technique for detecting metals and metalloids in environmental samples. The total 
heavy metal content of the sample KN was performed by Atomic Absorption 
Spectrometry (AAS) Model AA 240 Series. In order to determination the heavy metals 
such as mercury, arsenic, lead and cadmium concentrations in the test sample. 
 
Sample Digestion: 
Test sample digested with 1mol/L HCl for determination of arsenic and 
mercury. Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L of HNO3. 
Standard preparation: 
 As & Hg- 100 ppm sample in 1mol/L HCl 
 Cd &Pb- 100 ppm sample in 1mol/L HNO3 
 
4.4.4. TLC and HPTLC Analysis 
 
TLC Analysis: 
Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one-dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with 
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soft pencil. Micro pipette was used to spot the sample for TLC applied sample volume 
10-micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin trough 
chamber with different solvent system Toluene: Ethyl Acetate: Acetic Acid 
(1.5:1:0.5) After the run plates are dried and was observed using visible light Short-
wave UV light 254nm and light long-wave UV light 365 nm. 
 
High Performance Thin Layer Chromatography Analysis: 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and 
quantitatively. High performance thin layer chromatography (HPTLC) is a valuable 
quality assessment tool for the evaluation of botanical materials efficiently and cost 
effectively. HPTLC method offers high degree of selectivity, sensitivity and rapidity 
combined with single-step sample preparation. In addition, it is a reliable method for 
the quantitation of Nano grams level of samples. Thus, this method can be 
conveniently adopted for routine quality control analysis. It provides chromatographic 
fingerprint of phytochemicals which is suitable for confirming the identity and purity 
of medicinal plant raw materials. 
 
Chromatogram Development: 
It was carried out in CAMAG Twin Trough chambers. Sample elution was 
carried out according to the adsorption capability of the component to be analyzed. 
After elution, plates were taken out of the chamber and dried. 
 
Scanning: 
Plates were scanned under UV at 366nm. The data obtained from scanning 
were brought into integration through CAMAG software. Chromatographic finger 
print was developed for the detection of phytoconstituents present in each extract and 
Rf values were tabulated. 
 
 
 
 
4.4.5. STERILITY TEST BY POUR PLATE METHOD 
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Objective: 
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of 
colonies. The colonies are referred to as Colony Forming Units (CFUs).   
 
Methodology: 
About 1ml of the test sample was inoculated in sterile petri dish to which about 
15 mL of molten agar 45oC were added. Agar and sample were mixed thoroughly by 
tilting and swirling the dish. Agar was allowed to completely gel without disturbing it. 
(about 10 minutes). Plates were then inverted and incubated at 37o C for 24-48 hours. 
Grown colonies of organism was then counted and calculated for CFU. 
 
 
Observation: 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
 
Result: 
No growth / colonies were observed in any of the plates inoculates with the 
test sample. 
Table no:4.3, Sterility by pour plate method 
Test Result Specification As per 
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AYUSH/WHO 
Total Bacterial Count Absent NMT 105CFU/g As per AYUSH 
specification 
Total Fungal Count Absent NMT 103CFU/g 
 
                              4.5. TOXICOLOGICAL STUDY 
ACUTE ORAL TOXICITY STUDY OF MAHAMANJISHTATHI 
KASHAYAM (OECD GUIDELINES -423) 
  
Introduction: 
 
❖ The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
❖ Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance.  
❖ This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
❖ The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification 
purposes and hazard assessment.  
❖ In principle, the method is not intended to allow the calculation of a precise 
LD50,but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
❖ The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
❖ The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
 
 
Principle of the Test:  
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It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. 
Absence or presence of compound-related mortality of the animals dosed at one step 
will determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose level. The 
method will enable a judgment with respect to classifying the test substance to one of a 
series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and the 
weight (150-200gm) should fall in an interval within±20 % of the mean weight of any 
previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals may 
be group-caged by dose, but the number of animals per cage must not interfere with 
clear observations of each animal. 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept 
in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
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Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Sai meera foods, Bangalore). 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept 
in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
 
PREPARATION FOR ACUTE TOXICITY STUDIES 
Rats were deprived of food overnight (but not water 16-18 h) prior to administration of 
the, MAHA MANJISHTADHI KASHAYAM. 
The principles of laboratory animal care were followed and the Institutional Animal 
Ethical Committee approved the use of the animals and the study design 
 
IAEC approved  Number: 1248/AC/09/CPCSEA-9/DEC-2013/12 
 
Test Substance  : MAHA MANJISHTADHI KASHAYAM 
Animal Source  : TANUVAS, Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual 
                 marking by using Picric acid. 
Number of animals                : 3 Female/group,  
Route of administration        :   Oral  
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, 
                                                  Bangalore.                                               
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
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                              provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
 
Administration of Doses:  
 MAHA MANJISHTADHI KASHAYAM was suspended in coconut water 
and administered to the groups of wistar albino rats in a single oral dose by gavage 
using a feeding needle. The control group received an equal volume of the vehicle. 
Animals were fasted 12 hours prior to dosing. Following the period of fasting, the 
animals were weighed and then the test substance was administered. Three Female 
animals are used for each group. The dose level of 5, 50, 300 and 2000 mg/kg body 
weight was administered stepwise. After the substance has been administered, food was 
withheld for a further 3-4 hours. The principle of laboratory animal care was followed. 
Observations were made and recorded systematically and continuously as per the 
guideline after substance administration. The visual observations included skin 
changes, mobility, aggressively, sensitivity to sound and pain, as well as respiratory 
movements. Finally, the number of survivors was noted after 24 hrs and these animals 
were then monitered for a further 14 days and observations made daily. The 
toxicological effect was assessed on the basis of mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
Observations include changes in skin and fur, eyes and mucous membranes, and also 
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respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
 
Behavior: 
 The animals will be observed closely for behavior in the first four hours which 
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, 
convulsion, excitation, head twitches, lacrimation, loss of corneal reflex, loss of 
traction, piloerection reactivity of touch, salivation, scratching, sedation, chewing, head 
movements, sniffing, Staub, tremor and writhes, diarrhea, leathery, sleep and coma.  
 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
 
Food and water Consumption: 
Food and water consumed per animal was calculated for control and the treated 
dose groups.  
 
Mortality: 
Animals were observed for mortality throughout the entire period. 
 
 
 
 
REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
MAHA MANJISHTADHI KASHAYAM 
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Test Substance  : MAHA MANJISHTADHI KASHAYAM 
Animal Source  : TANUVAS, Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
 marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai Meera Foods PvtLtd,    
                               Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature :  between 22ºC±3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 4. 4  
 
 
MAHA MANJISHTADHI KASHAYAM 
Methodology: 
Groups No of Rats 
Group I Vehicle control (C.Water) 12(6male,6 female) 
Group II low dose X (20mg) 12 (6male,6 female) 
Group III Mid dose 5X (100mg) 12 (6male,6female) 
Group IV High dose 10X(200mg) 12(6male,6female) 
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Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for  28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose (5X), high dose (10X). X is calculated from the acute toxicity 
dose 2000mgand the X dose is (20mg/kg), 5X dose is (100mg/kg), 10X dose is 
(200mg/kg). 
 
Preparation and Administration of Dose: 
MAHA MANJISHTADHI KASHAYAM suspended in with water, It was 
administered to animals at the dose levels of X, 5X, 10X. The test substance 
suspensions were freshly prepared every two days once for 28 days. The control animals 
were administered vehicle only. The drug was administered orally by using oral gavage 
once daily for 28 consecutive days. 
Observations: 
Experimental animals were kept under observation throughout the course 
of study for the following: 
Body Weight: 
Weight of each rat was recorded on day 0, at weekly intervals throughout the 
course of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated 
dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of  the study. 
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Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy of 
all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Hematological Investigations: 
Hematological parameters were determined using Hematology analyzer.  
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
            Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto Technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten paraffin 
at 50°C and then in a cubical block of paraffin made by the                   “L” moulds. It 
was followed by microtome and the slides were stained with Hematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemistry were subjected to One-way ANOVA followed by 
dunnet t test using a computer software program – Graph pad version 7. All data were 
summarized in tabular form, (Table-6 to 12) 
4.6. PHARMACOLOGICAL ACTIVITY  
DETERMINATION OF INVITRO ANTI-PSORIATIC POTENTIAL ON 
CULTURED Hacat CELL LINE 
 Hacat cells (keratinocytes) were purchased from NCCS Pune were 
maintained in Dulbecco’s modified eagles media (HIMEDIA) supplemented with 
10% FBS (Invitrogen) and grown to confluency at 37°c in 5 % CO2 in a humidified 
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atmosphere in a CO2 incubator(NBS, EPPENDORF, GERMANY). The cells were 
trypsinized (500µl of 0.025% Trypsin in PBS/ 0.5mM EDTA solution (Himedia)) for 
2 minutes and passaged to T flasks in complete aseptic conditions.   The cells were 
then grown till 60% confluency followed by activation with 1µl LPS (1µg/ml). LPS 
stimulated hacat cells were exposed with different concentrations of samples such 
as.6.25,12.5,25,50,100µg/ml from 1mg/ml stock and incubated for 24 hours. The % 
difference in viability was determined by standard MTT assay after 24 hours of 
incubation. 
.   MTT ASSAY (Arung et al., 2000) 
 MTT is a colorimetric assay that measures the reduction of yellow 3-(4, 
5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate 
dehydrogenase. The MTT enters the cells and passes into the mitochondria where it is reduced 
to an insoluble, colored (dark purple) formazan product. The cells are then solubilized with an 
organic solvent Dimethyl sulfoxide (Himedia) and the released, solubilized formazan product 
was measured at 540nm. Since reduction of MTT can only occur in metabolically active cells 
the level of activity is a measure of the viability of the cells. 
 The cells was washed with 1x PBS and then added 30 µl of MTT solution to 
the culture (MTT -5mg/ml dissolved in PBS). It was then incubated at 370C for 3 hours. MTT 
was removed by washing with 1x PBS and 200µlof DMSO was added to the culture. Incubation 
was done at room temperature for 30 minutes until the cell got lysed and color was obtained. 
The solution was transferred to centrifuge tubes and centrifuged at top speed for 2minutes to 
precipitate cell debris. Optical density was read at 540 nm using DMSO as blank in a micro 
plate reader (ELISASCAN, ERBA). 
   
                 
   Table no :4.5 , % viability = (OD of Test/ OD of Control) X 100 
Sample   Concentration(µg/ml)  Average OD at 
540nm 
Percentage 
Viability 
Control (LPS Induced) 0.5969 100 
Sample code: Mahamanjishtathi   
6.25 0.5316 89.06 
12.5 0.473 79.24 
25 0.4247 71.15 
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50 0.2038 34.14 
100 0.2385 19.96 
 
                                4.7. CLINICAL STUDY 
This clinical study was conducted after getting approval from IEC Institutional 
Ethical Committee, GSMC, Chennai. IEC NO: GSMC–CH–ME-5/013/2016.This trail 
was also registered in (CTRI) Clinical Trail Registry of India CTRI REF NO 
:CTRI/2018/05/013686.This was done in Post graduate Department of Sirappu 
Maruthuvam ,Government Siddha Meducal college and Hospital, Aringar Anna 
Campus, Arumbakkam , Chennai -106  under the observation and guidance  of Head of 
the Department. 
In this clinical study totally 60 cases was enrolled out of which 20 cases were 
treated with Internal drug alone. 20 cases were treated with Internal drug,External drug 
and Deep relaxation Therapy. 20 cases were treated external drug and Deep relaxation 
Therapy. 
4.7.1. STUDY DESIGN: 
Study Type       : An open comparative clinical trial 
Study Place        : OPD of Aringar Anna Govt. Hospital of Indian medicine   
                               attached with  Govt. siddha medical college, Arumbakkam,  
                      Chennai-106. 
Study Period       : 12 Months after completion of Pre-clinical studies.  
Sample Size         :  60 patients(OPD) 
                      20 Patients-Under Internal drug alone.           
                                            20 Patients- External drug and Deep relaxation technique.    
                                20 Patients- Internal, external drugs and Deep relaxation 
   technique. 
.                                            
4.7.2. SUBJECT SELECTION: 
There is considerable number of patients reporting of OPD of Aringar Anna 
govt. hospital, GSMC, with the symptom of inclusion criteria will be subjected to 
screening test and documented using screening Performa. 
 
SELECTION CRITERIA:  
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INCLUSION CRITERIA: 
• Age: 18 – 60 years. 
• Sex : Both Male and Female 
• Patches with Scaling. 
• Auspitz Sign +ve 
• Koebner’s Phenomenon +ve 
• Patients willing to take photographs before and after treatment 
• Patients willing to fill Consent form 
EXCLUSION CRITERIA: 
History of 
• Alcohol 
•  Narcotic addicts 
• Anti –malarial drugs 
•  Cardiac disease 
•  Leprosy 
•  Peptic ulcer  
•  SLE, Progressive systemic sclerosis 
•  Evidences of secondary infection in the lesions 
•  Pregnancy and lactation 
•  HIV 
• Syphilis 
• History of long term intake of Steroids. 
WITHDRAWAL CRITERIA:  
• Intolerance to the drug and development of any serious adverse effect during 
drug trial.  
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• Patient turned unwilling to continue during Clinical trial any other systemic 
illness. 
ADR REPORTING: 
              If ADR is reported, it should be informed to SCRI (Peripheral Pharmaco 
vigilance center). Patient is directed to nearest Government Hospital. 
 
 
4.7.3. CLINICAL ASSESSMENT: 
    1. Psoriasis area severity index (PASI) 
     2. Photo Assessment: 
Photos of the patient before and after treatment for the evidence of clinical 
improvement. 
MODERN INVESTIGATION: 
Blood: 
Hb, TC, DC, ESR,  
Blood Sugar (F) (PP), 
Renal Function Tests:  
 Blood Urea,   
 Serum Creatinine. 
Liver Function Tests: 
      Serum total bilirubin, 
 Direct bilirubin, 
Indirect bilirubin, 
Alkaline phosphatase,  
SGOT, SGPT.  
 
Urine: 
      Albumin,  
Sugar,  
Deposits. 
 
 
PSORIASIS AREA AND SEVERITY INDEX (PASI) 
 77 
 
2018 MATERIALS AND METHODS 
 
PASI Score is assessment tool for the Psoriasis . 
PASI Score is calculated using measuring followings 
 E – Erythema    
D – Desquamation     
 I – Infiltration 
A – Area 
 
PASI=0.1(EH+IH+DH)AH+0.2(EU+IU+DU)AU+0.3(ET+IT+DT)AT+0.4(EL+IL+DL)AL 
Erythema/ Infiltration/Desquamation scoring  Area scoring  
           
       
0 – Nil                   0-Nil 
 
1- Mild       1-Less than 10%  
 
2- Moderate       2- 10%-30%  
 
3-Severe       3-31%-50% 
 
4-Very high       4-51%-70% 
 
5-71%-90%  
 
6-91%-100%  
PASI  SCORE IMAGES: 
 Absent Mild Moderate Severe           Very severe 
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PSORIASIS ASSESSMENT TOOLS: 
In this trial PSORIASIS AREA AND SEVERITY INDEX (PASI SCORE) is used 
to assess severity of Psoriasis. 
 
Mild to Moderate Psoriasis               : PASI <10 
Moderate Psoriasis                           : PASI 10 ≤ 12 
Moderate to Severe Psoriasis           : PASI 12 ≤ 02 
Severe Psoriasis                               : PASI > 20 
 
 
 
THE CALCULATIONS OF PSORIASIS AREA SEVERITY INDEX (PASI): 
     The Psoriasis Area severity index (PASI) is an index used to express the severity 
of Psoriasis. It combines the severity and percentage of affected area  
    
 
Erythema (Redness)                    - Symbol (E) 
Redness 
 
Score 0 
 
Score 1 
 
Score 2 
 
Score 3                    Score 4 
Thickness 
 
Score 0 
 
Score 1 
 
Score 2 
 
Score 3                    Score 4 
Scaling 
 
Score 0 
 
Score 1 
 
Score 2 
 
Score 3               Score 4 
 79 
 
2018 MATERIALS AND METHODS 
   Induration (Thickness)                - Symbol (I) 
                              Desquamation (Scaling)              - Symbol (D) 
                              Body surface area involvement   - Symbol (A) 
Over 4 body regions as  
                             Head (h) 
             Trunk (t) 
                        Upper limb (u) 
             Lower limb (l) 
 
The PASI Score is calculated by the formula: 
PASI=0.1(EH+IH+DH) AH+0.2(EU+IU+DU) AU+0.3(ET+IT+DT) AT+0.4(EL+IL+DL) AL 
 
PASI SCORE CALCULATION: 
PASI SCORE CALCULATION IN SEVERITY OF BODY REGION  
Table no :4.6 
 
DEGREE OF SEVERITY OF BODY 
REGION 
 
VALUE 
 
No symptom 
 
0 
 
Slight 
 
1 
 
Moderate  
 
2 
 
Marked  
 
3 
 
Very Marked 
 
4 
 
 
 
 
Table no :4.7 
PASI SCORE CALCULATION IN SURFACE AREA INVOLVED IN BODY REGION 
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SURFACE AREA INVOLVED IN BODY 
REGION 
 
 
VALUE 
<10%  
1 
 
10-29% 
 
2 
 
30-49% 
 
3 
 
50-69% 
 
4 
 
70-89% 
 
5 
 
90-100% 
 
6 
 
 
2.Photo Assessment: 
  Photos of the patients before and after treatment for the evidence of clinical 
improvement. 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION 
CRITERIA 
EXCLUSION 
CRITERIA 
EXCLUDED FROM 
TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT 
FORM 
ADVERSE REACTION 
ADVISED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMOCOVIGILANCE 
FURTHER MANAGEMENT OF 
ADVERSE DRUG REACTION 
 
Internal drug 
 
External drug 
and Deep 
relaxation 
technique 
 
Internal, 
external drugs 
and Deep 
relaxation 
technique 
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DATA COLLECTION FORMS 
Required information will be collected from each patient by using the following forms. 
           FORM l             : Screening Proforma  
FORM lI   : History taking Proforma 
FORM llI   : Clinical Assessment Proforma 
FORM IV     : Laboratory Investigation Proforma 
FORM V   : Informed Consent Form 
FORM VI   : Withdrawal Form 
FORM VII   :Drug compliance form 
FORM VIII     : Patient Information Sheet 
FORM IX   :Diet sheet 
 
STUDY ENROLLMENT: 
             In this study Patient reporting at the OPD with symptoms of erythema, itching, 
plaques, scaling, Auspitz Sign +, Koebner’s Phenomenon + are chosen for enrolment 
based on this inclusion criteria. 
The patients who are to be enrolled would be informed (Form III) about the 
study, trial drug, possible outcomes and the objectives of the study in the language and 
terms understandable to them. 
After ascertaining the patient’s willingness, informed consent would be 
obtained in writing from them in the consent form (Form V). All these patients will be 
given Address, Phone number etc. and also the doctor’s phone number, so as to report 
easily any complications arise. 
Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Proforma in the history and clinical assessment 
forms separately. Screening Form- I will be filled up: Form –II and Form –IV will be 
used for recording the patients’ history, clinical examination of symptoms and signs 
and laboratory investigations respectively. Patients would be advised to take the trial 
drug and appropriate dietary advice (Form IX) would be given according to the patients’ 
perfect understanding. 
 
 
CONDUCT OF THE STUDY: 
 83 
 
2018 MATERIALS AND METHODS 
        The Siddha herbal formulation Maha manjishtathi kashayam (Internal), 
Chemparuthi poo ennai (External) and Deep relaxation technique are given for 48 
days.  OP patients should visit the hospital once in 7 days.  At each clinical visit 
clinical assessment is done and prognosis is noted. Sample size is 60 patients. Among 
60 patients, 20 Patients are treated with Internal drug alone. 20 Patients are treated 
with Internal, external drugs and Deep relaxation technique. 20 Patients are treated 
with External medicine and Deep relaxation technique. The results will be compared 
at the end of the study. Laboratory investigations are done at 0 day & 48th day of the 
trial. After the end of the treatment, the patient is advised to visit the OPD for another 
2 months for follow-up. 
 
DATA MANAGEMENT: 
After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be kept in the file. Study No. and Patient No. will be entered 
on the top of file for easy identification. Whenever study patient visits OPD during the 
study period, the respective patient file will be taken, and necessary recordings will be 
made at the assessment form or other suitable form. The screening forms will be filed 
separately. The Data recordings will be monitored for completion and adverse event by 
HOD and Pharmacovigilance committee. All forms will be further scrutinized in 
presence of Investigators by Sr. Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid any bias. No modification in the results is permitted for 
unbiased reports. 
OUTCOME: 
Primary Outcome: 
• Primary outcome is mainly assessed by reduction in clinical symptoms like 
itching and scaling. 
• PASI Score (Psoriasis area severity index) 
• To evaluate the prevention of recurrence by follow-up after two months from 
the start of intervention. 
• To evaluate the days of outcome with in the treatment of 48 days. 
 
 
Secondary Outcome: 
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• Secondary outcome is assessed by comparing the safety parameters before and 
after treatment. 
 
ETHICAL ISSUES: 
• Informed consent will be obtained from the patients after explaining about the 
clinical trial in regional tongue. 
• After the consent of the patient (through consent form) if they are in the 
inclusion criteria they will be enrolled in the study. 
• Treatment will be provided free of cost. 
• Concomitant medications will be given when required. 
• Rescue medications will be given when needed. 
• The patients who withdrawal from are given proper treatment with full care at 
OPD. 
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RESULTS AND 
OBSERVATION 
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5. RESULTS AND OBSERVATION 
Table no :5.1. MAHA MANJISHTATHI KASHAYAM (MMK) - ORGANO           
LEPTIC CHARACTER 
S.No CHARACTERS RESULTS RESULTS 
1 
 
State Solid- Mixed Crude raw 
Material- Mostly Woody/ Hard 
solid 
Decoction- Water 
Extraction-  
2 Appearance Dark Brownish   Reddish Brown 
3 Nature Woody bark Consistency Clear Liquid 
4 Odor Mild Mild Aromatic 
5 Taste Astringent Astringent 
 
Table no :5.2.  PHYSICO – CHEMICAL ANALYSIS 
PHYSICO – CHEMICAL ANALYSIS RESULTS FOR MMK 
S.No Parameter Mean (n=3) SD 
7.  Loss on Drying at 105 °C (%) 9.76  ±  0.85 
8.  Total Ash (%)  8.51  ±  1.35 
9.  Acid insoluble Ash (%) 15.27  ±  0.83 
10.  Water Soluble Ash (%) 13.07  ±  0.70 
11.  Alcohol Soluble Extractive (%) 34  ±  2.88 
12.  Water soluble Extractive (%) 23.37  ±  0.94 
       7. PH  4.4 
 
                              Table no : 5.3.HEAVY METAL ANALYSIS 
S.No  HEAVY METALS RESULTS 
1 Mercury No detectable 
2 Lead No detectable 
3 Arsenic No detectable 
4 Cadmium No detectable 
5 Chromium No detectable 
Lkl;  
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OBSERVATION: 
Hg, Pb, Cd, Chromium is no detectable limit. Hence it proves the drug is safe for 
Internal administration. 
5.4.TLC AND HPTLC ANALYSIS 
 
HPTLC finger printing of Sample MMK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 Peak Table 
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TLC Analysis at254 nm TLC Analysis at 
366nm 
5.5. Sterility test by pour plate method for MMK 
 
 
Objective:  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of 
colonies. The colonies are referred to as Colony Forming Units (CFUs).   
Methodology: 
About 1ml of the test sample was inoculated in sterile petri dish to which about 
15 mL of molten agar 45oC were added. Agar and sample were mixed thoroughly by 
tilting and swirling the dish. Agar was allowed to completely gel without disturbing it. 
(about 10 minutes). Plates were then inverted and incubated at 37o C for 24-48 hours. 
Grown colonies of organism was then countedand calculated for CFU. 
Lkl;  
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Observation: 
No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
 
Result: 
No growth / colonies were observed in any of the plates inoculates with the test 
sample. 
Table no :5.5 
Test Result Specification As per 
AYUSH/WHO 
Total Bacterial Count Absent NMT 105CFU/g As per AYUSH 
specification 
Total Fungal Count Absent NMT 103CFU/g 
 
 
5.6. Acute oral toxicity study of MAHA MANJISHTADHI 
KASHAYAM 
Observation done: 
 
Table 5.6: Dose finding experiment and its behavioral Signs of acute oral 
Toxicity 
 
 
SL 
 
Group 
CONTROL 
 
Observation 
 
SL 
 
Group 
TEST GROUP 
 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of 
posture 
Normal 2 Assessments of 
posture 
Normal 
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3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No 
significant 
color change 
7 Change in skin 
color 
No significant 
color change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 
10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
 
 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intake 
No of animals in each group:3 
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Table 5.7 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming 5. Gripping 6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15. Lacrimation 16. 
Exophthalmos 17. Diarrhea 18. Writhing  
19. Respiration 20. Mortality. 
(+ Present, -  Absent) 
 
Table 5.8 ( Body weight Observation) 
 
 
 
 
 
 
 
 
 
 
 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 200.1±65.70  201.3 ± 41.11 201.6 ±02.12 
HIGH DOSE 202.3± 6.64 202.7 ±7.42 203.2 ± 2.70 
P value (p)* 
NS NS NS 
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Table 5.9 (Water intake (ml/day) of Wistar albino rats group exposed to 
MAHA MANJISHTADHI KASHAYAM): 
 
DOSE 
 
DAYS 
1 6 14 
CONTROL 54 ± 3.20 54±6.10 54.3±5.44 
HIGH DOSE 53.5±1.30 53.8±6.70       54.2±5.64 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One-
way ANOVA followed by Dunnett’s test) 
 
Table 5.10: Food intake (gm/day) of Wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM       
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 56.03±2.82 56.2±2.96 57.7±8.86 
High DOSE 58.6±5.44 58.4±5.20 59.8±6.67 
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5.7.SUB- ACUTE TOXICITY 
Repeated Dose 28- day oral toxic study of MAHA MANJISHTADHI 
KASHAYAM 
Table 5.11: Body weight of wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Table 5.12: Water intake (ml/day) of Wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM 
 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 51.3 ± 3.54      
51.4±1.27 
51.7±1.31 52.1±1.12 52.4±1.72 
LOW DOSE 65.1±1.21 65.6±4.22 66.6±1.02 65.2±2.06 66.4±1.20 
MID DOSE 62.1±1.02 62.3±1.21 62.1±2.62 63.4±4.32 63.4±1.64 
HIGH 
DOSE 
53.6±6.80 53.2±1.52 53.4±1.74 54.6±1.88 54.8±2.82 
P value (p)* NS NS NS NS NS 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 242.4±10.40  243.2 ± 15.04 243.4 ± 15.40 
244.6± 
16.50 
244.2 ± 16.10 
LOW DOSE 240.5 ± 55.25 241.7 ± 16.29 241.8± 15.24 242 ±16.30 242.8± 46.06 
MID DOSE 248.3± 14.72 248.3 ± 22.20 248.4 ± 17.42 
249.2 ± 
35.08 
249.4 ± 34.10 
HIGH DOSE 251.3± 23.51 251.7±33.07 252.4 ± 32.34 253 ± 4.08 253 ± 7.70 
P value (p)* NS NS NS NS NS 
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N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
 
Table 5.13: Food intake (gm/day) of Wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 42±5.21 42.2±4.22 42.8±3.13 43.2±6.72 44±6.80 
LOW DOSE 43.6±6.22 43.8±2.42 44.4±1.50 44.5±1.30 44.8±1.12 
MID DOSE 44.1±6.70 44.2±2.40 44.6±5.64 45.3±2.40 45.7±1.34 
HIGH DOSE 46.4±1.45 46.6±1.34 46.8±2.36 47.2±1.70 47.6±1.62 
P value (p)* NS NS NS NS NS 
 
 
Table 5.14: Haematological parameters of Wistar albino rats group exposed to 
MAHA MANJISHTADHI KASHAYAM 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 14.5±0.43 14.60±0.32 14.8±0.23 14.84±0.33 N.S 
Total WBC (×103   
l) 
12.71±0.40 12.82±0.21 12.94±0.60 13.06±1.40 N.S 
Neutrophils (%) 08.12±0.40 08.22±0.32 08.31±1.50 08.04±2.20 N.S 
lymphocyte (%) 90.12±1.60 90.14±1.40 90.16±1.44 91.20±1.64 N.S 
Monocyte (%) 0.1±0.02 0.1±0.01 0.1±0.04 0.1±0.03 N.S 
Eosinophil (%) 0.02±0.02 0.02±0.04 0.02±0.06 0.02±0.06 N.S 
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N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test 
 
 Table 5.15 : Biochemical Parameters of of Wistar albino rats group exposed to 
MAHA MANJISHTADHI KASHAYAM 
 
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) (mg/dl) 98.10±2.40 98.12±1.62 99.9±.08 99.9±5.25 N.S 
T.CHOLESTEROL(mg/dl) 109.14±3.10 109.25±2.40 109.30±1.58 110.21±1.60 N.S 
TRIGLY(mg/dl) 73.05±1.08 73.11±1.02 73.25±1.42 75.26±1.54 N.S 
LDL 68.5±4.13 68.4±1.05 68.3±1.03 
    
69.40±2.44 
NS 
VLDL 15.2±1.30 15.20±1.71 15.22±1.62 15.24±1.55 NS 
HDL 25.22±2.30 25.22±2.60 25.46±1.72 26.56±1.43 NS 
Ratio 
1(T.CHO/HDL) 
4.36±1.10 4.37±1.20 4.64±2.32 4.74±2.63 NS 
Ratio 2(LDL/HDL) 
 
2.76±2.33 2.72±1.40 2.79±2.10 2.84±04.02 NS 
Albumin (g/dL) 
3.9.42±0.50 3.9.62±0.54 3.9.48±4.20 4.02±3.24 NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Platelets cells103/µl 700.26±2.28 702.32±2.42 702.21±2.60 702.42±3.64 N.S 
Total RBC 106/µl 7.64±0.32 7.65±0.32 7.65±0.04 7.66±0.06 N.S 
PCV% 40.30±0.4 40.32±5.30 40.5±2.70 41.2±1.22 N.S 
MCHC g/dL 34.7±1.61 34.8±1.32 34.8±1.35 34.13±1.36 N.S 
MCV fL(µm3) 52.7±3.04 52.7±2.40 52.9±2.20 52.9±1.20 N.S 
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Table 5.16: Renal function test of of Wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM       
PARAMETERS CONTROL LOW DOSE 
MID 
DOSE 
HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 24.31±0.10 24.30±0.19 24.26±1.28 25.42±1.02 N.S 
CREATININE(mg/dl) 0.7±0.04 0.71±0.06 0.73±0.04 0.74±0.08 N.S 
BUN(mg/dL) 15.8±0.04 15.8±0.24 15.8±0.42 15.9±1.02 NS 
URIC ACID(mg/dl) 5.04±0.02 5.08±0.20 5.4±0.32 5.6±0.20 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
Table 5.17: Liver Function Test of Wistar albino rats group exposed to MAHA 
MANJISHTADHI KASHAYAM   
 
PARAMETERS CONTROL 
LOW 
DOSE 
MID DOSE HIGH DOSE 
P Value 
(p)*  
T 
BILIRUBIN(mg/dl). 
0.04±0.01 0.04±0.03 0.04±0.03 0.04±0.01 N.S 
SGOT/AST(U/L) 51.11±1.43 51.12±0.62 52.24±1.34 53.54±1.63 N.S 
SGPT/ALT(U/L) 87.11±1.43 87.24±1.14 88.44±1.36 88.33±0.21 N.S 
ALP(U/L) 166.30±2.11 166.1±2.10 166±1.14 167.3±2.01 N.S 
T.PROTEIN(g/dL) 6.9±0.14 6.9±0.41 7.00±0.60 7.2±0.41 N.S 
 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
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way ANOVA followed by Dunnett’s test 
 
5.8. HISTO-PATHOLOGY 
Fig no:5.2 
CONTROL GROUP                                    HIGH DOSE 
 
Kidney: 
 
 
 
Liver 
 
 
 
 Spleen 
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5.9.PHYTOCHEMOCAL ANALYSIS 
Table no :5.18 
S.NO TEST OBSERVATION 
1 ALKALOIDS - 
2 FLAVANOIDS - 
3 GLYCOSIDES + 
4 STEROIDS - 
5 TRITERPENOIDS + 
6 COUMARIN - 
7 PHENOL + 
8 TANIN + 
9 PROTEIN - 
10 SAPONINS + 
11 SUGAR + 
12 ANTHOCYANIN - 
13 BETACYANIN - 
 
 
PHYTOCHEMICAL ANALYSIS 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is           indicated by the formation of yellow color. 
Test for saponins:  
       To the test sample, 5 ml of water was added, and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
       To the test sample, ferric chloride was added, formation of a dark blue or greenish 
black color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water 
bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
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filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer 
is separated and 10% ammomia solution is added to it. Pink colour indicates 
presence of glycosides. 
Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow color 
indicates the presence of Flavonoids. 
 
Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was added.  
A bulky white precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
To the test sample,2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into 
red and sulphuric acid layer showed yellow with green fluorescence. It showed the 
presence of steroids. 
Triterpenoids 
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
Test for Cyanins 
A. Aanthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min at 
100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Proteins (Biuret Test) 
 To extracts 1% solution of copper sulphate was added followed by 5% solution 
of sodium hydroxide, formation of violet purple colour indicates the presence of 
proteins. 
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RESULTS 
Fig no :5.3                                  Fig no :5.4                                     Fig no :5.4 
 
 Test for Alkaloids                      Test for Flavonoids                   Test for Glycosides 
 
 
                                                                           
 
 
Fig no :5.5                         Fig no :5.6                                  Fig no :5.7 
Test for Steroids             Test for Triterpenoids           Test for Coumarins 
 
 
                                                             
  
Fig no :5.8                                   Fig no :5.9                       Fig no :5.10 
Test for Phenols                        Test for Proteins         Test for Carbohydrates 
 
                                                              
Lkl;  
100 
 
2018 RESULTS AND OBSRVATION 
Fig no :5.11,Test for Anthocyanins/ Beta cyanins 
 
 
                                          
 
                5.10. PHARMACOLOGICAL ACTIVITY  
 
ACTIVITY:  ANTI-PSORIATIC ACTIVITY  
CELL LINE MODEL:  Hacat CELL LINE 
    6.25                                                            12.5 
     
25                                                                        50 
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100 
 
 
     
                   Table no :5.19, % viability = (OD of Test/ OD of Control) X 100 
Sample   
Concentration(µg/ml) 
 Average OD 
at  540nm 
Percentage 
Viability 
Control(LPS Induced) 
0.5969 100 
Sample code : Maha 
manjishtathi 
Kashayam   
6.25 0.5316 89.06 
12.5 0.473 79.24 
25 0.4247 71.15 
50 0.2038 34.14 
100 0.2385 19.96 
 
 
Results of the study observed with respect to the following criteria 
 
1. Selection of cases 
2. Age distribution 
3. Gender distribution 
4. Occupational distribution 
5. Family history 
6. Diet habit 
7. Trigerring factors 
8. Socio economic status 
9. Clinical features 
10. Other general clinical features 
11. Results after improvement 
12. Improvement before and after treatment 
a) Group I Maha manjishtathi kashayam 
b) Group II Chemparuthi poo ennai & Deep relaxation technique 
c) Group III Maha manjishtathi kashayam ,Chemparuthi poo ennai & Deep 
relaxation technique. 
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13. Kaalam distribution 
14. Paruvakaalam 
15. Thinai reference 
16. Distribution of three doshas 
17. Udal kattugal reference 
18. En vagai tervugal 
19. Neer kuri, Nei kuri reference 
OBSERVATIONS: 
      In the present clinical study, 60 patients of Psoriasis were treated in the three 
group completed the study plan. Following are the demographical observation 
made in this clinical study. 
 
1.SELECTION OF CASES: 
Table no :5.20 
S.NO  SELECTION OF CASES 
 
NO OF 
 PATIENT 
PERCEN 
TAGE 
1 INTERNAL  MEDICINE 
 
20 33.3% 
2 
 
EXTERNAL & PRANAYAMAM 20 33.3% 
3 
 
INTERNAL, EXTERNAL 
& PRANAYAMAM 
20 33.3% 
 
 
 
OBSERVATION: 
Among 60 cases 20 cases (33.3%) were treated with internal and 20 cases (33.3%) 
were treated with external and deep relaxation technique, 20 cases (33.3%) were 
treated with internal, external and deep relaxation technique.  
 
 
 
 
Internal 
Medicine
34%
External 
Medicine & 
DRT
33%
Internal, 
External & 
DRT
33%
Selection of Cases
Internal Medicine
External Medicine
& DRT
Internal, External &
DRT
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 2.  AGE DISTRIBUTION: 
                               Table no :5.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
     Among 60 cases, high age incidence (40%) is between 51-60yrs, low age incidence 
(3.33%) is between 41-50yrs. 
 
 
3. GENDER DISTRIBUTION: 
Table no :5.22 
 
S.NO  SEX NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1 
 
MALE         28     46.66% 
2 
 
FEMALE          32      53.33% 
 
Age 18-30
27%
Age 31-40
27%
Age 41-50
14%
Age 51-60
32%
AGE DISTRIBUTION
Age 18-30 Age 31-40 Age 41-50 Age 51-60
S.NO AGE IN YEARS 
 
NO OF CASES PERCENTAGE 
1 
 
18 – 30 16 26.66% 
2 
 
31 – 40 16 26.66% 
3 
 
41 – 50 8 13.33% 
4 
 
51 – 60 19 31.66% 
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OBSERVATION: 
Among 60 patients, 28patients (46.66%) were male, 32 patients ( 53.33%) were 
female. 
 
 
4.OCCUPATION DISTRIBUTION: 
Table no :5.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Male
47%
Female
53%
Gender Distribution
S.NO NATURE OF 
WORK 
NO OF 
CASES 
PERCENTAGE 
1 HOME MAKER 
 
12 20% 
2 FARMER 
 
8 13.33% 
3 COOLI 
 
9 15% 
4 BUSINESS 
 
5 8.33% 
5 DRIVER 
 
5 8.33% 
6 STUDENT 
 
7 11.6% 
7 TEACHER 
 
3 5% 
                  
8 
ELECTRICIAN 
 
4 6.66% 
9 LAB TECHNICIAN 
 
1 1.66% 
10 
 
TAILOR 6 10% 
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OBSERVATION: 
    The patients were selected for the study belongs to various occupational statuses 
and no particular association was found. 
 
 
6. FAMILY HISTORY: 
Table no :24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
   Among 60 patients only 12 patients (20%) were having positive family history.  
20%
13%
15%8%
8%
12%
5%
7% 2%
10%
Occupation Distribution
Home Maker
Farmer
Cooli
Business
Driver
Student
Teacher
20%
80%
Family History
Positive History Negative History
S.NO 
 
FAMILY HISTORY NO OF CASS PERCENTAGE 
1 
 
POSITIVE HISTORY 12 20% 
2 
 
NEGATIVE HISTORY 48 80% 
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7. DIET HABIT 
Table no :5.25 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
     Among 60 patients, 51 patients (85%) were non vegetarian, 9 patients (15%) were 
vegetarian. 
 
 
7. TRIGERRING FACTORS: 
Table no :.5,26 
S.NO Triggering factors No of cases Percentage 
1 
 
Infection 1 1.6% 
2 Reaction to certain medicine 0 0% 
3 Skin injury 2 3.33% 
4 
 
Psycho- somatic 6 10% 
5 
 
Alcohol 11 18.33% 
6 Smoking 12 20% 
7 Unknown 18 30% 
 
15%
85%
Diet Habit
Veg Non Veg
S.NO DIET NO OF CASES PERCENTAGE 
 
1 
 
VEGETARIAN 9 15% 
2 
 
MIXED DIET 51 85% 
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OBSERVATION: 
 Among 60 patients, 30% of them had unknown triggering factor, while 20% had 
smoking as the factor, 18.33% due to alcohol, 10% has psycho-somatic reason, 3.33% 
were due to skin injury. 
 
8. SOCIO ECONOMIC STATUS: 
Table no :5.27 
 
SNO SOCIO ECONOMIC STATUS NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1 
 
POOR 35 58.33% 
2 
 
MODERATE 20 33.33% 
3 
 
HIGHER 5 8.33% 
 
 
 
 
0
5
10
15
20
25
30
No. of Cases
Percentage
59%33%
8%
Socio Economic status
Poor Moderate High
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OBSERVATION: 
58.33% of the patients were selected from poor and 33.33% of patients were from 
moderate and remaining 8.33% belongs to higher. 
9. CLINICAL FEATURES: 
Table no :5.28 
S.No CLINICAL FEATURES BEFORE TREATMENT AFTER TREATMENT 
No of 
patients 
Percentage 
 
No of 
patients 
Percentage 
1 ERYTHEMATOUS PATCHES 
WITH WHITE SILVERY SCALES  
60 
 
100% 3 5% 
2 
 
ITCHING 41 68% NIL 0% 
3 
 
SCALP LESION 21 21% NIL 0% 
4 
 
AUSPITZ SIGN 11 18.3% 2 3.3% 
5 
 
CANDLEGEASE SIGN 4 6.6% NIL 0% 
6 
 
KOBNER’S PHENOMENON 9 15% 2 3.3% 
7 
 
NAIL CHANGES 5 8.3% 3 5% 
8 PALM AND SOLE LESIONS 
 
28 46.6% 3 5% 
9 JOINT INVOLVEMENT 2 3.3% 1 1.6% 
 
 
 
 
OBSERVATION: 
     Among 60 patients Erythematous patches with silvery scales and Auspitz sign 
60
41
21 11 4 9 5
28
23 0 0 2 0 2 3 3 1
0
10
20
30
40
50
60
70
Before Treatment After Treatment
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,Itching , Koberner’s phenomenon as their predominant symptoms but After treatment 
, the symptoms are markedly reduced ,nail and joint involvements are mildly present. 
 
10. OTHER GENERAL CLINICAL FEATURES: 
Table no :5.29 
 
 
SNO 
 
Clinical features 
 
No of cases 
 
Percentage 
 
 
1 Constipation 
 
5  8.33 % 
2 Cough 
 
2 3.33% 
3 Insomnia 
 
2 3.33% 
4 
 
Loss of appetite 3 5% 
5 
 
Anaemia 6 10% 
 
 
 
 
 
 
 
 
OBSERVATION: 
 
Among 60 patients 5 had constipation, 2 had cough , 2 had insomnia, 3 had loss of 
appetite, 6 were anemic. 
28%
11%
11%17%
33%
Other General Clinical Features
Constipation
Cough
Insomnia
Loss of appetite
Anaemia
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RESULTS AFTER TREATMENT 
 
10. IMPROVEMENT IN PATIENTS TREATED WITH MAHA 
MANJISHTATHI KASHAYAM (INT) - GROUP I PATIENTS 
Table no :5.30 
S.No CLINICAL FEATURES BEFORE TREATMENT AFTER TREATMENT 
No of 
patients 
Percentage 
 
No of 
patients 
Percentage 
1 ERYTHEMATOUS PATCHES 
WITH WHITE SILVERY SCALES  
20 
 
100% 1 5% 
2 
 
ITCHING 12 60% NIL 0% 
3 
 
SCALP LESION 5 25% 1 5% 
4 
 
AUSPITZ SIGN 17 85% 1 5% 
5 
 
CANDLEGREASE SIGN 4 20% NIL 0% 
6 
 
KOBNER’S PHENOMENON 6 30% NIL 0% 
7 
 
NAIL CHANGES 2 10% NIL 0% 
8 PALM AND SOLE LESIONS 
 
11 55% 3 15% 
9 JOINT INVOLVEMENT 0 0% 0 0% 
 
 
 
OBSERVATION: 
 Majority of the cases have Erythema, Itching, Auspitz sign , Kobner’s phenomenon  
as their predominant symptoms.     
100
60
25
85
20
30
10
55
05 0 5 5 0 0 0
15
0
Group 1 – Improvement
Before Treatment % After Treatment %
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12. IMPROVEMENT IN PATIENTS TREATED WITH CHEMPARUTHI POO 
ENNAI (EXT) AND DEEP RELAXATION TECHNIQUE - GROUP II 
PATIENTS 
Table no :5.31 
S.No CLINICAL FEATURES BEFORE TREATMENT AFTER TREATMENT 
No of 
patients 
Percentage 
 
No of 
patients 
Percentage 
1 ERYTHEMATOUS 
PATCHES 
WITH WHITE SILVERY 
SCALES  
20 
 
100% 5 25% 
2 
 
ITCHING 17 85% 8 40% 
3 
 
SCALP LESION 8 40% 3 15% 
4 
 
AUSPITZ SIGN 10 50% 4 20% 
5 
 
CANDLEGEASE SIGN 6 30% 1 5% 
6 
 
KOBNER’S 
PHENOMENON 
3 15% 2 10% 
7 
 
NAIL CHANGES 3 15% 2 10% 
8 PALM AND SOLE 
LESIONS 
 
9 45% 5 25% 
9 JOINT INVOLVEMENT 1 1.6% 1 1.6% 
 
 
 
 
 
OBSERVATION:     
Majority of the cases have Erythema, Itching, Auspitz sign , Kobner’s phenomenon  
as their predominant symptoms.     
100 85
40 50 30 15 15
45
1.6
25 40 15 20 5 10 10
25
1.6
Group 2 – Improvement
Before Treatment % After Treatment %
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12.IMPROVEMENT IN PATIENTS TREATED WITH INTERNAL & 
EXTERNAL MEDICINE WITH THERAPY IN GROUP III PATIENTS 
 
Table no :5.32 
S.No CLINICAL FEATURES BEFORE TREATMENT AFTER TREATMENT 
No of 
patients 
Percentage 
 
No of 
patients 
Percentage 
1 ERYTHEMATOUS PATCHES 
WITH WHITE SILVERY 
SCALES  
20 
 
100% NIL 0% 
2 
 
ITCHING 13 65% NIL 0% 
3 
 
SCALP LESION 9 45% NIL 0% 
4 
 
AUSPITZ SIGN 11 55% 2 10% 
5 
 
CANDLEGEASE SIGN 4 20% NIL 0% 
6 
 
KOBNER’S 
PHENOMENON 
8 40% 1 5% 
7 
 
NAIL CHANGES 4 20% 2 10% 
8 PALM AND SOLE 
LESIONS 
 
12 60% 3 15% 
9 JOINT INVOLVEMENT 
 
2 10% 1 5% 
 
 
 
 
 
OBSERVATION: 
 
Majority of the cases have Erythema, Itching, Auspitz sign , Kobner’s phenomenon  
as their predominant symptoms.     
100
65
45
55
20
40
20
60
10
0 0 0
10
0 5
10 15 5
Group 3 – Improvement
Before Treatment % After Treatment %
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11. RESULTS AFTER TREATMENT: 
Table no :5.33 
S.NO RESULTS NO OF CASES PERCENTAGE 
1 GOOD 
 
     48       80% 
2 MODERATE 
 
      9       15% 
3 MILD 
 
      3        5% 
4 POOR 
 
       0        0% 
 
 
 
OBSERVATION: 
Among 80% of patients were treated with good, 15% of patients were treated with 
moderate, 5% of patients were treated with mild. 
 
12. KAALAM DISTRIBUTION: 
Table no :5.34 
 
 
 
 
 
 
80%
15%
5%
0%
RESULTS AFTER TREATMENT
GOOD
MODERATE
MILD
POOR
S.NO 
 
           Kaalam  No of cases   Percentage 
1 Vatha kaalam(1-33yrs)       19 
 
31% 
2 Pitha kaalam (34-66yrs)      41 
 
69% 
3 Kapha kaalam(67-100yrs)       0 
 
0% 
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OBSERVATION: 
 Out of 60 patients, 69 patients were reported in pitha kaalam, 31patients were in 
vatha kaalam. 
 
13. PARUVA KAALAM: 
Table no :5.35 
 
 
S.No 
 
               
Paruva kaalam 
 
No of cases 
 
Percentage 
1 Kaar kaalam(Aavani&Puratasi) 
(Aug16-Oct15) 
    10 16.6% 
2 Koothir kaalam(Aippasi&Karthigai) 
(Oct16-Dec15) 
    10 16.6% 
3 
 
Munpani kaalam(Margazhi&Thai) 
(Dec16-Feb15) 
     9 15% 
4 Pinpani kaalam(Maasi&Panguni) 
(Feb16-Aprl15) 
      0    0% 
5 
 
Elavenil kaalam(Chithirai&Vaikasi) 
(Aprl16-June15) 
       6 10% 
6 
 
Muthuvenil kaalam(Aani&Aadi) 
(June16-Aug15) 
      25 41.6% 
 
 
Vaatham(1-33yrs)
31%
Pitham(34-66yrs)
69%
Kabam(67-100yrs)
0%
Kaalam 
Vaatham(1-33yrs) Pitham(34-66yrs) Kabam(67-100yrs)
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OBSERVATION: 
   Among the 60 patients enrolled for this study, out of this 10 patients reported 
in Kaar kaalam, 10patients reported in Koothir kaalam,  9 patients in Munpani kaalam 
, 6 patients in Elavenil kaalam ,25 patients in Muthuvenil kaalam. 
 
14. THINAI REFERENCE: 
Table no :5.36 
 
S.No 
 
 
Thinai 
 
No of cases 
 
Percentage 
1 
 
Kurunji(Hill area)        0 0% 
2 
 
Mullai(Forest area)        0 0% 
3 
 
Marutham(Fertile land)        0 0% 
4 
 
Neithal(Coastal area)        60 100% 
5 
 
Pallai(Desert land)          0 0% 
 
 
10
10
9
0
6
25
PARUVA KAALAM
Kaar Kaalam
Koothir Kaalam
Munpani Kaalam
Pinpani Kaalam
Elavenil Kaalam
Muthuvenil Kaalam
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OBSERVATION: 
 Among the 60 patients, 60 patients were from Neithal (Coastal area). 
 
 
15. DISTRIBUTION OF THREE DOSHAS – VATHAM 
Table no :5.37 
 
 
 
 
 
0
0
0
60
0
0%
0%
0%
100%
0%
0 10 20 30 40 50 60 70
KURUNJI
MULLAI
MARUTHAM
NEITHAL
PALLAI
Percentage No of cases
 
S.No 
 
 
Classification of vatham 
 
No of cases 
 
Percentage 
1 
 
Pranan      0 0% 
2 
 
Abanan      2 3% 
3 
 
Uthanan      0 0% 
4 
 
Samanan     60 100% 
5 
 
Viyanan     60 100% 
6 
 
Nagan      0 0% 
7 
 
Koorman       0 0% 
8 
 
Kirukaran      5  8% 
9 
 
Devadhathan        2 3% 
10 
 
Dhananjayan         0 0% 
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OBSERVATION: 
Samanan and Viyanan were found to be affected in all the 60 patients, Abanan 
and Kirukaran were affected in 2 and 5 , 2 in devathathan. 
 
PITHAM 
Table no :5.38 
 
S.No 
 
 
Classification of Pitham 
 
No of cases 
 
 
Percentage 
1 Anar pithan      10 
 
17% 
2 
 
Ranjakam      10 17% 
3 
 
Santhikam       2 3.3% 
4 
 
Alosagam        0 0% 
5 
 
Prasakam        60 100% 
 
 
 
0 2 0
60 60
0 0 5 2 00% 3% 0% 100% 100% 0% 0% 8% 3% 0%
DISTRIBUTION OF THREE DOSHAS -
VATHAM
No. of Cases Percentage
12%
12%
3%
0%
73%
Pitham
Anar Pitham
Ranjakam
Santhikam
Alosagam
Prasakam
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OBSERVATION: 
 
Prasakam was affected in all 60 cases, Anar pitham was affected in 10 cases,  
Ranjaka pitham was affected in 10 cases.  Santhikam pitham was affected in 2 cases. 
 
KABAM 
Table no :5.39 
 
S.No 
 
Classification of Kabam 
 
No of cases 
 
 
Percentage 
1 Avalambagam     0 
 
0% 
2 Kilethagam     2 
 
3.3% 
3 
 
Pothagam      0 0% 
4 Tharpagam 
 
     0 0% 
5 
 
Santhigam       1 1.6% 
 
 
 
 
 
 
 
OBSERVATION: 
 
    Kilethagam was  found to be affected 3.33% of the cases.Santhigam were to be  
affected as  1.6% of the cases.  
 
 
0
2
0 0
1
3.3
1.6
Avalambagam Kilethagam Pothagam Tharpagam Snathigam
KABAM
No Of Cases Percentage %
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16. UDAL KATTUGAL REFERENCE: 
Table no :5.40 
 
S.No 
 
Udal kattual      
 
No of cases 
 
 
Percentage 
1 
 
Saaram        60    100% 
2 Senner        60    100% 
 
3 Oon 
 
       60    100% 
4 Kozhupu 
 
       20     33% 
5 Enbu        0 
 
    0% 
6 Moolai        0 
 
    0% 
7 Sukkilam/suronitham         0 
 
     0% 
 
 
 
 
 
 
OBSERVATION: 
 
   Among the 60 patients, Saaram, Senneer & Oon were affected in all the cases, and 
Kozhupu was seen affected in 20 patients. 
 
 
60 60 60
20
0 0 0
100 100 100
33
0 0 0
Udal Kattukal reference
No of cases Percentage
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17. EN VAGAI THERVUGAL: 
Table no :5.41 
 
 
 
 
 
OBSERVATION: 
 
 In En vagai thervugal, Niram  and sparism were found affected in all the 60 cases. 
Vizhi was affected in 10% of the cases. The naadi nadai seen in Psoriasis patients 
were vathapitham  37%, vatha kabam 13% and pitha kabam 50%. 
 
0
60
0 6
60
3 0
22
8
30
0
100
0
10
100
5 0
37
13
50
En Vagai Thervu
No of Cases Percentage
S.No 
 
En vagai thervugal No of cases Percentage 
1 Naa 
 
0 0% 
2 Niram 
 
60 100% 
3 Mozhi 
 
0 0% 
4 Vizhi 
 
6 10% 
5 Sparism 
 
60 100% 
6 Malam 
 
2 3% 
7 Moothiram 
 
0 0% 
8 
 
 
 
Naadi 
 
  
a.Vatha pitham 22 37% 
b. Vatha kabam 8 13% 
c. Pitha kabam 30 50% 
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18. NEERKURI, NEIKURI REFERENCE: 
Table no :5.42 
 
 
S.No 
 
 
Types of Test 
 
No of cases 
 
Percentage 
1 Neerkuri: 
‘‘Vaikkol niram’’(straw yellow) 
60 100% 
2 
 
a.(vatham) ‘‘Aravena neelal’’ 
 
16 27% 
b.(pitham) ‘‘Aazhi pol paravel’’ 24 40% 
c.(kabam) ‘‘Muthuthothu nitral’’ 
 
20 33% 
 
 
 
 
 
OBSERVATION: 
 
  Neerkuri showed vaikkol Niram in all the cases. Neikkuri showed vatha kuri among 
27%, pitha kuri in 40% and kaba kuri in 33% patients  
 
 
 
 
60
16
24 20
100
27
40
33
Neerkuri - Straw yelow Vatham Pitham Kabam
NEERKURI, NEIKURI REFERENCE
No of Cases Percentage
Lkl;  
122 
 
2018 RESULTS AND OBSRVATION 
PASI SCORE: 
 
The body is divided into four sections (head (H) (10% of a person’s skin); 
arms (A) (20%); Trunk (T)(30%); legs(L) (40%). Each of these areas is scored by 
itself and then the four scores are combined in to the final PASI. For each section, the 
percent of area of skin involved is estimated and then transformed into a grade from 0 
to 6. 
➢ 0% of involved area, grade: 0 
➢ <10% of involved area, grade:1 
➢ 10-29% of involved area,grade:2 
➢ 30-49% of involved area, grade:3 
➢ 50-69% of involved area, grade:4 
➢ 70-89% of involved area, grade:5 
➢ 90-100% of involved area, grade:6 
 Within each area, the severity is estimated by four clinical signs: The four signs are: 
1. Redness(Erythema) 
2. Thickness(induration) 
3. Scaling (Desquamation) 
 
The area intensity of each sign in each body region is assessed as: 
none(0),  
mild(1),  
moderate(2)  
and severe(3). 
 
Table no :5.43 
Score Indensity of Erythema, Induration, 
Scaling 
0 None, absent 
1 Mild 
2 Moderate 
3 Severe 
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Calculations: 
 
For each region, record the intensity for each of four signs and calculate the severity 
score. 
             
                   Severe score = Erythema + thickness+ scaling intensity. 
 
For each region, multiple the severity score by the area score and by a multiplier. The 
multiplier is different for each body site. 
 
Head and neck: severity score x area score x 0.1(in children 0-7 yrs, x 0.2) 
Trunk: severity score x area score x 0.3 
Upper limb: severity score x area score x 0.2 
Lower limb: severity score x area score x 0.4(in children 0-7 yrs, x 0.3) 
 
Add up the total scores for each region to determine the final PASI score. 
The minimum PASI score is 0 and the maximum PASI SCORE IS 72 
 
 
 
GROUP I MAHA MANJISHTATHI KASHAYAM (INT) PASI SCORE 
Table no :5.44 
S.No 
 
OP.No Age 
/Sex 
Initial  
PASI  
Score 
Post  
PASI  
Score 
% of 
reduction 
in PASI 
Score 
1 
 
8935 52/F     9.8     1.6 83% 
2 
 
1437 53/M     22      2.8  87% 
3 
 
483 53/M 13.1      0.5 96% 
4 
 
473 52/F    19.2      0.9 95% 
5 
 
67 58/F     5.3      0 100% 
6 
 
1631 55/M     18      0.4 98% 
7 
 
3757 48/F 8.4      0.2 97% 
8 6164 49/F 31.5      0.7 98% 
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9 
 
5783 55/F    18.5      0.4 98% 
10 
 
1129 36/M     2.6      0 100% 
11 
 
8251 28/M    10.4     0.5 95% 
12 
 
9493 33/F    2.4      0 100% 
13 
 
8262 40/M    20.9      1.2 94% 
14 
 
7966 37/M     12     3. 6 70% 
15 
 
2125 52/F    23.6     2.4 90% 
16 
 
8543 48/F 18.6  1.4 92% 
17 
 
8121 34/M    4.8      0 100% 
18 7849 58/F    13.8     1.6 88% 
19 
 
6906 36/M    26.2 7 73% 
20 
 
6430 38/M    10.8 4.5 58% 
 
 
 
 
CLINICAL IMPROVEMENT BASED ON PASI SCORE 
PATIENT TREATED WITH MAHA MANJISHTATHI KASHAYAM (INT) 
Table no :5.45 
 
S. No EFFECT OF TRIAL 
MEDICINE 
NO OF  
PATIENTS 
PERCENTAGE 
      % 
1 Marked improvement  
PASI ≥ 75% 
     17       85% 
2 
 
Moderate improvement 
PASI < 75% 
      2       10% 
3 
 
Mild improvement 
PASI ≥ 50% 
     1        5% 
4 
 
Poor improvement 
 PASI >25% 
    NIL        0% 
               TOTAL 
 
     20      100% 
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OBSERVATION: 
 
  Among the 20 patients treated with internal medicine, 17 out of 20(85%) patients 
had marked improvement, 2 out of 20(10%) patients had moderate improvement, 1out 
of 20(5%) patient had mild improvement. 
 
GROUP II PATIENTS TREATED WITH CHEMPARUTHI POO ENNAI 
(EXT) AND DEEP RELAXATION TECHNIQUE (THERAPY)  PASI SCORE 
 
Table no :5.46 
S.No 
 
OP.No Age 
/Sex 
Initial  
PASI  
Score 
Post  
PASI  
Score 
% of 
reduction 
in PASI 
Score 
1 4314 58/M     14.4    4.4 69% 
2 7651 50/F     11      0 100% 
3 2497 57/F      4.5     0.4 91% 
4 625 53/F     18.8     7.8 49% 
5 4752 18/F      5.4     1.2 77% 
6 2930 21/F     10.9      1.8 83% 
7 3695 42/F      3.6      0 100% 
8 4635 24/M     14.5      1.2 92% 
9 9502 34/M    4.9      0.2 96% 
10 4158 46/M     14      4.4 69% 
11 2355 55/M    6     0.7 88% 
12 3989 20/M     13.2      2 85% 
13 3612 52/M     8.4      1 88% 
14 9287 48/F     16.4 8.4 48% 
15 6983 37/F     4.5      0 100% 
16 8514 37/M     15.8      2.7 83% 
17 9039 22/F     7.4      1.2 84% 
85%
10% 5%
0%
Clinical Improvement Based on Pasi Score –
Internal Drug
Marked
Moderate
Mild
Poor
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18 8745 29/M     5.1      0 100% 
19 9864 53/M     2.8      0 100% 
20 7968 27/M     10.8       2.4 78% 
 
 
CLINICAL IMPROVEMENT BASED ON PASI SCORE  
PATIENT TREATED WITH CHEMPARUTHI POO ENNAI (EXT) & DEEP 
RELAXATION TECHNIQUE 
Table no :5.47 
 
S.No EFFECT OF TRIAL 
MEDICINE 
NO 
 OF  
PATIENTS 
PERCENTAGE 
         % 
1 Marked improvement  
PASI ≥ 75% 
     16       80% 
2 
 
Moderate improvement 
PASI < 75% 
     2       10% 
3 
 
Mild improvement 
PASI ≥ 50% 
     2        10% 
4 
 
Poor improvement PASI 
>25% 
    NIL       0% 
               TOTAL 
 
     20       100% 
 
 
 
 
OBSERVATION: 
  Among the 20 patients treated with external oil & Deep relaxation technique, 16 out 
of 20(80%) patients had marked improvement, 2 out of 20(10%) patients had 
moderate improvement.2 out of 20(10%) patients had mild improvement. 
 
 
 
80%
10%
10%
0%
Clinical Improvement Based on Pasi Score 
– External oil & Therapy
Marked
Moderate
Mild
Poor
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GROUP III - MAHA MANJISHTATHI KASHAYAM (INT),CHEMPARUTHI 
POO ENNAI  (EXT) DEEP RELAXATION TECHNIQUE (THERAPY)  PASI 
SCORE 
Table no :5.48 
 
S.No 
 
OP.No Age 
/Sex 
Initial  
PASI  
Score 
Post  
PASI  
Score 
% of reduction in 
PASI Score 
1 
 
7642 17/F     8.4      2 76% 
2 
 
7206 34/M     4.8      0 100% 
3 
 
3328 27/F 13.2      1.2 91% 
4 
 
2118 34/F     4.7      0 100% 
5 
 
1044 23/F 10.8      1.6 85% 
6 
 
1032 30/F     2.1      0 100% 
7 
 
8743 57/M      4.2      0 100% 
8 
 
5951 60/M     8.4      1.2 86% 
9 
 
7020 29/F  2      0 100% 
10 
 
6253 21/F  15.3      4.8 69% 
11 
 
3255 27/M    8.3     0 100% 
12 
 
4269 38/F  19.3      1.8 91% 
13 
 
2984 55/F     3.6      0 100% 
14 
 
8659 48/F  15.6      0 100% 
15 
 
6563 32/M  11.8      3.2 72% 
16 
 
2826 28/F     41.6      4.8 86% 
17 
 
2088 43/F     14.4      2.1 85% 
18 4189 30/M     2.8      0 100% 
19 
 
6727 32/M     19.4      4.1 79% 
20 
 
7153 51/M     10.8      0 100% 
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CLINICAL IMPROVEMENT BASED ON PASI SCORE 
PATIENT TREATED WITH MAHA MANJISHTATHI KASHAYAM(INT) , 
CHEMPARUTHI POO ENNAI (EXT) & DEEP RELAXATION TECHNIQUE 
Table no :5.49 
 
S.No EFFECT OF TRIAL 
MEDICINE 
NO OF  
PATIENTS 
PERCENTAGE 
1 Marked improvement  
PASI ≥ 75% 
      18      90% 
2 
 
Moderate improvement 
PASI < 75% 
       2       10% 
3 
 
Mild improvement 
PASI ≥ 50% 
    NIL       0% 
4 
 
Poor improvement PASI 
<25% 
   NIL       0% 
               TOTAL 
 
    20     100% 
 
 
 
Among the 20 patients treated with Internal, external medicine & deep relaxation 
technique, 18 out of 20(90%) patients had marked improvement, 2 out of 20(10%) 
patients had moderate improvement. 
 
 
 
 
 
 
90%
10%
0%
0%
Clinical Improvement Based on Pasi Score –
Internal, External & Therapy
Marked Moderate Mild Poor
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CASE REPORT FOR PATIENTS TREATED IN INTERNAL MAHA 
MANJISHTATHI KASHAYAM 
Table no :5.50 
 
S.No OP.No Age/ 
Sex 
Initial 
PASI 
Score 
Post 
PASI 
Score 
Symptoms 
Reduced 
Per weak 
Result 
1 
 
8935 52/F     9.8     1.6 3 Marked 
2 
 
1437 53/M 22      2.8 3 Marked 
3 
 
483 53/M 13.1      0.5 3 Marked 
4 
 
473 52/F 19.2      0.9 3 Marked 
5 
 
67 58/F 5.3      0 3 Marked 
6 
 
1631 55/M   18      0.4  3 Marked 
7 
 
3757 48/F   8.4      0.2  3 Marked 
8 
 
6164 49/F  31.5      0.7  3 Marked 
9 
 
5783 55/F  18.5      0.4  3 Marked 
10 
 
1129 36/M   2.6      0  3 Marked 
11 
 
8251 28/M  10.4     0.5 3 Marked 
12 
 
9493 33/F    2.4      0 3 Marked 
13 
 
8262 40/M   20.9      1.2 3 Marked 
14 
 
7966 37/M    12     3. 6 2 Moderate 
15 
 
2125 52/F   23.6     2.4 3 Marked 
16 
 
8543 48/F   18.6      1.4 3 Marked 
17 
 
8121 34/M    4.8      0 3 Marked 
18 
 
7849 58/F   13.8     1.6 1 Mild 
19 
 
6906 36/M   26.2      3.5 4 Moderate 
20 
 
6430 38/M   10.8     1.9 3 Marked 
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CASE REPORT PATIENT TREATED IN EXTERNAL CHEMPARUTHI POO 
ENNAI & DEEP RELAXATION TECHNIQUE  
Table no :5.51 
 
S.NO OP.No Age/ 
Sex 
Initial  
PASI 
Score 
Post 
PASI 
Score 
Symptoms  
Reduced 
Per weak 
Result 
1 
 
4314 58/M   14.4    0.5 3 Marked 
2 
 
7651 50/F    11      0 3 Marked 
3 
 
2497 57/F   4.5     0.4 3 Marked 
4 
 
625 53/F   18.8     4.4 2 Moderate 
5 
 
4752 18/F   5.4     1.2 3 Marked 
6 
 
2930 21/F   10.9      2.8 3 Marked 
7 
 
3695 42/F   3.6      0 3 Marked 
8 
 
4635 24/M   14.5      1.2 3 Marked 
9 
 
9502 34/M    4.9      0.2 3 Marked 
10 
 
4158 46/M     14      4.4 1 Mild 
11 
 
2355 55/M      6     0.7 3 Marked 
12 
 
3989 20/M   13.2      3.6 3 Marked 
13 
 
3612 52/M    8.4      1 3 Marked 
14 
 
9287 48/F   16.4      2.2 3 Marked 
15 
 
6983 37/F    4.5      0 3 Marked 
16 
 
8514 37/M   15.8      2.7 3 Marked 
17 
 
9039 22/F    7.4      1.2 3 Marked 
18 8745 29/M    5.1      0 3 Marked 
19 
 
9864 53/M    2.8      0 3 Marked 
20 
 
7968 27/M   10.8       4.4 1 Mild 
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CASE REPORT PATIENT TREATED IN MAHA MANJISHTATHI 
KASHAYAM (INT) & CHEMPARUTHI POO ENNAI(EXT) WITH DEEP 
RELAXATION TECHNIQUE 
Table no :5.52 
S.No OP.No Age/ 
Sex 
Initial  
PASI  
Score 
Post 
PASI 
Score 
Symptoms 
Reduced 
Per weak 
Result 
1 
 
7642 17/F     8.4      2 3 Marked 
2 
 
7206 34/M     4.8      0 3 Marked 
3 
 
3328 27/F     13.2     1.2 3 Marked 
4 
 
2118 34/F     4.7      0 3 Marked 
5 
 
1044 23/F     10.8     1.6 3 Marked 
6 
 
1032 30/F     2.1      0 3 Marked 
7 
 
8743 57/M      4.2      0 3 Marked 
8 
 
5951 60/M     8.4     1.2 3 Marked 
9 
 
7020 29/F      2      0 3 Marked 
10 
 
6253 21/F    15.3     4.8 2 Moderate 
11 
 
 
3255 27/M    8.3     0 3 Marked 
12 
 
4269 38/F    19.3     1.8 3 Marked 
13 
 
2984 55/F    3.6      0 3 Marked 
14 
 
8659 48/F    15.6      0 3 Marked 
15 
 
6563 32/M    11.8     3.2 3 Marked 
16 
 
2826 28/F    41.6     4.8 3 Marked 
17 
 
2088 43/F    14.4     2.1 3 Marked 
18 4189 30/M     2.8      0 3 Marked 
19 
 
6727 32/M    19.4     2.1 3 Marked 
20 
 
7153 51/M    10.8      0 3 Marked 
COMPARISON IN EFFECT OF TRAIL MEDICINE  
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GROUP I, II, III USING PASI SCORE 
Table no :5.53 
 
S.NO EFFECT OF 
TRAIL MEDICINE 
NO OF 
PATIENTS  
GROUP I 
NO OF 
PATIENTS  
GROUP II 
NO OF 
PATIENTS  
GROUP III 
% OF THE 
PASI 
SCORE 
1 Marked 
improvement  
PASI ≥ 75% 
17 16 18 85% 
2 Moderate 
improvement  
PASI< 75% 
2 2 2 10% 
3 Mild improvement  
PASI ≥ 50% 
1 2 NIL 5% 
4 Poor improvement  
PASI> 25% 
NIL NIL NIL 0% 
 
 
 
 
 
 
OVERALL RESULT: 
IMPROVEMENT IN PSORIASIS: 
 
MARKED IMPROVEMENT - 85% 
MODERATE IMPROVEMENT - 10% 
MILD IMPROVEMENT-5%. 
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GROUP I BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH MAHA MANJISHTATHI KASHAYAM (INT) 
 
LAB INVESTIGATIONS 
 
SI. 
No 
OP. 
NO 
 
AGE/ 
SEX 
Hb (gm) TC (cu.mm)                      DC ESR Bl sugar 
N L E ½ 
hr 
1/2 
hr 
1hr 1hr R 
BT AT BT AT BT AT BT AT BT AT AT BT AT BT BT AT 
1 8935 52/F 11.8 12.9 7,000 6,810 68 61 25 18 7 5 15 22 35 38 116 120 
2 1437 53/M 12.8 12.7 8,000 9,500 65 59 28 16 7 4   8 25 13 39 199 210 
3 483 53/M 12.9 13.2 8,200 7,100 60 57 32 21 8 4 7 31 15 56 239 173 
4 473 52/F 11.9 10.6 8,000 7,790 59 43 34 23 7 3 10 12 25 28 190 140 
5 67 58/F 11.3 11.0 6,900 5,600 69 51 25 19 6 5 12 23 22 31 170 157 
6 1631 55/M 13.7 15.8 7,600 8,250 56 42 36 21 8 4 8 13 15 24 103 90 
7 3757 48/F 10.7 10.3 8,100 7,270 53 37 41 28 6 4 8 15 16 27 102 98 
8 6164 49/F 12.6 11.2 8,700 7,880 71 59 23 21 6 5 10 33 22 41 230 212 
9 5783 55/F 12.9 10.7 11,700 9,110 69 61 23 18 8 5 7 19 15 31 185 176 
10 1129 36/M 15.4 15.2 9,900 10,300 63 61 31 20 6 4 16 17 24 28 127 78 
11 8251 28/M 14.6 16.2 6,200 5,760 60 58 32 27 8 6 7 9 18 21 131 101 
12 9493 33/F 12.5 13.1 11,000 10,140 57 51 37 21 6 3 8 11 15 27 190 183 
13 8262 40/M 13.5 15.8 8,200 8,180 52 48 39 27 9 5 9 10 16 17 184 152 
14 7966 37/M 13.9 14.8 11,300 8,790 63 51 15 12 2 4 12 14 25 21 102 105 
15 2125 52/F 12.1 10.6 9,000 7,890 59 50 35 29 6 4 13 11 25 24 160 113 
16 8543 48/F 9.8 10.4 6,800 8,500 62 52 30 21 8 6 5 15 12 31 245 227 
17 8121 34/M 16.1 16.5 10,400 9,310 64 58 29 20 7 6 5 16 10 30 204 186 
18 7849 58/F 13.6 13.9 8,300 7,100 60 52 32 31 8 5 14 12 26 29 108 74 
19 6906 36/M 13.3 13.1 7,400 6,770 61 58 33 27 6 5 12 12 22 28 92 105 
20 6430 38/M 14.5 16.8 6,800 5,450 61 43 31 22 8 4  8 13 12 26 175 119 
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PATIENTS TREATED WITH CHEMPARUTHI POO ENNAI AND DEEP RELAXATION TECHNIQUE 
 
LAB INVESTIGATIONS - GROUP II- BLOOD ANALYSIS FOR 
OPD  
 
SI. 
No 
OP. NO  
AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ hr 1/2 hr 1hr 1hr R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 4314 58/M 13.3 16.1 7,400 6,810 62 54 29 20 9 6 6 4 18 12 158 172 
2 7651 50/F 11.3 13.0 8,600 8,840 57 54 34 30 9 6 10 12 22 26 250 216 
3 2497 57/F 12.0 13.2 9,000 8,660 68 61 28 29 4 2 16 18 32 27 98 110 
4 625 53/F 12.5 12.0 8,700 7,600 62 58 32 39 6 5 8 13 20 24 91 101 
5 4752 18/F 12.4 13.7 11,200 9,300 65 52 29 23 6 4 10 12 25 16 81 120 
6 2930 21/F 11.8 12.1 10,000 9,100 52 48 43 31 5 6 7 15 18 30 78 98 
7 3695 42/F 10.3 12.0 9,200 9,300 73 67 23 22 4 2 23 22 40 38 96 128 
8 4635 24/M 13.5 14.9 10,200 9,800 60 43 28 19 9 6 10 28 20 35 140 119 
9 9502 34/M 14.1 15.3 11,000 10,400 71 57 32 24 8 5 8 10 16 22 180 199 
10 4158 46/M 13.8 13.1 8,900 8,100 58 39 27 21 7 4 5 13 10 24 176 132 
11 2355 55/M 12.9 13.4 9,200 9,300 64 54 21 18 8 6 9 9 16 18 154 120 
12 3989 20/M 16.2 15.8 10,100 7,900 59 56 31 39 6 5  5 8 12 21 116 98 
13 3612 52/M 13.8 14.3 8,300 8,100 64 58 29 25 7 6 17 16 27 48 146 178 
14 9287 48/F 10.1 11.3 9,320 9,400 55 41 32 29 5 4 13 8 20 12 128 140 
15 6983 37/F 9.9 10.8 8,900 9,300 52 61 40 28 6 5 10 11 18 26 132 152 
16 8514 37/M 14.2 15.1 11,100 8,400 54 32 38 32 7 6 24 27 38 42 154 168 
17 9039 22/F 9.8 10.0 7,500 7,100 58 57 37 36 5 5 48 31 69 62 124 114 
18 8745 29/M 13.8 13.7 9,800 9,300 53 55 39 41 8 4 10 16 24 21 97 104 
19 9864 53/M 14.5 16.1 8,200 7,300 63 51 31 34 7 5 12 19 28 47 132 116 
20 7968 27/M 13.2 13.4 8,400 8,200 67 58 37 33 5 4 18 14 30 23 130 126 
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PATIENTS TREATED WITH INTERNAL AND EXTERNAL THERAPY 
 
LAB INVESTIGATIONS - GROUP III- BLOOD ANALYSIS FOR 
OPD  
 
SI. 
No 
OP. 
NO 
 
AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Blood sugar 
N L E ½ 
hr 
1/2 
hr 
1hr 1hr R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 7642 17/F 12.5 11.3 8,200 8,100 65 58 41 28 4 5 18 14 25 21 121 96 
2 7206 34/M 11.6 11.9 11,200 9,400 61 60 32 36 6 4 24 16 32 26 132 140 
3 3328 27/F 10.8 11.2 6,400 6,900 56 52 38 36 6 5 9 8 15 11 110 98 
4 2118 34/F 10.3 10.1 8,500 7,900 59 58 39 40 5 4 22 18 38 27 125 101 
5 1044 23/F 11.4 12.2 9,400 9,600 68 62 28 30 6 3 10 7 22 13 120 74 
6 1032 30/F 11.2 10.8 8,200 7,500 57 59 32 29 6 7 12 8 22 18 122 148 
7 8743 57/M 14.5 14.2 7,800 9,300 63 55 27 21 8 6 14 10 26 21 105 130 
8 5951 60/M 10.6 12.3 9,100 8,200 58 53 37 33 7 5 23 12 40 25 134 123 
9 7020 29/F 10.7 11.1 10,000 9,400 56 60 42 39 7 5 12 10 26 20 90 99 
10 6253 21/F 12.4 12.1 10,200 10,300 63 61 31 34 6 5 23 19 55 31 102 108 
11 3255 27/M 14.1 14.4 9,400 8,600 64 58 38 38 5 4 24 20 43 27 130 126 
12 4269 38/F 11.6 11.9 6,800 7,000 57 56 37 39 6 5 14 8 36 32 110 98 
13 2984 55/F 12.7 12.5 7,200 7,300 70 68 25 28 5 4 8 6 16 12 125 96 
14 8659 48/F 12.8 11.3 9,220  8,400 61 59 32 34 8 6 24 20 34 10 99 110 
15 6563 32/M 10.7 10.9 9,200 9,300 73 71 21 24 6 5 11 8 22 16 128 112s 
16 2826 28/F 11.3 11.1 8,100 8,400 55 62 38 32 7 6 15 12 32 28 119 124 
17 2088 43/F 10.8 11.0 7,500 7,100 58 57 37 36 5 5 23 19 52 38 154 101 
18 4189 30/M 13.5 13.7 9,600 9,800 53 55 39 41 8 4 7 6 14   9 97 104 
19 6727 32/M 12.4 12.1 10,200 10,300 63 61 31 34 6 5 12 10 36 26 102 79 
20 7153 51/M 14.1 13.4 8,400 8,200 67 58 28 38 5 4 13 11 29 21 160 148 
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URINE ANALYSIS : GROUP I URINE ANALYSIS FOR OPD PATIENTS 
TREATED WITH MAHA MANJISHTATHI KASHAYAM (INT) 
 
S.N 
O 
OP.N 
O 
AGE/S 
EX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
   ALBU 
MIN 
SUGAR DEPOSITS ALBUMI 
N 
SUGA 
R 
DEPOSITS 
     PUS 
CEL 
LS 
EPITHEL 
IAL 
CELLS 
  PUS 
CELLS 
EPITHELIA 
L CELLS 
1 8935 52/F NIL NIL NIL NIL NIL NIL NIL NIL 
2 1437 53/M NIL NIL NIL 2-3 NIL NIL 0-1 NIL 
3 483 53/M NIL NIL 1-2 NIL NIL NIL 1-2 NIL 
4 473 52/F NIL NIL NIL 1-3 NIL NIL NIL 1-2 
5 67 58/F NIL NIL 1-3 NIL NIL NIL 1-3 2-3 
6 1631 55/M NIL NIL 0-1 0-2 NIL NIL NIL NIL 
7 3757 48/F NIL NIL NIL 4-6 NIL NIL 2-4 0-1 
8 6164 49/F NIL NIL NIL NIL NIL NIL NIL NIL 
9 5783 55/F NIL NIL NIL 2-3 NIL NIL 2-3 0-1 
10 1129 36/M NIL NIL 0-4 NIL NIL NIL 1-3 NIL 
11 8251 28/M NIL NIL NIL 3-4 NIL NIL NIL NIL 
12 9493 33/F NIL NIL NIL NIL NIL NIL 0-3 NIL 
13 8262 40/M NIL NIL 0-1 1-2 NIL NIL 0-2 NIL 
14 7966 37/M NIL NIL 2-3 NIL NIL NIL NIL NIL 
15 2125 52/F NIL NIL NIL NIL NIL NIL NIL 1-2 
16 8543 48/F NIL NIL 1-3 1-2 NIL NIL NIL 1-2 
17 8121 34/M NIL NIL NIL NIL NIL NIL NIL NIL 
18 7849 58/F NIL NIL NIL NIL NIL NIL NIL 2-3 
19 6906 36/M NIL NIL NIL 0-1 NIL NIL 0-1 NIL 
20 6430 38/M NIL NIL NIL NIL NIL NIL NIL NIL 
 
 
 
 
 
 
 
 
 
 
 
Lkl;  
137 
 
2018 
RESULTS AND OBSERVATIONS 
 
GROUP II URINE ANALYSIS FOR OPD PATIENTS TREATED WITH 
CHEMPARUTHI POO ENNAI (EXT)  AND DEEP RELAXATION 
TECHNIQUE (THERAPY) 
 
 
 
S.N 
O 
OP.N 
O 
AGE/ 
SEX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
    
ALBUMIN 
 
SUGAR 
 
DEPOSITS 
 
ALBUMIN 
 
SUGAR 
 
DEPOSITS 
     PUS 
CEL 
LS 
EPITHEL 
IAL 
CELLS 
  PUS 
CELLS 
EPITHELIA 
L CELLS 
1. 4314 58/M NIL NIL NIL 0-3 NIL NIL 2-3 NIL 
2. 7651 50/F NIL NIL 0-1 NIL NIL NIL 2-3 NIL 
3. 2497 57/F NIL NIL NIL 1-3 NIL NIL NIL 2-3 
4. 625 53/F NIL NIL 2-4 NIL NIL NIL 2-3 NIL 
5. 4752 18/F NIL NIL 2-3 1-3 NIL NIL NIL 1-3 
6. 2930 21/F NIL NIL NIL 0-1 NIL NIL 1-2 NIL 
7. 3695 42/F NIL NIL 2-5 NIL NIL NIL NIL NIL 
8. 4635 24/M NIL NIL NIL 3-5 NIL NIL NIL 0-1 
9. 9502 34/M NIL NIL 1-3 NIL NIL NIL 3-5 NIL 
10. 4158 46/M NIL NIL 1-4 0-4 NIL NIL NIL 0-4 
11. 2355 55/M NIL NIL NIL NIL NIL NIL 3-4 NIL 
12 3989 20/M NIL NIL 1-3 2-4 NIL NIL NIL NIL 
13 3612 52/M NIL NIL 0-2 0-1 NIL NIL 1-2 0-1 
14 9287 48/F NIL NIL NIL 2-3 NIL NIL NIL 2-3 
15 6983 37/F NIL NIL NIL NIL NIL NIL NIL NIL 
16 8514 37/M NIL NIL 2-3 1-3 NIL NIL 1-2 1-3 
17 9039 22/F NIL NIL NIL NIL NIL NIL NIL NIL 
18 8745 29/M NIL NIL 2-3 NIL NIL NIL 1-2 NIL 
19 9864 53/M NIL NIL 0-1 NIL NIL NIL NIL 2-3 
20 7968 27/M NIL NIL 3-4 NIL NIL NIL 0-1 NIL 
 
 
 
 
 
 
 
 
 
 
Lkl;  
138 
 
2018 
RESULTS AND OBSERVATIONS 
 
 
 
GROUP III URINE ANALYSIS  - TRAETED WITH MAHAMANJISTATHI 
KASHAYAM,  CHEMPARUTHI POO ENNAI (EXT), DEEP RELAXATION 
TECHNIQUE 
 
S.N 
O 
OP.N 
O 
AGE/S 
EX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
   ALBU 
MIN 
SUGAR DEPOSITS  
ALBUMI 
N 
SUGA 
R 
DEPOSITS 
     PUS 
CEL 
LS 
EPITHEL 
IAL 
CELLS 
  PUS 
CELLS 
EPITHELI
A L CELLS 
1 7642 17/F NIL NIL 2-4 NIL NIL NIL 2-3 3-4 
2 7206 34/M NIL NIL 1-3 2-4 NIL NIL 2-3 1-4 
3 3328 27/F NIL NIL 0-2 0-1 NIL NIL NIL 0-3 
4 2118 34/F NIL NIL NIL 2-3 NIL NIL 2-3 NIL 
5 1044 23/F NIL NIL NIL NIL NIL NIL NIL 1-3 
6 1032 30/F NIL NIL 2-3 1-3 NIL NIL 1-2 NIL 
7 8743 57/M NIL NIL NIL NIL NIL NIL 0-2 4-5 
8 5951 60/M NIL NIL 3-5 NIL NIL NIL NIL NIL 
9 7020 29/F NIL NIL 0-1 NIL NIL NIL 3-4 NIL 
10 6253 21/F NIL NIL 3-4 NIL NIL NIL NIL 2-4 
11 3255 27/M NIL NIL 2-3 3-5 NIL NIL NIL 1-3 
12 4269 38/F NIL NIL 2-3 NIL NIL NIL 2-3 NIL 
13 2984 55/F NIL NIL NIL 2-3 NIL NIL 1-2 1-3 
14 8659 48/F NIL NIL 2-3 NIL NIL NIL 2-4 NIL 
15 6563 32/M NIL NIL NIL 1-3 NIL NIL 2-3 1-3 
16 2826 28/F NIL NIL 1-2 NIL NIL NIL NIL 0-1 
17 2088 43/F NIL NIL 4-6 NIL NIL NIL 2-5 NIL 
18 4189 30/M NIL NIL NIL NIL NIL NIL NIL 3-5 
19 6727 32/M NIL NIL 3-5 NIL NIL NIL 1-3 NIL 
20 7153 51/M NIL NIL NIL 0-4 NIL NIL 0-3 1-4 
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LIVER FUNCTION TEST 
GROUP I LFT -  MAHA MANJISHTADHI 
KASHAYAM (INT) 
 
 
 
S.NO 
 
 
OP.NO 
 
 
AGE/ 
SEX 
 
LIVER FUNCTION TEST – 
BEFORE TREATMENT 
 
LIVER FUNCTION TEST – AFTER 
TREATMENT 
TOTAL 
BILUR 
UBIN 
  
SGOTT 
 
SGPT 
SERUM 
ALKALINE      
PHOSPHA 
TASE 
TOTAL 
BILURUBIN 
SGOT SGPT SERUM 
ALKALINE 
PHOSPHATASE 
1. 8935 52/F 0.7  26.1 28.1 87 0.6 25.3 31.3 85 
2. 1437 53/M 0.8  21.5 22.3 72 0.5 29.2 27 69 
3. 483 53/M 0.5  26.2 24.0 86 0.7 14 16 72 
4. 473 52/F 0.7  34 13 82 0.6 36   19 76 
5. 67 58/F 0.7  21.6 20.1 97 0.6 20.9 29 73 
6. 1631 55/M 0.7  20.5 14.9 104 0.5 13 16 91 
7. 3757 48/F 0.6  19.3 14.6 96 0.5 23.1 19 82 
8. 6164 49/F 0.7  14.1 13.4 85 0.6 12 20 77 
9. 5783 55/F 0.6  18 23 79 0.8 13 22 91 
10. 1129 36/M 0.6  17 18 101 0.7 10 18 105 
11. 8251 28/M 0.8  23.5 28.9 97 0.7 21.1 30.8 66 
12 9493 33/F 0.6  20 14 69 0.5 18 24  74 
13 8262 40/M 0.5  29 31 91 0.4 25 33 89 
14 7966 37/M 0.6  35 28 78 0.6 20 19.2 71 
15 2125 52/F 0.7  44.7 48.1 92 0.5 36 36.4 75 
16 8543 48/F 0.7  15.9 14.1 95 0.6  23  19 89 
17 8121 34/M 0.7  18.6 28 75 0.7 15 23 68 
18 7849 58/F 0.8  27.1 26.0 72 0.6 26 20.9 61 
19 6906 36/M 0.6  21.0 19.2 65 0.5 28 17 83 
20 6430 38/M 0.7  22.0 21.0 90 0.7 14 18.3 77 
 
 
 
 
 
 
GROUP II –LFT- CHEMPARUTHI POO ENNAI (EXT) & DEEP       
RELAXATION TECHNIQUE (THERAPY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIVER FUNCTION TEST – BEFORE 
TREATMENT 
 
 LIVER FUNCTION TEST – AFTER 
TREATMENT 
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S.NO 
 
OP.NO 
 
AGE/SEX 
 
TOTAL 
BILURUBIN 
 
SGOT 
 
SGP 
T 
 
SERUM 
ALKALINE     
PHOSPHATASE 
 
 
TOTAL 
BILURUBIN 
 
 
SGOT 
 
 
SGPT 
 
SERUM 
ALKALINE 
PHOSPHATASE 
1. 4314 58/M 0.9 18.6 22.4 62 0.7 19 21.8 58 
2. 7651 50/F 0.4 28 12 59 0.6 32 23.3 74 
3. 2497 57/F 0.4 23 15 51 0.5 21 17 55 
4. 625 53/F 0.6 11 10 48 0.6 18 14 36 
5. 4752 18/F 0.53 18.4 18.3 65 0.4 20.3 19.7 71 
6. 2930 21/F 0.5 30.1 21.2 54 0.5 25.2 21.6 49 
7. 3695 42/F 0.7 16.9 9.4 46 0.4 20.1 11.9 52 
8. 4635 24/M 0.8 17.3 21.1 61 0.7 16.8 18 43 
9. 9502 34/M 0.6 31.4 36.4 78 0.8 29 32.8 80 
10. 4158 46/M 0.7 21.3 18.4 95 0.3 18.9 15.7 78 
11. 2355 55/M 0.5 34 16 59 0.4 25 18 49 
12 3989 20/M 0.7 19.8 13.1 43 0.6 15.4 30.1 51 
13 3612 52/M 0.7 32.2 37.1 55 0.5 32 35.0 64 
14 9287 48/F 0.9 15.9 14.1 92 0.9 21 24 102 
15 6983 37/F 0.5 30.3 26 79 0.5 26.7 18.9 88 
16 8514 37/M 0.7 24.5 18.0 53 0.6 20 15.1 58 
17 9039 22/F 0.6 29.3 21 74 0.5 30.9 27 49 
18 8745 29/M 0.4 32 19 54 0.6 26 12 54 
19 9864 53/M 0.8 28.4 27 71 0.5 32 25.8 68 
20 7968 27/M 0.5 40 40 61 0.4 34 34 56 
 
 
 
 
 
 
 
 
 
 
 
 
GROUP III –LFT-CHEMPARUTHI POO ENNAI (EXT) & DEEP 
RELAXATION TECHNIQUE (THERAPY) 
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S.N
O 
 
 
 
 
OP.N
O 
 
 
 
 
AGE/SE
X 
 
LIVER FUNCTION TEST – BEFORE 
TREATMENT 
 
LIVER FUNCTION TEST – 
AFTER TREATMENT 
 
TOTAL 
BILURUB
IN 
 
SGO
T 
 
SGP T 
SERUM 
ALKALINE     
PHOSPHAT
ASE 
 
TOTAL 
BILURUBI
N 
 
 
SGO
T 
 
 
SGP
T 
SERUM 
ALKALINE 
PHOSPHATA
SE 
1. 7642 17/F 0.4 28 21 48 0.6 21 29.5 52 
2. 7206 34/M 0.8 29.0 31.0 76 0.8 32 29.6 79 
3. 3328 27/F 0.9 22 19 63 0.5 25 17 57 
4. 2118 34/F 0.4 14.9 9.8 35    0.9 20 15 32 
5. 1044 23/F 0.9 25.4 29 71 1.0 22.3 21.6 80 
6. 1032 30/F 0.5 18.5 16 52 0.57 20.5 19.2 46 
7. 8743 57/M 0.4 24.5 27.3 76 0.4 20.1 16.8 69 
8. 5951 60/M 0.6 17.3 19.1 53 0.7 19.8 21 41 
9. 7020 29/F 1.0 28.4 22 98 0.68 17 18.8 88 
10. 6253 21/F 0.3 19.4 19.3 92 0.37 16.2 17.5 82 
11. 3255 27/M 0.7 34 16 59 0.58 25 18 49 
12 4269 38/F 0.6 21.3 15 41 0.4 19 12 56 
13 2984 55/F 0.5 29 19 75 0.53 22 18.3 73 
14 8659 48/F 0.7 26.9 20 102 0.6 21 23 100 
15 6563 32/M 0.4 30.2 26.9 62 0.5 28 23.4 88 
16 2826 28/F 0.5 18.4 21.0 61 0.4 20 19.5 78 
17 2088 43/F 0.4 21.3 18.9 55 0.5 17.2 21 41 
18 4189 30/M 0.6 32 17.5 64 0.6 26 15.8 72 
19 6727 32/M 0.5 32 20.7 62 0.4 29 23 62 
20 7153 51/M 0.5 19.3 14.6 71 0.5 20.5 14.9 66 
 
 
 
                               
                              RENAL FUNCTION TEST 
GROUP I RENAL FUNCTION TEST FOR OPD PATIENTS TREATED 
WITH MAHA MANJISHTATHI KASHAYAM (INT) 
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S.NO 
 
OP 
NO 
 
AGE/SEX 
 
UREA 
 
CREATININE 
 
UREA 
 
CREATININE 
 
1 
 
8935 
 
52/F 
 
26 
 
24 
 
23 
 
22 
 
2 
 
1437 
 
53/M 
 
32 
 
19 
 
26 
 
20 
 
3 
 
483 
 
53/M 
 
28 
 
35 
 
24 
 
23 
 
4 
 
473 
 
52/F 
 
22 
 
20 
 
21 
 
18 
 
5 
 
67 
 
58/F 
 
22 
 
20 
 
20 
 
21 
 
6 
 
1631 
 
55/M 
 
20 
 
18 
 
18 
 
20 
 
7 
 
3757 
 
48/F 
 
26 
 
28 
 
23 
 
22 
 
8 
 
6164 
 
49/F 
 
27 
 
24 
 
18 
 
22 
 
9 
 
5783 
 
55/F 
 
28 
 
30 
 
25 
 
21 
 
10 
 
1129 
 
36/M 
 
26 
 
26 
 
20 
 
23 
 
11 
 
8251 
 
28/M 
 
0.5 
 
0.5 
 
0.5 
 
0.4 
 
12 
 
9493 
 
33/F 
 
0.7 
 
0.5 
 
0.7 
 
0.5 
 
13 
 
8262 
 
40/M 
 
0.8 
 
0.5 
 
0.6 
 
0.5 
 
14 
 
7966 
 
37/M 
 
0.4 
 
0.4 
 
0.3 
 
0.6 
 
15 
 
2125 
 
52/F 
 
0.5 
 
0.5 
 
0.5 
 
0.6 
 
16 
 
8543 
 
48/F 
 
0.5 
 
0.5 
 
0.4 
 
0.5 
 
17 
 
8121 
 
34/M 
 
0.4 
 
0.5 
 
0.7 
 
0.4 
 
18 
 
7849 
 
58/F 
 
0.7 
 
0.5 
 
0.3 
 
0.4 
 
19 
 
6906 
 
36/F 
 
0.7 
 
0.7 
 
0.3 
 
0.5 
 
20 
 
6430 
 
38/M 
 
0.5 
 
0.7 
 
0.3 
 
0.4 
 
 
 
 
 
 
 
 
GROUP II RENAL FUNCTION TEST FOR OPD PATIENTS TREATED 
WITH  CHEMPARUTHI POO ENNAI(EXT) AND DEEP 
RELAXATION TECHNIQUE (THERAPY) 
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S.NO 
 
OP 
NO 
 
AGE/SEX 
 
UREA 
 
CREATININE 
 
UREA 
 
CREATININE 
1 4314 58/M 28 0.9 20 0.5 
2 7051 50/F 18 0.3 21 0.4 
3 2497 57/F 24 0.5 22 0.5 
4 625 53/F 24 0.4 27 0.5 
5 4752 18/F 24 0.8 23 0.4 
6 2930 21/F 18 0.4 20 0.6 
7 3695 42/F 18 0.4 18 0.5 
8 4635 24/M 28 0.5 25 0.5 
9 9502 34/M 26 0.6 22 0.6 
10 4158 46/M 20 0.7 18 0.4 
11 2355 55/M 24 0.4 25 0.4 
12 3989 20/M 22 0.4 20 0.3 
13 3612 52/M 30 0.8 26 0.5 
14 9287 48/F 17 0.8 19 0.6 
15 6983 37/F 19 0.6 23 0.6 
16 8514 37/M 28 0.6 25 0.4 
17 9039 22/F 30 0.7 26 0.3 
18 8745 29/M 16 0.8 20 0.4 
19 9864 53/M 21 0.6 20 0.5 
20 7968 27/M 29 0.8 27 0.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GROUP III RENAL FUNCTION TEST FOR OPD PATIENTS 
TREATED WITH MAHA MANJISHTATHI KASHAYAM 
CHEMPARUTHI POO ENNAI(EXT) AND DEEP RELAXATION 
TECHNIQUE (THERAPY) 
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S.NO 
 
OP 
NO 
 
AGE/SEX 
 
UREA 
 
CREATININE 
 
UREA 
 
CREATININE 
1 7642 17/F 17 0.7 21 0.4 
2 7206 34/M 23 0.4 20 0.5 
3 3328 27/F 28 0.5 23 0.3 
4 2118 34/F 21 0.5 23 0.5 
5 1044 23/F 24 0.6 20 0.5 
6 1032 30/F 14 0.4 18 0.6 
7 8743 57/M 18 0.8 15 0.4 
8 5951 60/M 21 0.5 23 0.5 
9 7020 29/F 15 0.6 17 0.7 
10 6253 21/F 24 0.7 19 0.5 
11 3255 27/M 29 0.5 24 0.4 
12 4269 38/F 23 0.4 20 0.3 
13 2984 55/F 17 0.8 22 0.4 
14 8659 48/F 24 0.6 20 0.4 
15 6563 32/M 19 0.7 21 0.3 
16 2826 28/F 25 0.6 19 0.4 
17 2088 43/F 14 0.7 18 0.3 
18 4189 30/M 18 0.8 20 0.4 
19 6727 32/M 17 0.5 15 0.5 
20 7153 51/M 21 0.6 25 0.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PASI SCORE 
 
GROUP I MAHA MANJISHTATHI KASHAYAM (INT) PASI SCORE 
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S.NO 
 
OP.NO AGE 
/SEX 
INITIAL  
PASI  
SCORE 
POST  
PASI  
SCORE 
1 
 
8935 52/F     9.8     1.6 
2 
 
1437 53/M 22      2.8 
3 
 
483 53/M 13.1      0.5 
4 
 
473 52/F 19.2      0.9 
5 
 
67 58/F 5.3      0 
6 
 
1631 55/M   18      0.4 
7 
 
3757 48/F   8.4      0.2 
8 
 
6164 49/F  31.5      0.7 
9 
 
5783 55/F  18.5      0.4 
10 
 
1129 36/M   2.6      0 
11 
 
8251 28/M  10.4     0.5 
12 
 
9493 33/F    2.4      0 
13 
 
8262 40/M   20.9      1.2 
14 
 
7966 37/M    12     3. 6 
15 
 
2125 52/F   23.6     2.4 
16 
 
8543 48/F   18.6      1.4 
17 
 
8121 34/M    4.8      0 
18 7849 58/F   13.8     1.6 
19 
 
6906 36/M   26.2      3.5 
20 
 
6430 38/M   10.8     1.9 
 
 
 
GROUP II - CHEMPARUTHI POO ENNAI (EXT) AND DEEP RELAXATION 
TECHNIQUE (THERAPY) PASI SCORE 
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S.No 
 
OP.No Age 
/Sex 
Initial  
PASI  
Score 
Post  
PASI  
Score 
1 4314 58/M   14.4    0.5 
2 7651 50/F    11      0 
3 2497 57/F   4.5     0.4 
4 625 53/F   18.8     4.4 
5 4752 18/F   5.4     1.2 
6 2930 21/F   10.9      2.8 
7 3695 42/F   3.6      0 
8 4635 24/M   14.5      1.2 
9 9502 34/M    4.9      0.2 
10 4158 46/M     14      4.4 
11 2355 55/M      6     0.7 
12 3989 20/M   13.2      3.6 
13 3612 52/M    8.4      1 
14 9287 48/F   16.4      2.2 
15 6983 37/F    4.5      0 
16 8514 37/M   15.8      2.7 
17 9039 22/F    7.4      1.2 
18 8745 29/M    5.1      0 
19 9864 53/M    2.8      0 
20 7968 27/M   10.8       4.4 
 
 
 
 
 
 
GROUP III – MAHA MANJISHTATHI KASHAYAM ,CHEMPARUTHI POO 
ENNAI  (EXT) DEEP RELAXATION TECHNIQUE (THERAPY)  PASI 
SCORE 
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S.No 
 
OP.No Age 
/Sex 
Initial  
PASI  
Score 
Post  
PASI  
Score 
1 
 
7642 17/F     8.4      2 
2 
 
7206 34/M     4.8      0 
3 
 
3328 27/F     13.2     1.2 
4 
 
2118 34/F     4.7      0 
5 
 
1044 23/F     10.8     1.6 
6 
 
1032 30/F     2.1      0 
7 
 
8743 57/M      4.2      0 
8 
 
5951 60/M     8.4     1.2 
9 
 
7020 29/F      2      0 
10 
 
6253 21/F    15.3     4.8 
11 
 
3255 27/M    8.3     0 
12 
 
4269 38/F    19.3     1.8 
13 
 
2984 55/F    3.6      0 
14 
 
8659 48/F    15.6      0 
15 
 
6563 32/M    11.8     3.2 
16 
 
2826 28/F    41.6     4.8 
17 
 
2088 43/F    14.4     2.1 
18 4189 30/M     2.8      0 
19 
 
6727 32/M    19.4     2.1 
20 
 
7153 51/M    10.8      0 
 
                                STATISTICAL ANALYSIS 
CLINICAL FEATURESIMPROVEMENT IN PATIENTS TREATED WITH 
MAHA MANJISHTATHI KASHAYAM (INT) - GROUP I PATIENTS 
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RESULTS AND OBSERVATIONS 
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a hypothesis. 
IMPROVEMENT OF GROUP I SUBJECTS:  
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. ERYTHEMATOUS 
PATCHES 
WITH WHITE SILVERY 
SCALES  
20(100) 
 
1(5)** 
2. ITCHING 12(60) 0(0)** 
3. SCALP LESION 5(25) 1(5)* 
4. AUSPITZ SIGN 17(85) 1(5)** 
5. CANDLE GREASE 
SIGN 
4(20) 0(0)* 
6. KOBNER’S 
PHENOMENON 
6(30) 0(0)** 
7. NAIL CHANGES 2(10) 0(0)* 
8. PALM AND SOLE 
LESIONS 
11(55) 3(15)** 
9. JOINT INVOLVEMENT 0(0) 0(0) 
 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
 
 
Inference:  
Since the p value is significant in all clinical featuresexcept joint 
involvement.So there is significant reducing of clinical features among the patients for 
the treatment of ThadippuPerunoi (Psoriasis).Hence it is concluded that the treatment 
was effectiveand significant.  
 
 
 
GROUP II PATIENTS - IMPROVEMENT IN PATIENTS TREATED WITH 
CHEMPARUTHI POO ENNAI (EXT), DEEP RELAXATION THERAPY  
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The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a hypothesis. 
 
IMPROVE MENT OF GROUP II SUBJECTS:  
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. ERYTHEMATOUS 
PATCHES 
WITH WHITE SILVERY 
SCALES  
20(100) 
 
5(25)** 
2. ITCHING 17(85) 8(40)** 
3. SCALP LESION 8(40) 3(15)* 
4. AUSPITZ SIGN 10(50) 4(20)** 
5. CANDLE GREASE 
SIGN 
6(30) 1(5)** 
6. KOBNER’S 
PHENOMENON 
3(15) 2(10)* 
7. NAIL CHANGES 3(15) 2(10)* 
8. PALM AND SOLE 
LESIONS 
9(45) 5(25)* 
9. JOINT INVOLVEMENT 1(5) 1(5) 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
 
Number of cases: 20 
 
Inference:  
Since the p value is significant in all clinical featuresexcept joint 
involvement.So there is significant reducing of clinical features among the patients for 
the treatment of ofThadippuPerunoi (Psoriasis).Hence it is concluded that the treatment 
was effectiveand significant. 
 
 
GROUP III – IMPROVEMENT IN CLINICAL FEATURES 
 
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
Lkl;  
150 
 
2018 
RESULTS AND OBSERVATIONS 
 
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. ERYTHEMATOUS 
PATCHES 
WITH WHITE SILVERY 
SCALES  
13 0 
2. ITCHING 9(45) 0(0)** 
3. SCALP LESION 11(55) 0(0)** 
4. AUSPITZ SIGN 4(20) 2(10)* 
5. CANDLE GREASE 
SIGN 
8(40) 0(0)** 
6. KOBNER’S 
PHENOMENON 
4(20) 1(5)* 
7. NAIL CHANGES 12(60) 2(10)** 
8. PALM AND SOLE 
LESIONS 
2(10) 3(15)* 
9. JOINT INVOLVEMENT 13(65) 1(5)** 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
 
Number of cases: 20 
 
Inference:  
Since the p value is significant in all clinical features.So there is significant reducing of 
clinical features among the patients for the treatment of ofThadippuPerunoi 
(Psoriasis).Hence it is concluded that the treatment was effectiveand significant. 
 
Group I Subjects :Liver Function Test 
 
S.No. Investigations Before 
Treatment 
After 
Treatment 
P value 
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Mean±SD 
n= 20 
Mean±SD 
n= 20 
2 SGPT 22.48±8.43 22.94±6.15 0.735 
3 SGOT 23.75±7.41 21.13±7.63 0.073 
4 Alkaline Phosphatase 85.65±11.28 78.70±10.62 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
Group II Subjects :Liver Function Test 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 20.77±8.74 21.78±7.12 0.479 
3 SGOT 25.12±7.51 25.12±7.51 0.331 
4 Alkaline Phosphatase 63.00±14.43 61.75±16.32 0.609 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
 
Group IIISubjects :Liver Function Test 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 20.15±5.18 19.74±4.48 0.671 
3 SGOT 24.59±5.65 22.08±4.18 <0.05 
4 Alkaline Phosphatase 65.80±17.53 65.55±18.44 0.918 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP I SUBJECTS :RFT 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 24.70±3.25 20.55±4.26 <0.001 
2 Creatinine 0.69±0.13 0.58±0.11 <0.001 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant.  
 
 
GROUP II SUBJECTS :RFT 
 
S.No. Investigations Before After P value 
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Treatment 
Mean±SD 
n= 20 
Treatment 
Mean±SD 
n= 20 
1 Urea 23.20±4.65 22.35±2.99 0.606 
2 Creatinine 0.60±0.18 0.46±0.09 <0.001 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP IIISUBJECTS :RFT 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 20.60±4.38 20.15±2.73 0.398 
2 Creatinine 0.59±0.13 0.43±0.10 <0.001 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP I SUBJECTS:BLOOD INVESTIGATION 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 12.99±1.53 13.24±2.27 0.398 
2 ESR1hr 29.85±8.56 19.15±6.33 <0.001  
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP II SUBJECTS:BLOOD INVESTIGATION 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 12.67±1.72 13.46±1.75 <0.001 
2 ESR1 hr 28.70±13.00 25.15±12.98 0.106 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP III SUBJECTS:BLOOD INVESTIGATION 
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S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 12.00±1.29 11.97±1.17 0.872 
2 ESR1 hr 30.75±11.36 29.90±9.86 0.639 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
 
 
PASI SCORE 
 
GROUP I SUBJECTS:  
 
S.No. Investigatio 
ns 
Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 PASI Score 14.73±8.26 1.05±1.02 <0.001  
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP II SUBJECTS:  
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 PASI Score 9.62±4.95 1.54±1.61 <0.001  
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
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GROUP III SUBJECTS:  
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 PASI Score 
 
 
11.08±9.30 1.41±1.70 <0.001  
 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
 
         Since the P value is highly significant (<0.001) in 3 groups. So there is 
significant reducing of PASI Score among the patients for the treatment of 
ThadippuPerunoi (Psoriasis).Hence it is concluded that the treatment was effective 
and significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL IMPROVEMRNT PHOTOS 
OP.NO : 6430 
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AGE/SEX: 38/ Male 
 
 
\ 
 
 
 
 
 
 
CLINICAL IMPROVEMRNT PHOTOS 
 
BEFORE TREATMENT 
Passi Score 10.8 
AFTER TREATMENT 
Passi Score : 0 
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OP.NO : 6983 
AGE/SEX: 37/ Female 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL IMPROVEMRNT PHOTOS 
BEFORE TREATMENT 
Passi Score : 4.5 
AFTER TREATMENT 
Passi Score : 0 
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OP.NO : 7153 
AGE/SEX: 51/ Male 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
CLINICAL IMPROVEMRNT PHOTOS 
BEFORE TREATMENT 
Passi Score : 3.6 
AFTER TREATMENT 
Passi Score : 0 
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OP.NO : 9864 
AGE/SEX: 53/ Male 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL IMPROVEMRNT PHOTOS 
OP.NO : 1032 
BEFORE TREATMENT 
Passi Score : 2.8 
BEFORE TREATMENT 
Passi Score : 0 
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AGE/SEX: 30/ Female 
 
 
 
 
 
 
 
 
       
BEFORE TREATMENT 
Passi Score : 2.1 
BEFORE TREATMENT 
Passi Score : 0 
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DISCUSSION: 
 
Thadippu Perunoi (psoriasis) is a chronic, inflammatory and proliferative skin 
disease with Erythematous, itching and scaling. The raised, scaly, and erythematous 
plaques associated with psoriasis can be cosmetically disfiguring, which may provoke 
disgust, fear, and aversion in others. Consequently, the social stigma of psoriasis can 
be devastating for patients, evoking feelings of shame and anxiety about how they are 
perceived. Significantly more disability, psychological distress and disease-related 
stressors are found among highly strained patients. 
The trail drugs were prepared by the Author in Government Siddha Medical 
College, after getting proper authentication for raw drugs from the Medicinal Botany 
Department under the supervision of the members of the teaching faculty and guided 
by the Head of the Department of Sirappu Maruthuvam of the Government Siddha 
Medical College, Chennai-106. 
In clinical study, 60 patients were selected, 20 patients were treated with 
internalmedicine,20 patients were treated with external oil deep relaxation therapy. 20 
patients were treated with internal medicine, external oil and deep relaxation Therapy. 
Patients were treated in the out-patient department of Sirappu Maruthuvam. 
 
TRAIL DRUGS: 
 
INTERNAL MEDICINE: Maha manjishtathi kashayam 
EXTERNAL MEDICINE: Chemparuthi poo ennai 
THERAPY                       : Deep relaxation technique 
Based on various criteria, the data were collected and tabulated. The criteria were 
distribution of age, gender, occupation, family history, diet, clinical Manifestations 
and assessment of the improvement in the prognosis of the disease with trail drugs. 
 
1.AGE DISTRIBUTION: 
Among 60 cases, high age incidence (31.66%) is Between 51 – 60yr, low age 
incidence (13.33%) is Between 41 – 50yr. Thadippu Perunoi can appear at birth as 
well as very old age. In this present study, considerable numbers of patients were 
reported between the age of 51-60yrs among study sample. 
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2. GENDER DISTRIBUTION: 
Among 60 patients, 28 patients (46.6%) were male, 32patients (53.3%) were Female. 
Generally Thadippu Perunoi occurs with almost equal frequency in malesand females, 
but a slightly more number of female cases were reported. 
3. OCCUPATIONAL DISTRIBUTION: 
Among 60 patients, 12 Out of 60 patients were Home makers (20%), and 9 patients 
were cooli and 6 were tailor because due to mechanical stress. 
4. FAMILY HISTORY: 
Among 60 patients only 12 patients (20%) were having positive family history. 
5. SOCIO ECONOMIC STATUS: 
Among 60 patients 35 patients were low income group (58.3%), 20 patients were 
middle Income group (33.3%), 5 patients were higher income group (8.33%). 
6. DIET: 
Among 60 patients, 51 patients were non-vegetarian (85%), 9 patients were vegetarian 
(15%). 
7. TRIGERRING FACTORS: 
Among 60 patients, 18 patients were unknown origin (30%), 51 patients were non 
vegetarian (85%),11 patients due to had alcohol (18.33%), 1 patients due to infection 
(1.6%), 12 patients due to had smoking as a factor (20%), 2 patients were skin injury 
(3.33%), 0 patients were Reaction to certain drug (0%), 6 patients were in Psycho 
somatic origin (10%) . 
8.CLINICAL FEATURES: 
Among 60 patients have Erythematous patches with white silvery scales and 
Auspitz sign, Itching, Koebner’s phenomenon as their predominant symptoms in 
BT, but after treatment symptoms is fully reduced, nail and joint involvement 
mildly present. 
9. CLINICAL IMPROVEMENT IN WEAK BASED ON PASI SCORE: 
The clinical efficacy of MMK was apparent from the PASI score at weak, Among the 
60 patients,2 patients (3.3%) had symptoms reduction in 3 weeks, 4 patients (6.6%) 
had symptoms reduction in 4 weeks, 13patients (21.6%) had symptoms reduction in 5 
weeks, 20 patients (33.3%) had symptoms reduction in 6 weeks, 21 patients (35%) 
had symptoms reduction in 7 weeks were noticed per week. 
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10. CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH INTERNAL& EXTERNAL MEDICINE & DRT 
Among 60 patients treated in OPD, out of 20 patients given internal drug, external oil 
& Drt , 18 out of 20 patients had marked improvement (90%),2 out of 20 patients had 
moderate improvement (10%). 
11.CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH INTERNAL MEDICINE 
Among 60 patients treated in OPD, out of 20 patients given internal drug, 17out of 20 
patients had marked improvement (85%), 2 out of 20 patients had moderate 
improvement (10%),1out of 20 patients had moderate improvement (5%). 
12. CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH EXTERNAL MEDICINE & DRT 
Among 60 patients treated in OPD, out of 20 patients given external drug & Drt, 
16out of 20 patients had marked improvement (80%), 2 out of 20patients had 
moderate improvement (10%), 2 out of 20 patients had mild improvement (10%). 
13. STATISTICAL RESULTS 
Since the p value is significant in all clinical features. So, there is significant reducing 
of clinical features among the patients for the treatment of psoriasis. Hence it is 
concluded that the treatment was effective and significant .Since the P value is highly 
significant (<0.001). So there is significant reducing of PASI Score among the patients 
for the treatment (internal medicine, external medicine & Drt ) of Thadippu Perunoi 
(psoriasis).Hence it is concluded that the treatment was effective and significant. 
The outcome of the study was clinically observed by PASI Score. Which showed 
encouraging results of marked improvement in 51 patients (85%), moderate 
improvement in 6 patients (10%), and mild improvement in 3 patients (5%). 
 
MARKED IMPROVEMENT - 85% 
MODERATE IMPROVEMENT - 10% 
MILD IMPROVEMENT-5% 
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SUMMARY 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON“THADIPPU 
PERUNOI” (PSORIASIS) WITH SIDDHA TRIALDRUGS“MAHA 
MANJISHTATHI KASHAYAM”(INT) ,“CHEMPARUTHI POO ENNAI  
(EXT)’’ AND “DEEP RELAXATION TECHNIQUE” has been chosen for the 
dissertation work by the author. 
 
➢ The aim of the study was to evaluate the safety and efficacy of Herbal Siddha 
Drugs “Maha manjishatahi kashayam” (Int), “Chemparuthi poo ennai (Ext)’’ and 
“Dee relaxation technique” in management of Thadippu Perunoi(Psoriasis). 
➢ Literatures evidence has been collected from siddha and modern text book sand 
also the drug review also said. 
➢ Standard operative procedure for both trial drugs was standardized. 
➢ Pre - clinical toxicity study was done for the trial drug “Maha manjishtathi 
kashayam” (Int), in using of female Wister albino rats. Toxicity study was carried 
out after getting proper permission in Institutional Animal Ethical Committee 
(IAEC). 
➢ The study is conducted after the drug being screened by the screening 
committee and the trial is also approved by the Institutional Ethical 
Committee(IEC). The clinical trial also registered in Clinical Trial Registry of 
India(CTRI). 
➢ Qualitative and Quantitative study on the trial drug such as Physico-chemical 
analysis had been done, results are normal in range. 
➢ Anti-Psoriatic activity of “Maaha manjishatathi kashayam” (Int), was studied in 
Human Keratinocytes cell line (HaCaT) in vitro method. 
➢ 60 Patients of both sex and in age group between 18-60 years were selected for 
this clinical trial. 
➢ Among 60 patients were from OPD, 20 Patients were selected for treating with 
trial drugs Internal,20 patients were treated with external oil and Deep relaxation 
technique,20 patients were treated with internal drug, external oil and therapy. 
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➢ All the details about this study and the trial drug MMK consent forms duly signed 
by them, separate Performa was maintained for each patients. 
➢ Photos of the patient before and after treatment for the evidence of clinical 
improvement. 
➢ Before and after treatment blood samples are collected for the laboratory 
investigation. 
➢ The safety of the trial drug MAHA MANJISHTAHI KASHAYAM was assessed by 
comparing the safety parameters such as LFT AND RFT before and after 
treatment was taken. 
➢ From the first day onwards MAHA MANJISHTATHI KASHAYAM,30 ml, twice daily 
was given internally and CHEMPARUTHI POO ENNAI - 100mlfor external 
application & DEEP RELAXATION TECHNIQUE given to the patients. 
➢ Clinical improvement was assessed using of PASI SCORE. 
➢ Among 60 patients, out of 20 patients given internal drug, external drug & DRT 
,18 out of 20patients had marked improvement (90%),2 out of20 patients had 
moderate improvement (10%). 
➢ Out of 20 patients given internal drug ,17 out of 20 patients had marked 
improvement (85%),2 out of 20 patients had moderate improvement (10%) ,1out 
of 20 patients had mild improvement (5%). 
➢ Out of 20 patients given external drug& DRT,16out of 20patients had marked 
improvement (80%),2out of 20patients had moderate improvement (10%),2 out 
of 20 patients had mild improvement (10%). 
➢ Finally statistical analysis was performed to assess the significance of the clinical 
trial. 
➢ Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Thadippu 
Perunoi (psoriasis).Hence it is concluded that the treatment was effective and 
significant. 
➢ Since the P value is highly significant (<0.001). So, there is significant reducing of 
PASI Score among the patients for the treatment (internal medicine & external 
medicine) of Thadippu Peru noi (psoriasis). Hence it is concluded that the 
treatment was effective and significant. 
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CONCLUSION: 
 
❖ Heavy metal analysis of Maha manjishtathi kashayam (MMK) reveals that the 
drug does not contain any metals like lead, Cadmium, Arsenic and mercury. 
 
❖ Qualitative and Quantitative study on the trail drug results are normal in range. 
 
❖ Acute and sub- acute toxicity study with 2 doses given in female Wister albino 
rats (10 mg/ kg, 20 mg/kg of body weight) were administered orally repeated 
for 28 days. Animals are observed for physiological and behavioral changes, 
after animal sacrificed and changes in organ and histo pathological changes 
were examined, reveals that the trial drug Maha manjishtathi Kashayam 
considered as safe. 
 
❖ Anti-Psoriatic activity of Maha Manjishatahi Kashaym was studied in Human 
Keratinocytes cell line (HaCaT), LPS treatment produced effects similar to 
psoriasis as reported and the compound was effective in limiting the increased 
proliferation in HaCaT cells. 100ug/ml reduced the cell viability to 19.96% 
which is significant. 
 
❖ Among 60 patients treated in OPD, 51 patients had marked improvement 
(85%), 6 patients had moderate improvement (10%), 3 patients had mild 
improvement (5%). Result of the study was concluded by reducing PASI 
SCORE. 
 
❖ Deep relaxation technique may have treating ability of psoriasis by reducing 
stress. And it is along with the Siddha trial drugs was very effective in overall 
improvements were good. And itching and scaling was reduced in group I and 
III are very effective when comparing to group II. 
 
❖ The LFT & RFT before and after treatment do not show any significant 
change in psoriasis cases, hence it is safe in human trial. In my clinical trial 
during the trial were no adverse effects or unwanted drug reactions in GIT, 
RS, CVS & excretory system. 
 
❖ Statistical analysis shows , since the p value (<0.01) is significant in all 
clinical features. so there is a significant reducing of clinical features among 
the patients for the treatment of Thadippu perunoi (Psoriasis).Hence it is 
concluded that the treatment was effective and significant. 
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❖ Nowadays the modern treatment of Psoriasis includes Steroidal medications 
such as Methotextrates which may lead to many adverse effects. But MMK 
intake for long term has no adverse effects since there are no variations in the 
safety parameters such as LFT and RFT. So, it’s the time to bring back our old 
traditional medicines for the effective treatment for Psoriasis. 
 
❖ The results of the clinical trial indicate that the trial drug Maha manjishtathi 
Kaashayam (Internal) Chemparuthi poo ennai (External) and Deep relaxation 
technique are clinically, more effective in THADIPPU PERUNOI 
(PSORIASIS) Patients. 
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Public Title of Study A study on Siddha trail drug Maha manjishtathi kashayam(INT)Chemparuthi poo ennai (EXT)and
Aasanam in patients having Psoriasis
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Study
An open comparative clinical evalution on Thadippu perunoi (Psoriasis)with Siddha herbal
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Brief Summary This is a Single Non Randomized open clinical trail to study the Safety and efficacy of Siddha
traildrug Maha Manjishtathi K ashayam. The trail drug is given30ml twice a day for 48 days .Clinical
trail is coonducted after conducting Preclinical toxicity study. The trail drug Maha Manjishtathi
Kashayam is mentioned in Agathiyar Vaithiya Pillai Tamil . During the trail all the study related data
will be recorded and documented .After the completion of trail all the data will be analysed
statistically
Powered by TCPDF (www.tcpdf.org)
page 3 / 3
  
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI  – 600 106. 
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
PRINICIPAL INVESTIGATOR: Dr. E. NANDHINI                  REG NO: 321513103 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with 
the evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM 
”(internal) and  “CHEMPARUTHI POO ENNAI” (external), DEEP RELAXATION 
TECHNIQUE. 
 
FORM l - SCREENING & SELECTION  PROFORMA 
 
1. OP NO                  : …………………………… 
 
2. NAME                  : …………………………………………. 
  
3. AGE                      : ……… 
 
4. GENDER             : …………....... 
 
5. OCCUPATION   : ……………………………….. 
 
6. INCOME             : ……………… 
 
7. ADDRESS           : …………………………………………………….    
…………………………………………………… 
 
8. CONTACT NO   : ……………………………………              
  
 
 
INCLUSION CRITERIA 
• Age :15-60 years                Yes / No 
• Sex : Both male and female                                                                                     Yes / No 
• Patches with Scaling             Yes / No 
• Auspitz sign +            Yes / No 
• Koebner’s phenomenon +           Yes / No 
• Patients Willing to fill consent form                                                                        Yes / No                                                                                        
• Patients willing to take photograph before& after treatment                                   Yes / No 
EXCLUSION CRITERIA: 
HISTORY OF 
• Narcotic Addicts 
• Leprosy 
• Cardiac disease 
• Peptic ulcer 
• SLE, Progressive systemic sclerosis 
• Pregnancy women and lactation 
• HIV 
• Alcohol 
• Evidence of secondary infections in the lesions 
• Syphilis 
• History of long term intake of steroids 
ADMITTED TO TRIAL: 
  YES                        NO                 
 
    If yes,             OPD/IPD                    
 
Date:        
Station: 
Signature of the Investigator:                                                Signature of the Guide:  
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CHENNAI – 600 106 
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRINICIPAL INVESTIGATOR:  Dr. E. NANDHINI                          REG NO: 321313103 
 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with 
the evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM 
”(internal) and  “CHEMPARUTHI POO ENNAI” (external), DEEP RELAXATION 
TECHNIQUE. 
  
FORM II - HISTORY TAKING PROFORMA ON ENROLLMENT  
 
1.SERIAL NO OF THE CASE: ………………… 
 
2.OP / IP NO: ...................................... 
3. NAME: ……………………………    4.AGE: …………       5.GENDER: .................    
 
6. MARITAL STATUS    1.Married   2.Unmarried        
 
7. COMPLAINTS & DURATION:                                                                                                                                                                                        
 
 
 
 8. CHIEF COMPLAINTS WITH DURATION 
 
Present   Absent  Duration (indays) 
1.Itching   : 
 
2. Dryness of the skin : 
  
 
 
 
 
3. Roughness   : 
 
4. Circular  erythema            : 
 
5. Exfoliation   : 
 
6. Hyper Pigmentation : 
 
7. Hypo-Pigmentation : 
 
8. Maceration  : 
 
9. Pin point bleeding 
After removal of skin : 
 
10. Papule/Pustule/Vesicle : 
 
11. Fissures   : 
 
9. HISTORY OF PRESENT ILLNESS 
 
1. Onset of disease  :            Acute    Insidious 
 
2. Duration of disease  : 
3. Treatment given so far :  Ayurvedic medicine   Modern Medicine 
 
Unani     Homeopathy 
 
10. PERSONAL HISTORY: 
 
         PERSONAL HABITS YES NO IF YES 
SPECIFY 
DURATION  
           Habits of  smoking    
           Habit of Tobacco Chewing    
           Habit of Alcohol    
           Any Habit of Narcotic  Drug Addiction    
 
  
 
 
11. DRUG HISTORY: 
 
 
12. FAMILY HISTORY: 
Whether this problem runs in family? 
  1. Yes                               2.No         
If yes, mention the relationship of affected person(s) --------------------- 
History of previous investigations if any ------------------------------ 
13. DIETARY STYLE:     
  1. Pure vegetarian              
 2. Non-vegetarian 
14. BOWEL HABITS & MICTURITION: 
 
 
 
15. MENSTURAL AND OBSTETRIC HISTORY: 
 
 
 
16. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY 
 
 
 
 
 
Date:         Signature of the guide: 
Station:                                                            
                                                                                        Signature of the Investigator: 
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ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106. 
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
PRINICIPAL INVESTIGATOR: Dr. E. Nandhini                         REG NO: 321513103 
An open comparitive clinical evaluation on “THADIPPU  PERUNOI (PSORIASIS)” 
with the evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM 
”(internal) and  “CHEMPARUTHI POO ENNAI” (external)  and RELAXATION TECHNIQUE. 
 
 
FORM III - CLINICAL ASSESSMENT ON ENROLLMENT PROFOMA 
1. OP NO: ------------ 2.IP NO: ---------------    3.BED NO: ------   4.SI NO:   -------- 
 
5. NAME: ----------------------        6. AGE:   ---------              7.GENDER:    ---------- 
 
8. DATE OF BIRTH: 
               D      M            Y   E   A   R 
 9. DATE OF INITIAL ASSESSMENT:     ----------------------   
 
 SIDDHA SYSTEM OF EXAMINATION: 
 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal 
 
2. Pitha udal 
 
3. Kaba udal 
 
4. Thontha udal 
  
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji  
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai  
3. KAALAM: 
1. Kaar kaalam    (Aavani-Puratasi) 
 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
 
3. Munpani kaalam     (Maargazhi-Tai) 
 
4. Pinpani kaalam       (Maasi-Panguni) 
 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
 
6. Muthuvenil kaalam    (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
  
5. PORIPULANGAL (SENSORY ORGANS):                  
      Normal            Affected   
1. Mei                                      .............................................................................. 
2. Vaai   (Naaku)   .............................................................................. 
3. Kan                                  .............................................................................. 
4. Mookku                          .............................................................................. 
5. Sevi                                      .............................................................................. 
 
  
 
 
6. KANMENDRIYAM (MOTOR ORGANS) :          
        Normal       Affected  
1. Vaai                                    .............................................................................. 
2. Kaal                                  .............................................................................. 
3. Kai                                     .............................................................................. 
4. Eruvaai                                 .............................................................................. 
5. Karuvaai                               ..............................................................................     
 
7. KOSANGAL (SHEATH):          
         Normal       Affected  
1. Annamaya kosam       .....                     ................................................................... 
2. Pranamaya kosam                                 ..................................................................... 
3. Manomaya kosam                       .         ....................................................................     
4. Vignanamaya kosam                             .................................................................... 
5. Anandhamaya kosam                            .....................................................................     
 
8. UYIR THATHUKKAL (THREE HUMOURS): 
8a.VALI:              Normal   Affected 
1. Praanan                          .............................................................................. 
2. Abaanan                                .............................................................................. 
3. Viyaanan                                .............................................................................. 
4. Uthaanan                                 .............................................................................. 
5. Samaanan                                 .............................................................................. 
6. Naagan                                     .............................................................................. 
7. Koorman                                  .............................................................................. 
8. Kirukaran                                 .............................................................................. 
9. Devathathan                              .............................................................................. 
10. Dhananjayan              ..............................................................................  
  
 
8b. AZHAL:              Normal    Affected 
1. Analam                                   .............................................................................. 
2. Ranjagam                              .............................................................................. 
3. Saathagam                              .............................................................................. 
4. Aalosagam                               .............................................................................. 
5. Praasagam                                .............................................................................  
 
8c.IYAM:              Normal    Affected 
1. Avalambagam                         .............................................................................. 
2. Kilethagam                              .............................................................................. 
3. Pothagam                                 .............................................................................. 
4. Tharpagam                               .............................................................................. 
5. Santhigam                                .............................................................................. 
 
9. EN VAGAI THERVU (EIGHT FOLDS OF EXAMINATION): 
1.Naadi      :           ………………………................. 
2.Parisam :           ………………………................. 
3.Naa         :           ............……………….................. 
4.Niram     :           .....……………………................. 
5.Mozhi     :           .....……………………................. 
6.Vizhi       :           ...................................................... 
7.Malam    :           ..................................................... 
8. Moothiram :      …………………………………. 
         8a.Neerkuri: 
Niram      :  1.Whitish             2. Yellowish          3.Straw coloured            4. Crystal clear 
Edai         :  1.Present              2.Absent 
Manam    :               1.Nil                     2.Reduced                    3. Increased 
Nurai:                 1. Normal             2.Increased                  3. Decreased  
Enjal: 
   
 
 
8b: Neerkuri (Oil –in urine sign): 
 Vatha Neer                Pitha Neer              Kaba Neer 
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS):         
                                   Normal          Affected   
 1. Saaram                                                 .................................................................. 
2. Senneer    ....         .............................................................. 
3. Oon                                                   .................................................................. 
4. Kozhuppu                                       .................................................................. 
5. Enbu                                           ..................................................................
 6. Moolai                                                .................................................................. 
7. Sukkilam / Suronitham                        .................................................................. 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cm]                        :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mmHg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.  :   
  
            Yes              No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
  
 
VITAL ORGAN EXAMINATION:                                                      
 Normal          Abnormal 
1.  Heart  
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION: 
 Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Genital urinary system     
6.  Endocrine system        
 
11. CLINICAL EXAMINATION:                  
 
CLINICAL EXAMINATION OF SKIN 
1.Site:     -----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------- 
2. Colour:   Normal          Reddish      Black              Greyish 
  
3. Shape:    Irregular         Coin shape     Dispersed  
4. Itching:  No         Mild                   Moderate             Severe 
5. Scaling:  Mild                      Moderate                  Severe 
6. Erythema:         Present    Absent 
7. Bleeding:           Present                  Absent 
8. Crusting:         Present                Absent 
9. Lichenification:         Present                Absent 
10. Oozing: No  Mild            Moderate                severe 
11. Auspitz sign:   Present Absent 
12. Koebner’s phenomenon: Present Absent 
13. Candle grease sign:  Present Absent 
 
                YES                               NO 
 14. Ulcération: 
 15. Macule:   
 16. Papule: 
 17. Pustule:  
       18. Blister: 
 19. Vesicle:   
 20. Pigmentation:  Normal      Hypo                        Hyper  
 
 
  
EXAMINATION OF NAILS: 
1.  Pitting:     Present  Absent 
2   Thickening:    Present                  Absent 
3.  Collection of Hyperkeratotic debris: Present              Absent 
4.  Separation of distal portion of nail: Present              Absent 
 
EXAMINATION OF JOINTS: 
                      YES                            NO 
Joint Involvement      
 
 
 
Date     :                                                                         
Station:                                                                                      Signature of the guide:                                                           
 
 
                                                                                                   Signature of the Investigator: 
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CHENNAI – 600 106 
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
PRINICIPAL INVESTIGATOR: Dr. E. NANDHINI                    REG NO: 321513103 
 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with the 
evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM ”(internal) 
and  “CHEMPARUTHI POO ENNAI” (external)  and DEEP RELAXATION TECHNIQUE. 
FORM IV: LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE TMT 
(WITH DATE) 
AFTER TMT 
(WITH DATE) 
 
HB( gm/dl) 
M:12-15 
W:11.5-14 
  
 
T.WBC (cells/cu.mm) 
4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
 
 
 
 
 
 
 
 
 
 Basophils 0-1   
 
T.RBC(million cells/cu.mm) 
 
M:4.0-5.5 
     W:3.5-4.5 
 
 
 
 
 
  ESR(mm/hour) ½ hr. M:6-12 
W:7-18 
  
  1 hr.   
Blood Investigations Normal Values 
Before 
TMT(WITH 
DATE) 
After TMT (WITH 
DATE) 
Blood 
glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
RFT 
(mg/dl) 
Blood urea    16-50   
 
Serum creatinine 
   0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect bilirubin    0.2-0.7   
SGOT     0-40   
SGPT     0-35   
Alkaline 
phosphatase 
   80-290   
 
  
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
          Sugar   
Deposits   
 
 
 
 
Date:          
Station: 
 
                                                              Signature of the Guide: 
     
                                                                                                            Signature of the Investigator: 
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PRINICIPAL INVESTIGATOR: Dr. E. NANDHINI                                REG NO: 321213103 
 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with the 
evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM ”(internal) 
and  “CHEMPARUTHI POO ENNAI” (external)  and DEEP RELAXATION TECHNIQUE. 
     
FORM V: INFORMED CONSENT FORM 
 
“I have read the foregoing information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions I have asked have been answered to my satisfaction. 
 I   consent voluntarily to participate in this study and understand that I have the   right to 
withdraw from the study at any time without in any way it affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual has 
given consent freely.”                                                   
 
Date: 
 
 

 
 
 
 
 
 
அரசு சித்த மருத்துவ கல்லூரி, சென்னை - 106 
 
அறிஞர் அண்ணா மருத்துவமனை சென்னை 
 
தடிப்பு பெருந ோய்க்கோன சித்த மருத்துவ மருந்தின் மஹோ மஞ்சிஷ்டோதி கஷோயம்  
 
  ெரிகரிப்பு திறனன கண்டறியும் மருத்துவ ஆய்விற்கோன தகவல் ெடிவம், ஒப்புதல் ெடிவம். 
ஆய்வோளரோல் சோன்றளிக்க ெட்டது. 
  
 ோன் இந்த ஆய்னவ குறித்த அனைத்து விெரங்களும் ந ோயோளிக்கு புரியும் வனகயில் எடுத்து 
உனரத்துள்நளன் என்று உறுதி அளித்து உள்நளன்  
 
நததி   :                                                                                                    னகயப்ெம் : 
   
இடம் :                                                                                                    பெயர்        : 
 
ந ாயாளியின் ஒப்புதல் : 
என்னிடம் இந்த மருத்துவ ஆய்வின் கோரைத்னதயும், மருந்தின் தன்னம மற்றும் மருத்துவ வழிமுனற 
ெற்றியும், பதோடர்ந்து எனது உடல் இயக்கத்னத கண்கோணிக்கவும், அதனன ெோதுகோக்கவும் ெயன்ெடும் 
மருத்துவ ஆய்வுக்கூட ெரிநசோதனனகள் ெற்றி திருப்தி அளிக்கும் வனகயில் ஆய்வு மருத்துவரோல் விழுங்கிக்  
கூறப்ெட்டுள்ளது.  
 ோன் இந்த மருத்துவ ஆய்வின் நெோது, கோரைம் எதுவும் கூறோமல், எப்பெோழுது நவண்டுமோனோலும் 
இந்த ஆய்விலிருந்து என்னன விடுவித்து பகோள்ளும் உரினமனயத்பதரிந்திருக்கின்றோன்.  ோன் என்னுனடய 
சுதந்திரமோக நதர்வு பசய்யும் உரினமனயக் பகோண்டு தடிப்பு பெரு ந ோய்க்கோன மகோ மஞ்சிஷ்டோதி கஷோயம் 
மருந்தின் ெரிகரிப்பு திறனன கண்டறிந்து மருத்துவ ஆய்விற்கு என்னன உட்ெடுத்த ஒப்புதல் அளிக்கின்நறன். 
 
இம்மருந்துகளினோல் ஏற்ெடும் ெக்க வினளவுகள் குறித்தும் விவரிக்கப்ெட்டுள்ளது. 
 
நததி   :                                                                                                    னகயப்ெம் : 
   
இடம் :                                                                                                     பெயர்        : 
 
நததி   :                                                                                                     சோட்சிக்கோரர் னகயப்ெம் : 
   
இடம் :                                                                                                    பெயர்        : 
 
உறவு முனற : 
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PRINICIPAL INVESTIGATOR: Dr. E. NANDHINI                         REG NO: 321213103 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with the 
evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM ”(internal) 
and  “CHEMPARUTHI POO ENNAI” (external)  and  DEEP RELAXATION TECHNIQUE. 
 FORM VI - WITHDRAWAL FORM 
SERIAL NO OF THE CASE:                                  OP / IP NO:  
  
 NAME:                                                            AGE/GENDER:                          
 DATE OF TRIAL COMMENCEMENT:  
DATE OF WITHDRAWAL FROM TRIAL: 
 REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
 
Irregular treatment:                           Yes/ No 
 
Shift of locality:                                     Yes/No 
 
Increase in severity of symptoms:     Yes/No 
 
Development of severe adverse drug reactions:   Yes/No 
 
Development of adverse event:                                               Yes/No 
 
Date:    
Station: 
Signature of the Investigator:     Signature of the Guides:   
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PRINICIPAL INVESTIGATOR: Dr. E. NANDHINI                             REG NO: 321213103 
 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with 
the evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM 
”(internal) and  “CHEMPARUTHI POO ENNAI” (external)  and  DEEP RELAXATION 
TECHNIQUE . 
            FORM VII – PATIENT INFORMATION SHEET 
Name of Co- Investigator: E.Nandhini.  
Name of the college: Govt. Siddha Medical College 
                         Arumbakkam 
                        Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL 
TRIAL. 
 I, E.Nandhini   studying M.D (Siddha) at Govt Siddha Medical College, Chennai, is 
doing a clinical trial on “THADIPPU PERUNOI (PSORIASIS)”. It is becoming a most common 
disease, occurring throughout the world. In this regard, I am in need to ask you few questions. I 
will maintain confidentiality of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is involved by taking 
part in this study. Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. There 
is no specific benefit for you if you take part in the study. However, taking part in the study may  
 
 
 
be of benefit to the community, as it may help us to understand the problem of defaulters and 
potential solutions. 
             If you agree to be a participant in this study, you will be included in the study primarily 
by signing the consent form and then you will be given the internal medicine“MAHA 
MANJISHTATHI KASHAYAM” (Internal medicine) 30 ml bid  for 48 days.  
 The information I am collecting in this study will remain between you and the Co- 
investigator (myself). I will ask you few questions through a questionnaire. I will not write your 
name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact E.Nandhini , PG Scholar cum Co- investigator of this study, 
attached to Govt. Siddha Medical College, Chennai-106. You can also contact the Member-
secretary of Ethics committee, Govt Siddha Medical College, Chennai. 
 
 
 
Date:    
Station: 
Signature of the Investigator:     Signature of the Guides: 
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An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with the 
evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM ”(internal) 
and  “CHEMPARUTHI POO ENNAI” (external)  and DEEP RELAXATION TECHNIQUE. 
FORM VIII  (DRUG COMPLIANCE FORM) 
STUDYNO: OP/IP NO: 
NAME:                        AGE/GENDER:                                           
DRUG NAME: MAHA MANJISHTATHI KASHAYAM 
 
Day Date Morning 
 
Evening 
 
Day Date Morning 
 
Evening 
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Day2    Day26    
Day3    Day27    
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Date     :                                                                              
Station:  
                                                                                       Signature of the Guide:  
 
 Signature of the Investigator:                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRINICIPAL INVESTIGATOR: E.NANDHINI                                        REG NO: 321213103 
An open comparitive clinical evaluation on “THADIPPU PERUNOI (PSORIASIS)” with the 
evaluation on Siddha Herbal formulation  “MAHA  MANJISHTATHI  KASHAYAM ”(internal) 
and  “CHEMPARUTHI POO ENNAI” (external)  and DEEP RELAXATION TECHNIQUE. 
FORM VIII  ( DIETARY ADVICE ) 
 
சேர்க்க கூடிய உணவுகள்: 
 
காய்கள்: 
 
❖ முருங்னக பிஞ்சு,  
❖ அவனர பிஞ்சு  
❖ கோரட்  
❖ பிரண்னட,  
❖ பீட்ரூட் 
 
கீரைகள்: 
  
❖ கரிசாலை,  
❖ ப ான்னாங்கண்ணி,  
❖ மணத்தக்காளி,    
❖ முருங்லககீலை,  
❖  சலைகீலை,    
❖ சிறுகீலை,  
❖ கறிவேப் ிலை   
               
பழங்கள்: 
 
❖ மாதுலள,  
❖ ஆப் ிள்,  
 
 
 
 
❖ ோலை,  
❖ வ ரீச்லச,  
❖ அத்தி,  
❖ திைாட்லச,  
❖ பகாய்யா,  
❖ ஆைஞ்சு,   
❖ எலுமிச்லச,  
❖ நாேல்,  
❖ தக்காளி 
 
தானியங்கள்:  
 
❖ வகாதுலம,  
❖ வசாயா னீ்ஸ்,  
❖  ட்டாணி,  
❖ பகாண்லடகடலை, 
❖  ாதாம்  
 
அரேவம்: 
 
❖ பேள்ளாட்டு கறி,  
❖ ஈைல்,  
❖ எலும்பு மஜ்லை  
 
சேர்க்க கூடாதரவகள்: 
 
❖ மந்தப் ப ாருள் 
❖ அகத்திக் கீலை 
❖ புளிப்பு 
❖ புலகயிலை 
❖ மது அருந்துதல் 
❖ நகோழி கறி, 
❖  ண்டு,  
❖ கருவோடு,  
❖ நவர்க்கடனை 
